https://flcube.com/ocumension-therapeutics-gains-cde-approval-for-phase-iii-presbyopia-trial/2025-06-11T12:08:50+08:00https://flcube.com/jiangxi-rimag-plans-acquisition-of-changsha-zhongya-medical-for-rmb-29-5-million/2025-06-10T22:57:38+08:00https://flcube.com/biogen-launches-qalsody-in-china-for-sod1-als-treatment/2025-06-10T22:42:35+08:00https://flcube.com/boehringer-ingelheim-and-echosens-expand-partnership-to-tackle-mash/2025-06-10T22:04:51+08:00https://flcube.com/china-expands-medical-insurance-coverage-in-new-state-council-guidelines/2025-06-10T21:51:20+08:00https://flcube.com/wuxi-biologics-commences-construction-on-microbial-production-base-in-chengdu/2025-06-10T21:44:31+08:00https://flcube.com/sihuan-pharmas-xuanyuening-granted-new-indication-review-in-china/2025-06-10T21:22:02+08:00https://flcube.com/johnson-johnson-launches-tremfya-iv-in-china-for-inflammatory-bowel-diseases/2025-06-10T21:01:47+08:00https://flcube.com/deep-surgery-secures-pre-series-a-funding-for-microsurgery-robot-expansion/2025-06-10T17:59:26+08:00https://flcube.com/immuneonco-appoints-zhuli-wu-as-chief-medical-officer-to-lead-clinical-strategy/2025-06-10T17:40:52+08:00https://flcube.com/hengrui-pharmaceuticals-launches-aiweida-for-her2-mutated-nsclc-in-china/2025-06-10T17:33:16+08:00https://flcube.com/suzhou-sinus-medtech-wins-fda-breakthrough-designation-for-ohcm-ablation-system/2025-06-10T17:28:53+08:00https://flcube.com/novartis-psmaddition-trial-yields-positive-results-for-pluvicto-in-mhspc/2025-06-10T17:20:23+08:00https://flcube.com/innovent-biologics-xinbiyue-approved-for-macau-market/2025-06-10T17:14:12+08:00https://flcube.com/innogen-pharma-resubmits-hong-kong-ipo-application-with-promising-diabetes-drug/2025-06-10T17:07:49+08:00https://flcube.com/harrow-signs-licensing-deal-for-formosas-byqlovi-in-us-market/2025-06-10T16:50:23+08:00https://flcube.com/fda-approves-mercks-enflonsia-for-infant-rsv-protection/2025-06-10T14:45:46+08:00https://flcube.com/sino-biopharmaceutical-gains-cde-approval-for-tqc3721-copd-trial/2025-06-10T14:27:08+08:00https://flcube.com/huadong-medicines-hdm1010-gets-fda-nod-for-phase-i-trial-in-t2d/2025-06-10T14:18:12+08:00https://flcube.com/sanyou-biopharma-partners-with-medicovestor-to-advance-next-gen-adcs/2025-06-10T14:11:26+08:00https://flcube.com/huahai-pharma-receives-fda-warning-letter-after-inspection/2025-06-10T12:11:18+08:00https://flcube.com/burning-rock-reports-q1-2025-revenue-growth-and-rd-progress/2025-06-09T17:04:38+08:00https://flcube.com/sinopep-allsino-partners-with-vazyme-to-advance-synthetic-biology/2025-06-09T16:52:58+08:00https://flcube.com/circ-and-qianlong-international-collaborate-to-advance-bnct-and-nuclear-medicine/2025-06-09T16:38:42+08:00https://flcube.com/astrazenecas-calquence-combo-approved-by-eu-for-cll-treatment/2025-06-09T16:32:08+08:00https://flcube.com/bayers-confidence-study-shows-kerendia-and-empagliflozin-reduce-uacr-in-t2d-ckd/2025-06-09T16:12:46+08:00https://flcube.com/lifetech-scientific-plans-rmb-150-million-investment-in-affector-medtech/2025-06-09T15:53:35+08:00https://flcube.com/obi-pharma-partners-with-tegmine-to-develop-antibody-drug-conjugates/2025-06-09T15:33:02+08:00https://flcube.com/neocura-bio-medical-gains-nmpa-approval-for-mrna-cancer-vaccine-trial/2025-06-09T13:02:46+08:00https://flcube.com/yoltech-receives-fda-clearance-for-pcsk9-targeted-base-editing-drug-yolt-101/2025-06-09T12:37:51+08:00https://flcube.com/kindstar-global-partners-with-biostate-ai-to-advance-precision-medicine/2025-06-09T12:32:00+08:00https://flcube.com/genesis-medtech-wins-nmpa-approval-for-locally-developed-thrombus-aspiration-catheter/2025-06-09T12:26:48+08:00https://flcube.com/zelgen-bio-collaborates-with-merck-kgaa-for-rhtsh-promotion-in-china/2025-06-06T23:33:42+08:00https://flcube.com/help-therapeutics-ipsc-derived-cardiomyocyte-therapy-enters-us-clinical-trials/2025-06-06T23:17:11+08:00https://flcube.com/lancet-robotics-secures-series-a-funding-for-surgical-robot-development/2025-06-06T23:01:37+08:00https://flcube.com/biocytogens-renmab-platform-wins-japanese-patent-expanding-ip-portfolio/2025-06-06T22:52:09+08:00https://flcube.com/bayers-vividion-gains-global-rights-to-wrn-inhibitor-vvd-214/2025-06-06T21:58:31+08:00https://flcube.com/nanjing-leads-biolabs-files-for-hong-kong-ipo-amid-product-pipeline-progress/2025-06-06T21:20:34+08:00https://flcube.com/acotec-scientific-gains-nmpa-approval-for-acoart-verbena-vertebral-balloon/2025-06-06T21:15:49+08:00https://flcube.com/hengrui-pharmaceuticals-gains-nmpa-approval-for-phase-ib-ii-study-of-shr-a1811-adebrelimab-and-famitinib-in-solid-tumors/2025-06-06T21:11:58+08:00https://flcube.com/qure-biotechnology-secures-rmb-100-million-series-c1-financing/2025-06-06T21:05:40+08:00https://flcube.com/lianhuan-pharma-gains-nmpa-approval-for-no-spa-generic/2025-06-06T20:57:37+08:00https://flcube.com/roches-evrysdi-5mg-tablet-gains-eu-commission-approval-for-spinal-muscular-atrophy/2025-06-06T20:48:26+08:00https://flcube.com/shanghai-opm-biosciences-plans-acqusition-of-pharmalegacy-labs-for-rmb-1-45-billion/2025-06-06T19:00:14+08:00https://flcube.com/sunshine-guojians-ssgj-613-meets-phase-iii-endpoints-in-acute-gouty-arthritis/2025-06-06T18:51:07+08:00https://flcube.com/nhsa-strengthens-pharmaceutical-pricing-and-procurement-credit-evaluation-mechanism/2025-06-06T18:43:31+08:00https://flcube.com/china-issues-whistleblower-incentives-for-drug-and-medical-device-safety-violations/2025-06-06T18:38:12+08:00https://flcube.com/chinas-national-health-commission-mandates-labor-pain-management-services-expansion/2025-06-06T18:34:26+08:00https://flcube.com/intragrand-pharma-licenses-lenamilast-to-transpire-bio-for-global-development/2025-06-06T18:28:14+08:00https://flcube.com/consun-pharma-partners-with-dp-technology-to-accelerate-ai-driven-kidney-disease-drug-rd/2025-06-06T18:15:41+08:00https://flcube.com/innovent-biologics-ibi363-receives-breakthrough-therapy-designation-from-cde/2025-06-05T20:14:03+08:00https://flcube.com/bms-secures-nmpa-approval-for-reblozyl-in-myelodysplastic-syndromes/2025-06-05T20:02:14+08:00https://flcube.com/shanghai-pharma-partners-with-chugai-pharma-china-to-enhance-bone-health-products/2025-06-05T18:32:10+08:00https://flcube.com/genrix-bio-partners-with-cullinan-therapeutics-for-gr1803-license/2025-06-05T18:26:26+08:00https://flcube.com/astrazenecas-imfinzi-approved-for-limited-stage-small-cell-lung-cancer-in-china/2025-06-05T18:20:50+08:00https://flcube.com/akeso-biopharma-wins-nmpa-approval-for-new-cadonilimab-indication/2025-06-05T18:16:09+08:00https://flcube.com/salubris-pharmaceuticals-allisartan-indapamide-hybrid-wins-nmpa-approval/2025-06-05T18:11:56+08:00https://flcube.com/wantai-biopharms-cecolin-9-hpv-vaccine-approved-by-chinas-nmpa/2025-06-05T18:04:45+08:00https://flcube.com/biocytogen-and-chia-tai-tianqing-win-nmpa-approval-for-ntb003-clinical-trials/2025-06-05T17:58:25+08:00https://flcube.com/nmpa-accepts-nda-for-innovent-and-hutchmeds-tyvyt-and-elunate-combination/2025-06-05T17:52:53+08:00https://flcube.com/scibrunch-therapeutics-secures-rmb-200-million-in-angel-financing-round/2025-06-05T17:43:10+08:00https://flcube.com/jw-therapeutics-carteyva-approved-by-macau-health-bureau/2025-06-05T17:34:53+08:00https://flcube.com/sichuan-kelun-biotech-raises-250m-in-hong-kongs-largest-follow-on-offering/2025-06-05T17:15:17+08:00https://flcube.com/easton-pharmas-oxazepam-receives-nmpa-approval-and-partners-with-nhwa/2025-06-05T16:27:00+08:00https://flcube.com/sanofis-rilzabrutinib-granted-orphan-drug-designation-for-sickle-cell-disease/2025-06-04T17:52:46+08:00https://flcube.com/ascletis-pharmas-denifanstat-meets-phase-iii-endpoints-in-severe-acne-trial/2025-06-04T17:45:55+08:00https://flcube.com/eli-lilly-partners-with-camurus-on-long-acting-cardiovascular-and-metabolic-health-products/2025-06-04T17:36:42+08:00https://flcube.com/circode-biomeds-circular-rna-drug-hm2002-approved-for-us-clinical-trials/2025-06-04T17:23:07+08:00https://flcube.com/bio-heart-launches-iberis-renal-ablation-system-at-occ-2025/2025-06-04T17:11:28+08:00https://flcube.com/bioage-labs-partners-with-jikang-for-apj-agonist-nanobody-license/2025-06-04T17:01:00+08:00https://flcube.com/bayers-nubeqa-gets-fda-approval-for-mhspc-treatment/2025-06-04T16:46:00+08:00https://flcube.com/sainte-nutritional-files-for-ipo-in-hong-kong-as-fsmp-pioneer/2025-06-04T16:37:24+08:00https://flcube.com/sino-biopharmaceutical-presents-campass-phase-iii-results-at-asco-2025/2025-06-04T16:27:57+08:00https://flcube.com/harbin-gloria-partners-with-eisai-to-promote-methycobal-in-china/2025-06-04T16:16:55+08:00https://flcube.com/lepu-medical-wins-nmpa-approval-for-polylactic-acid-facial-filler/2025-06-04T16:09:17+08:00https://flcube.com/jnj-reveals-positive-amplitude-phase-iii-results-for-akeega-in-mhspc-at-asco-2025/2025-06-04T15:59:01+08:00https://flcube.com/hansoh-pharmas-almonertinib-approved-in-uk-for-egfr-mutated-nsclc/2025-06-04T15:51:31+08:00https://flcube.com/eu-bars-chinese-medical-device-makers-from-public-tenders-over-e5m-for-five-years/2025-06-04T15:42:34+08:00https://flcube.com/legend-biotech-presents-5-year-carvykti-data-at-asco-2025/2025-06-04T15:36:29+08:00https://flcube.com/eu-approves-pfizer-and-takedas-adcetris-in-hodgkin-lymphoma-combination-regimen/2025-06-04T15:16:18+08:00https://flcube.com/biokin-pharma-enrolls-first-patient-in-bl-m07d1-phase-iii-trial-for-her2-low-breast-cancer/2025-06-03T23:36:11+08:00https://flcube.com/sanofi-to-acquire-blueprint-medicines-for-9-1-billion-to-expand-rare-disease-pipeline/2025-06-03T23:24:58+08:00https://flcube.com/biontech-partners-with-bms-to-jointly-develop-bnt327-for-solid-tumors/2025-06-03T23:12:43+08:00https://flcube.com/harbin-pharma-agrees-to-acquire-clinical-approval-for-jesduvroq-from-bocimed/2025-06-03T22:44:26+08:00https://flcube.com/zelgen-biopharmaceuticals-presents-clinical-updates-for-alveltamig-nilvanstomig-and-zggs15-at-asco-2025/2025-06-03T21:57:49+08:00https://flcube.com/alphamab-oncology-presents-jskn003-clinical-data-at-2025-asco-annual-meeting-2/2025-06-03T21:50:34+08:00https://flcube.com/hengrui-pharmaceuticals-gains-nmpa-approval-for-hrs9531-clinical-study-in-type-2-diabetes/2025-06-03T21:38:03+08:00https://flcube.com/huadong-medicine-files-for-nmpa-approval-of-ranibizumab-biosimilar/2025-06-03T21:32:43+08:00https://flcube.com/hansoh-pharmaceutical-partners-with-regeneron-for-hs-20094-global-rights/2025-06-03T18:04:43+08:00https://flcube.com/cspc-pharmaceuticals-jmt101-receives-breakthrough-therapy-designation-for-colorectal-cancer/2025-06-03T17:57:20+08:00https://flcube.com/zai-lab-presents-zl-1310-clinical-results-for-small-cell-lung-cancer-at-asco/2025-06-03T17:51:40+08:00https://flcube.com/alphamab-oncology-presents-jskn003-clinical-data-at-2025-asco-annual-meeting/2025-06-03T17:44:48+08:00https://flcube.com/innovent-biologics-presents-ibi363-clinical-results-at-2025-asco-annual-meeting/2025-06-03T17:38:51+08:00https://flcube.com/beone-medicines-wins-conditional-approval-for-ziihera-in-her2-positive-btc/2025-06-03T17:33:03+08:00https://flcube.com/longbio-pharma-secures-rmb-200-million-series-c-funding-for-clinical-studies/2025-06-03T17:25:36+08:00https://flcube.com/neowise-biotech-licenses-tcr-molecule-to-beone-medicines-for-next-gen-cell-therapy/2025-06-03T17:21:01+08:00https://flcube.com/nurix-therapeutics-announces-sanofis-acquisition-of-stat6-program-rights/2025-06-03T17:11:04+08:00https://flcube.com/msd-presents-zilovertamab-vedotin-results-at-asco-annual-meeting/2025-06-03T17:03:25+08:00https://flcube.com/hanx-bio-files-for-hong-kong-ipo-with-icbc-international-as-sole-sponsor/2025-06-03T16:58:47+08:00https://flcube.com/rb-biotech-receives-fda-approval-for-zs805-gene-therapy-in-fabry-disease/2025-06-03T16:48:06+08:00https://flcube.com/gsks-linerixibat-nda-accepted-by-fda-for-cholestatic-pruritus-in-pbc-patients/2025-06-03T16:37:51+08:00https://flcube.com/shanghai-ark-bio-and-partex-collaborate-on-atr-inhibitor-ak0658-development/2025-06-03T16:33:01+08:00https://flcube.com/bayer-files-for-approval-of-gadoquatrane-mri-contrast-agent-in-japan/2025-06-03T16:22:43+08:00https://flcube.com/microport-cardioflow-to-acquire-49-stake-in-la-ronda-for-rmb-171-million/2025-06-03T16:11:16+08:00https://flcube.com/msd-appoints-kyle-tattle-as-president-of-china-operations/2025-05-30T22:11:05+08:00https://flcube.com/zelgens-jaktinib-receives-nmpa-approval-for-myelofibrosis-treatment/2025-05-30T22:05:45+08:00https://flcube.com/msd-and-daiichi-sankyo-withdraw-us-filing-for-patritumab-deruxtecan-in-egfr-mutated-nsclc/2025-05-30T19:41:19+08:00https://flcube.com/fosun-pharmas-fcn-159-and-fcn-437c-win-nmpa-marketing-approvals/2025-05-30T19:34:36+08:00https://flcube.com/cspc-pharmaceutical-in-advanced-talks-for-5b-licensing-deals/2025-05-30T19:18:17+08:00https://flcube.com/acotec-scientifics-e-peridge-balloon-catheter-approved-by-chinas-nmpa/2025-05-30T19:14:06+08:00https://flcube.com/jiangsu-hengrui-secures-nmpa-approvals-for-trastuzumab-rezetecan-famitinib-and-hr20013/2025-05-30T19:07:49+08:00https://flcube.com/nmpa-approves-mabwells-8mw0511-for-febrile-neutropenia-prevention/2025-05-30T19:02:16+08:00https://flcube.com/hinovas-deutenzalutamide-approved-for-metastatic-prostate-cancer-in-china/2025-05-30T18:56:07+08:00https://flcube.com/sino-biopharmaceuticals-tqb2868-shows-strong-results-in-phase-ii-pancreatic-cancer-trial/2025-05-30T18:45:40+08:00https://flcube.com/hansoh-pharma-gains-nmpa-clinical-approvals-for-hs-10510-hs-10542-and-hs-20118/2025-05-30T18:39:28+08:00https://flcube.com/genor-biopharma-gains-nmpa-approval-for-cdk4-6-inhibitor-lerociclib-in-china/2025-05-30T18:33:05+08:00https://flcube.com/astellas-pharma-licenses-evopoints-cldn18-2-adc-for-global-development/2025-05-30T18:26:24+08:00https://flcube.com/danaher-partners-with-astrazeneca-to-advance-precision-medicine/2025-05-30T18:19:58+08:00https://flcube.com/innovent-biologics-doses-first-patient-in-phase-iii-psoriasis-trial-for-picankibart/2025-05-30T16:29:25+08:00https://flcube.com/gsk-halts-pivot-po-trial-early-as-tebipenem-hbr-meets-efficacy-targets-for-cuti/2025-05-30T16:13:43+08:00https://flcube.com/amoytop-biotech-wins-nmpa-approval-for-weekly-inpegsomatropin-in-pediatric-growth-deficiency/2025-05-30T16:06:21+08:00https://flcube.com/regend-therapeutics-gains-nmpa-approval-for-phase-i-ii-study-of-regend003-in-diabetes-related-ckd/2025-05-30T15:58:09+08:00https://flcube.com/ganzhou-hemay-pharma-files-for-hk-ipo-with-sdic-securities-sponsorship/2025-05-30T15:51:23+08:00https://flcube.com/genemind-biosciences-closes-rmb-280-million-series-c-round-to-fuel-dna-sequencer-innovation/2025-05-29T17:23:32+08:00https://flcube.com/abbott-laboratories-receives-fda-approval-for-tendyne-tmvr-system/2025-05-29T17:16:14+08:00https://flcube.com/ausperbio-secures-50m-in-oversubscribed-series-b-round-to-advance-hepatitis-b-therapy/2025-05-29T17:11:33+08:00https://flcube.com/bms-gains-european-approval-for-opdivo-subcutaneous-formulation/2025-05-29T17:07:04+08:00https://flcube.com/novartis-fabhalta-approved-for-previously-treated-pnh-patients-in-china/2025-05-29T17:01:13+08:00https://flcube.com/innocare-pharma-gains-nmpa-clinical-approval-for-bcl2-inhibitor-icp-248/2025-05-29T16:55:33+08:00https://flcube.com/fosun-pharma-and-jiuyuan-gene-partner-to-commercialize-biologics-in-global-markets/2025-05-29T16:36:05+08:00https://flcube.com/lupeng-pharmas-rocbrutinib-near-approval-for-mantle-cell-lymphoma/2025-05-29T15:59:53+08:00https://flcube.com/viva-biotech-establishes-rmb-300m-fund-for-early-stage-pharma-projects/2025-05-29T15:56:11+08:00https://flcube.com/bayers-sevabertinib-receives-fda-priority-review-for-her2-mutant-nsclc/2025-05-29T15:50:06+08:00https://flcube.com/jw-therapeutics-carteyva-receives-fourth-sbla-for-r-r-lbcl/2025-05-29T12:51:31+08:00https://flcube.com/sino-medical-sciences-technologys-aucura-flow-diverting-stent-approved-by-nmpa/2025-05-29T12:25:03+08:00https://flcube.com/changchun-pharma-wins-fda-approval-for-gensci128-in-tp53-y220c-solid-tumors/2025-05-29T12:10:43+08:00https://flcube.com/yantai-dongcheng-pharma-gains-nmpa-approval-for-sodium-fluoride-18f/2025-05-28T17:21:03+08:00https://flcube.com/guided-therapeutics-receives-payment-from-shandong-yaohua-for-luviva-commercialization/2025-05-28T17:12:55+08:00https://flcube.com/remegens-telitacicept-approved-for-myasthenia-gravis-in-china/2025-05-28T16:59:19+08:00https://flcube.com/biogen-and-city-therapeutics-collaborate-on-rnai-therapies-for-cns-diseases/2025-05-28T16:53:17+08:00https://flcube.com/hksh-medical-partners-with-united-imaging-to-advance-ct-technology/2025-05-28T16:40:13+08:00https://flcube.com/astrazenecas-imfinzi-gets-positive-opinion-for-bladder-cancer-perioperative-treatment/2025-05-28T16:27:50+08:00https://flcube.com/eyepoints-partner-betta-completes-enrollment-for-duravyus-pivotal-phase-iii-study/2025-05-28T16:21:47+08:00https://flcube.com/ema-recommends-tevimbra-for-nasopharyngeal-cancer-first-line-treatment/2025-05-28T16:11:28+08:00https://flcube.com/abelzeta-pharmas-c-car168-secures-fda-rmat-designation-for-lupus-treatments/2025-05-28T16:02:36+08:00https://flcube.com/fda-rejects-data-from-two-chinese-testing-labs-over-compliance-concerns/2025-05-28T15:56:59+08:00https://flcube.com/carsgens-satricabtagene-autoleucel-granted-priority-review-by-chinas-cde/2025-05-28T15:52:49+08:00https://flcube.com/salubris-pharmas-xinchaotuo-gains-nmpa-approval-for-primary-hypertension/2025-05-28T15:46:26+08:00https://flcube.com/jiangsu-nhwas-investee-jiangsu-haoxinqing-plans-overseas-listing/2025-05-28T15:39:18+08:00https://flcube.com/shenyang-xingqi-pharmaceuticals-plans-private-placement-to-fund-rd-center/2025-05-28T15:14:58+08:00https://flcube.com/novartis-beovu-approved-by-nmpa-for-diabetic-macular-edema-treatment/2025-05-28T15:05:12+08:00https://flcube.com/mabworks-mil62-gains-nmpa-review-for-nmosd-treatment/2025-05-28T14:59:05+08:00https://flcube.com/epimab-biotherapeutics-and-juri-biosciences-ink-global-licensing-deal-for-klk2-cd3-t-cell-engager/2025-05-28T14:40:09+08:00https://flcube.com/eli-lilly-to-acquire-siteone-therapeutics-for-up-to-usd-1-billion/2025-05-28T11:53:13+08:00https://flcube.com/junshi-biosciences-junshida-wins-nmpa-approval-for-hefh-and-statin-intolerant-patients/2025-05-28T11:41:32+08:00https://flcube.com/sino-biopharmaceutical-presents-tqb2102-phase-i-results-at-asco-2025/2025-05-28T11:30:22+08:00https://flcube.com/beigene-rebrands-to-beone-medicines-and-relocates-to-switzerland/2025-05-28T11:17:32+08:00https://flcube.com/betta-pharmaceuticals-partners-with-bioray-for-herceptin-biosimilar-anruize/2025-05-28T11:03:14+08:00https://flcube.com/chinas-nmpa-approves-lifetechs-aortic-fenestration-stent-system/2025-05-28T10:52:56+08:00https://flcube.com/phanes-therapeutics-doses-first-patient-in-cd73-antibody-clinical-study/2025-05-28T10:47:33+08:00https://flcube.com/starrygene-initiates-phase-ii-study-of-xmva09-for-wet-amd-treatment/2025-05-27T17:17:28+08:00https://flcube.com/sinotau-pharma-files-for-hk-ipo-focused-on-radiopharmaceutical-pipeline/2025-05-27T17:03:07+08:00https://flcube.com/drug-farm-and-amoytop-biotech-collaborate-on-df-006-for-hbv-and-hcc/2025-05-27T16:47:11+08:00https://flcube.com/eisais-dayvigo-granted-nmpa-approval-for-insomnia-treatment/2025-05-27T16:38:50+08:00https://flcube.com/harbin-gloria-partners-with-kowa-pharmaceuticals-to-promote-parmodia-in-china/2025-05-27T16:32:35+08:00https://flcube.com/beigene-and-amgen-report-positive-results-for-tarlatamab-in-chinese-es-sclc-patients/2025-05-27T16:18:21+08:00https://flcube.com/ayshealth-technology-secures-angel-funding-for-artificial-blood-vessel-research/2025-05-27T16:02:45+08:00https://flcube.com/shanghai-pharma-collaborates-with-novartis-china-on-ophthalmic-products/2025-05-27T15:32:29+08:00https://flcube.com/kexing-pharmas-gb18-receives-nmpa-approval-for-cancer-cachexia-trial/2025-05-27T15:15:52+08:00https://flcube.com/gilead-sciences-to-acquire-hookipas-hb-400-and-hb-500-vaccine-programs/2025-05-27T14:54:57+08:00https://flcube.com/hengrui-pharmaceuticals-gains-nmpa-approval-for-shr-4712-clinical-trial/2025-05-27T14:46:29+08:00https://flcube.com/bio-thera-solutions-terminates-bat3306-trial-amid-biosimilar-policy-shifts/2025-05-27T12:57:03+08:00https://flcube.com/fosun-pharmas-hlx22-granted-orphan-drug-designation-by-eu-commission/2025-05-27T12:50:48+08:00https://flcube.com/ucb-launches-rystiggo-in-china-for-generalized-myasthenia-gravis/2025-05-27T12:45:12+08:00https://flcube.com/bio-thera-solutions-bat2206-biosimilar-of-stelara-gains-fda-approval/2025-05-27T12:15:08+08:00https://flcube.com/hainan-introduces-new-pricing-rules-for-digital-therapeutics-effective-june-1/2025-05-27T12:05:52+08:00https://flcube.com/kanghong-pharma-wins-nmpa-approval-for-kh617-in-glioblastoma-trial/2025-05-27T11:32:53+08:00https://flcube.com/shandong-kanghua-biotechnology-announces-ipo-plans-on-beijing-stock-exchange/2025-05-27T11:25:36+08:00https://flcube.com/salubris-pharma-inks-licensing-deal-for-gowells-gw906-in-greater-china/2025-05-27T11:19:22+08:00https://flcube.com/walvax-biotechnology-secures-exclusive-rights-to-notitias-gut-microbiota-therapy/2025-05-26T17:00:40+08:00https://flcube.com/guangdong-zhongsheng-wins-peking-university-peoples-hospital-nod-for-ray1225-phase-iii-trials/2025-05-26T16:38:17+08:00https://flcube.com/jemincares-irinotecan-liposome-injection-gains-nmpa-approval-for-pancreatic-cancer/2025-05-26T16:27:47+08:00https://flcube.com/novo-nordisks-wegovy-demonstrates-early-cardioprotective-effects-in-select-trial/2025-05-26T16:19:46+08:00https://flcube.com/gsks-blenrep-recommended-for-eu-approval-in-multiple-myeloma/2025-05-26T16:01:52+08:00https://flcube.com/dizal-pharma-presents-dzd8586-and-dzd6008-results-at-asco-2025/2025-05-26T15:49:44+08:00https://flcube.com/abbisko-therapeutics-fgfr4-inhibitor-irpagratinib-granted-breakthrough-therapy-designation-for-hcc/2025-05-26T15:40:51+08:00https://flcube.com/elpiscience-files-for-hong-kong-ipo-focusing-on-immunotherapy-pipeline/2025-05-26T15:03:25+08:00https://flcube.com/medilink-therapeutics-collaborates-with-wuhan-union-hospital-on-clinical-trials/2025-05-26T14:55:40+08:00https://flcube.com/duality-biologics-receives-fda-ind-approval-for-egfr-her3-adc-avzo-1418/2025-05-26T14:43:21+08:00https://flcube.com/zhejiang-huahai-gains-medsafe-and-hdec-approval-for-hb0043-phase-i-trial/2025-05-26T14:34:33+08:00https://flcube.com/bayers-eylea-8-mg-close-to-eu-approval-for-longer-treatment-intervals/2025-05-26T14:19:26+08:00https://flcube.com/sichuan-kelun-biotech-finalizes-licensing-deal-for-tslp-monoclonal-antibody/2025-05-26T12:57:13+08:00https://flcube.com/roches-itovebi-recommended-for-eu-approval-in-pik3ca-mutated-breast-cancer/2025-05-26T12:28:59+08:00https://flcube.com/jenscare-announces-positive-30-day-results-for-lux-valve-plus-in-trinity-study/2025-05-26T12:19:02+08:00https://flcube.com/roche-partners-with-broad-clinical-labs-to-advance-sbx-sequencing-technology/2025-05-26T12:12:22+08:00https://flcube.com/grand-pharmas-gpn01768-approved-in-macau-for-demodectic-blepharitis/2025-05-26T11:54:48+08:00https://flcube.com/medtronics-prevail-dcb-gains-ce-mark-for-expanded-coronary-disease-indications/2025-05-26T11:47:18+08:00https://flcube.com/tonghua-dongbao-to-sell-stake-in-amoytop-biotech-for-usd-181-million/2025-05-24T00:57:14+08:00https://flcube.com/shandong-boan-biotechnology-partners-with-hkust-for-biomedicine-innovation/2025-05-24T00:16:01+08:00https://flcube.com/pacbio-appoints-haorui-gene-as-official-distributor-in-china/2025-05-24T00:04:58+08:00https://flcube.com/zhongsheng-pharmas-anruiwei-receives-nmpa-approval-for-influenza-a/2025-05-23T23:52:06+08:00https://flcube.com/carsgens-satri-cel-shows-significant-efficacy-in-gastric-cancer-study/2025-05-23T23:39:31+08:00https://flcube.com/viz-ai-partners-with-sanofi-and-regeneron-to-deploy-ai-solution-for-copd/2025-05-23T23:29:49+08:00https://flcube.com/gsks-nucala-receives-fda-approval-for-copd-treatment/2025-05-23T23:18:20+08:00https://flcube.com/mercks-welireg-launched-in-china-for-rare-genetic-disorder-treatment/2025-05-23T23:13:35+08:00https://flcube.com/nmpa-approves-bayer-regenerons-eylea-hd-for-wet-amd-treatment/2025-05-23T23:08:05+08:00https://flcube.com/ascentage-pharma-to-present-data-on-lisaftoclax-and-alrizomadlin-at-asco-2025/2025-05-23T22:57:32+08:00https://flcube.com/meinian-onehealth-partners-with-alibaba-damo-academy-for-ai-driven-disease-screening/2025-05-23T22:46:29+08:00https://flcube.com/lead-healthcare-raises-rmb-100m-in-angel-financing-to-boost-ai-driven-life-science-instruments/2025-05-23T22:41:03+08:00https://flcube.com/winhealth-pharma-expands-long-term-partnership-with-merz-therapeutics/2025-05-23T19:47:54+08:00https://flcube.com/servier-acquires-bionovas-bn104-for-acute-leukemia-treatment/2025-05-23T19:43:24+08:00https://flcube.com/immuneonco-and-instil-bio-announce-clinical-updates-for-imm2510-in-nsclc/2025-05-23T19:37:52+08:00https://flcube.com/ucbs-keppra-procurement-resumed-in-shanghai-after-regulatory-halt/2025-05-23T19:32:08+08:00https://flcube.com/remegen-plans-hong-kong-share-placement-to-fund-telitacicept-expansion/2025-05-23T19:27:05+08:00https://flcube.com/ascletis-pharma-starts-phase-i-study-of-asc50-for-psoriasis-in-the-us/2025-05-23T19:22:18+08:00https://flcube.com/jacobio-pharmas-glecirasib-approved-by-nmpa-for-kras-g12c-nsclc/2025-05-23T19:17:47+08:00https://flcube.com/astrazeneca-shuts-down-neuroscience-research-group-to-focus-on-core-areas/2025-05-23T19:10:07+08:00https://flcube.com/hengrui-pharmaceuticals-retagliptin-and-metformin-approved-by-nmpa-for-type-2-diabetes/2025-05-23T19:05:58+08:00https://flcube.com/roches-susvimo-gets-fda-approval-for-diabetic-retinopathy/2025-05-23T19:00:30+08:00https://flcube.com/joincare-pharmaceutical-plans-to-acquire-64-81-stake-in-imexpharm-for-usd-220m/2025-05-23T18:55:06+08:00https://flcube.com/chongqing-genrix-bios-gr2001-tetanus-monoclonal-antibody-nda-accepted-by-nmpa/2025-05-23T18:48:29+08:00https://flcube.com/medtronic-plans-to-spin-off-diabetes-business-into-publicly-traded-entity/2025-05-23T01:08:19+08:00https://flcube.com/bayer-launches-phase-i-study-of-bay-3670549-for-atrial-fibrillation/2025-05-23T01:03:16+08:00https://flcube.com/innocare-pharmas-minjuvi-gains-nmpa-approval-for-dlbcl-treatment/2025-05-23T00:57:30+08:00https://flcube.com/uni-bio-sciences-generic-diquas-accepted-for-nmpa-review/2025-05-23T00:50:13+08:00https://flcube.com/micusrxs-contezolid-sodium-nda-accepted-for-review-by-nmpa/2025-05-23T00:44:24+08:00https://flcube.com/sanofi-to-acquire-vigil-neuroscience-to-boost-neurology-pipeline/2025-05-23T00:37:16+08:00https://flcube.com/eli-lillys-kisunla-approved-in-australia-for-alzheimers-treatment/2025-05-23T00:28:18+08:00https://flcube.com/shanghai-int-medical-instruments-to-acquire-majority-stake-in-endonom-medical/2025-05-22T22:12:09+08:00https://flcube.com/medtronic-reports-q4-and-fy2025-results-with-revenue-growth-across-key-segments/2025-05-22T22:00:24+08:00https://flcube.com/genentech-and-orionis-enter-second-collaboration-on-small-molecule-oncology-drugs/2025-05-22T21:55:18+08:00https://flcube.com/kexing-biopharms-gb18-receives-fda-approval-for-tumor-cachexia-clinical-trial/2025-05-22T21:49:19+08:00https://flcube.com/accropeutics-ac-201-shows-positive-phase-ii-results-in-psoriasis-treatment/2025-05-22T21:44:40+08:00https://flcube.com/simceres-fgfr2b-targeting-adc-sim0686-enters-phase-i-clinical-study/2025-05-22T21:28:20+08:00https://flcube.com/triasteks-t22-gastric-retention-capsules-gain-nmpa-ind-clearance/2025-05-22T21:21:26+08:00https://flcube.com/boehringer-ingelheims-metalyse-approved-in-china-for-acute-ischemic-stroke/2025-05-22T21:16:06+08:00https://flcube.com/well-lead-medical-to-set-up-subsidiary-and-manufacturing-base-in-indonesia/2025-05-22T10:53:00+08:00https://flcube.com/kelun-biotechs-sacituzumab-tirumotecan-accepted-for-nmpa-review-for-hr-her2-breast-cancer/2025-05-22T10:46:23+08:00https://flcube.com/shandong-buchang-pharmaceuticals-partners-with-fbc-for-mf59-adjuvant-rd/2025-05-22T00:41:19+08:00https://flcube.com/hhs-implements-trumps-order-for-most-favored-nation-drug-pricing/2025-05-22T00:32:11+08:00https://flcube.com/nuance-pharmas-ohtuvayre-meets-primary-endpoints-in-copd-study/2025-05-22T00:28:55+08:00https://flcube.com/accuredit-therapeutics-art001-receives-fda-rmat-designation-for-attr/2025-05-22T00:21:38+08:00https://flcube.com/astrazeneca-completes-acquisition-of-esobiotec-for-up-to-usd-1-billion/2025-05-22T00:00:33+08:00https://flcube.com/pulnovo-medical-raises-tens-of-millions-in-new-financing-round-2/2025-05-21T23:55:34+08:00https://flcube.com/phase-scientific-completes-series-a-financing-to-advance-urine-based-diagnostics/2025-05-21T23:33:09+08:00https://flcube.com/chinas-cde-announces-94th-batch-of-reference-preparations-for-generic-evaluation/2025-05-21T22:09:44+08:00https://flcube.com/merck-kgaa-partners-with-imec-to-develop-advanced-microphysiological-systems-platform/2025-05-21T22:05:40+08:00https://flcube.com/antengene-and-msd-collaborate-on-atg-022-for-advanced-solid-tumors/2025-05-21T21:59:23+08:00https://flcube.com/chinas-county-hospitals-show-improved-medical-service-capability-in-2024/2025-05-21T21:46:59+08:00https://flcube.com/3sbio-registers-phase-iii-study-for-ssgj-707-in-advanced-nsclc/2025-05-21T21:16:26+08:00https://flcube.com/ascletis-pharma-initiates-asc47-103-study-in-us-for-obesity-treatment/2025-05-21T21:06:19+08:00https://flcube.com/yifan-pharma-licenses-ryzneuta-to-lenis-for-balkan-markets/2025-05-21T20:09:38+08:00https://flcube.com/abbiskos-pimitinib-granted-priority-review-for-tgct-treatment-in-china/2025-05-21T18:36:52+08:00https://flcube.com/minghui-pharmaceutical-launches-phase-ii-study-of-combination-therapy-for-advanced-nsclc/2025-05-21T12:55:39+08:00https://flcube.com/cspc-pharmaceutical-gains-nmpa-approval-for-jmt106-clinical-study-in-solid-tumors/2025-05-21T09:11:03+08:00https://flcube.com/zhaoke-ophthalmologys-cyclosporine-eye-gel-nda-accepted-by-nmpa/2025-05-21T09:05:21+08:00https://flcube.com/johnson-johnson-medtech-completes-first-pfa-surgeries-with-varipulse-catheter-in-china/2025-05-21T08:57:25+08:00https://flcube.com/shanghai-curegene-completes-series-b-financing-to-advance-cg-0255-study/2025-05-21T08:52:19+08:00https://flcube.com/regeneron-wins-auction-for-23andmes-core-business-units/2025-05-21T08:44:48+08:00https://flcube.com/gsks-blenrep-receives-marketing-approval-in-japan-for-multiple-myeloma/2025-05-21T08:38:35+08:00https://flcube.com/accurate-biotechnology-secures-rmb-100m-in-series-b-funding-for-organoid-technology/2025-05-21T02:08:03+08:00https://flcube.com/hainan-shuangchengs-generic-eptifibatide-gains-tga-marketing-approval-in-australia/2025-05-21T01:58:01+08:00https://flcube.com/strykers-optablate-bvn-system-gains-fda-510k-clearance/2025-05-21T01:27:25+08:00https://flcube.com/sirius-therapeutics-partners-with-crispr-therapeutics-to-develop-srsd107-for-thrombosis/2025-05-21T01:21:35+08:00https://flcube.com/zai-labs-zl-1310-receives-fda-fast-track-designation-for-sclc/2025-05-21T01:13:50+08:00https://flcube.com/porton-and-hualong-biological-partner-to-advance-matc-therapy/2025-05-21T01:07:04+08:00https://flcube.com/ab-science-secures-chinese-patent-for-masitinib-in-covid-19-treatment/2025-05-20T23:08:26+08:00https://flcube.com/4b-technologies-gains-nmpa-approval-for-als-drug-4b02-01-clinical-trials/2025-05-20T18:59:59+08:00https://flcube.com/pfizer-licenses-3sbios-bispecific-antibody-ssgj-707-in-global-deal-excluding-china/2025-05-20T18:53:21+08:00https://flcube.com/bayers-jivi-receives-fda-approval-for-pediatric-hemophilia-a-treatment/2025-05-20T18:47:22+08:00https://flcube.com/alibaba-health-reports-strong-2025-financial-results-with-revenue-hike/2025-05-20T18:43:15+08:00https://flcube.com/cspc-pharmaceuticals-cpo301-receives-third-fda-fast-track-designation-for-nsqnsclc/2025-05-20T18:38:57+08:00https://flcube.com/merck-sharp-dohme-initiates-phase-iii-trial-of-ifinatamab-deruxtecan-for-esophageal-cancer/2025-05-20T18:31:30+08:00https://flcube.com/terumo-corporation-acquires-wuxi-biologics-germany-plant-for-eur-150-million/2025-05-19T18:15:01+08:00https://flcube.com/grand-pharmas-chengdu-rdc-megafactory-secures-class-a-radiation-safety-license/2025-05-19T18:07:39+08:00https://flcube.com/shanghai-henlius-biotech-doses-first-patient-in-phase-i-iii-study-of-hlx13-for-hepatocellular-carcinoma/2025-05-19T18:02:56+08:00https://flcube.com/shanghai-microports-minos-stent-graft-secures-egyptian-marketing-approval/2025-05-19T17:57:04+08:00https://flcube.com/sino-biopharmaceuticals-qp001-meloxicam-approved-by-nmpa-and-fda-for-postoperative-pain/2025-05-19T17:52:59+08:00https://flcube.com/porton-pharma-partners-with-tong-eye-on-ipsc-derived-rpe-cell-therapies-for-ophthalmic-diseases/2025-05-19T17:48:02+08:00https://flcube.com/innocare-pharma-doses-first-patient-in-phase-ii-iii-trial-of-tyk2-inhibitor-for-vitiligo/2025-05-19T17:42:01+08:00https://flcube.com/chinas-aim-vaccine-launches-clinical-trials-for-mrna-shingles-vaccine-in-china-and-us/2025-05-19T17:36:19+08:00https://flcube.com/suzhous-pegbio-launches-hong-kong-ipo-amid-pipeline-progress/2025-05-19T17:34:54+08:00https://flcube.com/novo-nordisk-ceo-lars-fruergaard-jorgensen-to-step-down-amid-market-challenges/2025-05-19T17:28:21+08:00https://flcube.com/bms-receives-ec-approval-for-opdivo-based-perioperative-regimen-in-nsclc/2025-05-19T17:23:45+08:00https://flcube.com/mercks-keytruda-meets-primary-endpoint-in-phase-iii-ovarian-cancer-trial/2025-05-19T17:19:17+08:00https://flcube.com/fda-approves-mercks-welireg-for-locally-advanced-or-metastatic-pheochromocytoma-and-paraganglioma/2025-05-16T15:56:15+08:00https://flcube.com/innovent-biologics-commences-phase-iii-glory-3-study-of-mazdutide-for-metabolic-dysfunction-associated-fatty-liver-disease/2025-05-16T15:50:04+08:00https://flcube.com/boehringer-ingelheim-and-tempus-forge-multi-year-ai-driven-oncology-drug-development-partnership/2025-05-16T15:40:58+08:00https://flcube.com/hainan-haiyao-and-elken-global-form-five-year-strategic-partnership-in-wellness-products/2025-05-16T15:25:38+08:00https://flcube.com/beijing-balance-medicals-renato-system-gets-nmpa-approval-for-valve-in-valve-therapy/2025-05-16T15:11:09+08:00https://flcube.com/north-china-pharma-wins-nmpa-approval-for-clinical-trials-of-recombinant-tetanus-vaccine/2025-05-16T14:35:17+08:00https://flcube.com/rznomics-and-eli-lilly-collaborate-on-rna-editing-therapies-for-sensorineural-hearing-loss/2025-05-16T13:00:22+08:00https://flcube.com/merck-kgaa-reports-q1-2025-financials-with-2-5-organic-sales-growth/2025-05-16T12:40:12+08:00https://flcube.com/cansino-biologics-gets-indonesian-approval-for-phase-i-trial-of-inhalable-tuberculosis-vaccine/2025-05-16T12:34:11+08:00https://flcube.com/haisco-pharmas-hsk21542-approved-by-nmpa-for-post-abdominal-surgery-pain/2025-05-16T12:28:03+08:00https://flcube.com/lifetech-scientifics-aortic-arch-stent-system-approved-by-chinas-nmpa/2025-05-16T12:03:02+08:00https://flcube.com/sihuan-pharmaceuticals-bireociclib-approved-by-nmpa-for-advanced-breast-cancer/2025-05-16T11:52:28+08:00https://flcube.com/canbridges-velaglucerase-%ce%b2-approved-by-nmpa-for-gauchers-disease-long-term-therapy/2025-05-16T11:14:46+08:00https://flcube.com/merck-kgaa-and-jd-health-launch-online-thyroid-care-center-in-china/2025-05-16T10:53:38+08:00https://flcube.com/novartis-scemblix-approved-by-nmpa-for-newly-diagnosed-ph-cml-cp-patients/2025-05-15T15:23:09+08:00https://flcube.com/abbvies-emrelis-granted-fda-accelerated-approval-for-nsclc-with-high-c-met-overexpression/2025-05-15T15:18:24+08:00https://flcube.com/beigene-announces-plans-to-relocate-headquarters-to-switzerland-from-cayman-islands/2025-05-15T15:06:46+08:00https://flcube.com/chengdu-kanghongs-kh607-approved-for-clinical-trials-in-postpartum-depression/2025-05-15T15:01:42+08:00https://flcube.com/nmpa-releases-updated-list-of-medical-devices-exempted-from-clinical-evaluation/2025-05-15T14:56:39+08:00https://flcube.com/boehringer-ingelheims-nerandomilast-filing-accepted-for-review-in-progressive-pulmonary-fibrosis/2025-05-15T14:51:43+08:00https://flcube.com/novartis-kisqali-receives-nmpa-approval-for-high-risk-early-breast-cancer/2025-05-15T14:46:48+08:00https://flcube.com/mgi-tech-partners-with-genoks-to-enhance-clinical-testing-services-in-turkiye/2025-05-15T14:42:15+08:00https://flcube.com/jiangsu-hengrui-pharmaceuticals-launches-hong-kong-ipo-of-h-shares/2025-05-15T14:35:07+08:00https://flcube.com/cspc-pharma-licenses-irinotecan-liposome-injection-to-cipla-for-us-market/2025-05-15T14:25:48+08:00https://flcube.com/wuhan-hamilton-biotechs-huc-mscs-product-approved-for-clinical-trials-in-premature-ovarian-failure/2025-05-15T14:16:54+08:00https://flcube.com/abbvie-pays-335-million-upfront-to-adarx-for-next-gen-sirna-therapeutics/2025-05-15T12:52:54+08:00https://flcube.com/roches-ventana-met-sp44-rxdx-assay-gains-fda-approval-for-nsq-nsclc-patients/2025-05-15T12:40:34+08:00https://flcube.com/novo-nordisk-and-septerna-ink-2-2-billion-deal-for-gpcr-drug-discovery/2025-05-15T12:27:14+08:00https://flcube.com/sanofi-announces-20-billion-investment-in-us-rd-and-manufacturing-by-2030/2025-05-15T11:26:50+08:00https://flcube.com/gsk-signs-deal-to-acquire-boston-pharmaceuticals-efimosfermin-alpha/2025-05-14T17:54:11+08:00https://flcube.com/acchrom-technologies-secures-pre-series-b-funding-to-expand-chromatography-solutions/2025-05-14T17:42:29+08:00https://flcube.com/ningbo-jansen-files-star-ipo-for-mri-technology-expansion/2025-05-14T17:27:55+08:00https://flcube.com/chinas-q1-2025-pharmaceutical-exports-rise-4-39-despite-import-decline/2025-05-14T16:54:32+08:00https://flcube.com/porton-pharma-collaborates-with-henan-hualong-for-matc-therapy-development/2025-05-14T16:42:35+08:00https://flcube.com/bayer-reports-flat-q1-revenue-amid-crop-science-decline/2025-05-14T16:32:57+08:00https://flcube.com/medilink-therapeutics-gains-fda-ind-approval-for-vegf-targeted-adc-yl242/2025-05-14T16:15:37+08:00https://flcube.com/zhongsheng-pharmas-anruiwei-shows-promising-results-in-pediatric-influenza-a-study/2025-05-14T15:48:58+08:00https://flcube.com/sinovac-biotech-gains-hong-kong-approval-for-influenza-vaccines/2025-05-14T15:38:14+08:00https://flcube.com/innocare-pharma-reports-129-92-revenue-surge-in-q1-2025-turns-profitable/2025-05-14T15:13:54+08:00https://flcube.com/nmpa-releases-92nd-batch-of-reference-drugs-for-generic-quality-evaluation/2025-05-14T15:03:55+08:00https://flcube.com/gan-lee-pharmaceuticals-signs-pdp-agreement-with-brazilian-health-ministry/2025-05-14T14:58:50+08:00https://flcube.com/zelgen-biopharmaceuticals-submits-new-indication-application-for-jacktinib-in-severe-alopecia-areata/2025-05-14T14:53:21+08:00https://flcube.com/meheco-acquires-golden-harvest-for-e-commerce-expansion/2025-05-14T14:44:23+08:00https://flcube.com/jd-healthcare-reports-25-5-revenue-growth-in-q1-2025/2025-05-14T14:18:30+08:00https://flcube.com/ocumension-therapeutics-receives-approval-for-ot-703-real-world-study-in-china/2025-05-14T12:33:22+08:00https://flcube.com/legend-biotechs-q1-2025-results-highlight-carvykti-sales-growth/2025-05-14T12:04:59+08:00https://flcube.com/sanyou-biopharmaceuticals-and-transreco-biotechnology-partner-to-advance-novel-drug-formulations/2025-05-14T11:36:54+08:00https://flcube.com/novo-nordisk-partners-with-pingan-good-doctor-to-promote-scientific-weight-loss-in-china/2025-05-14T11:15:18+08:00https://flcube.com/brl-medicine-reports-positive-results-for-tyu19-in-refractory-sle-trial/2025-05-14T11:05:26+08:00https://flcube.com/innocare-pharma-partners-with-westlake-university-for-innovative-drug-research/2025-05-14T10:54:55+08:00https://flcube.com/betta-pharmaceuticals-secures-macau-approval-for-ensartinib/2025-05-13T16:49:45+08:00https://flcube.com/oymotion-technologies-secures-rmb-100-million-in-series-b-funding-for-exoskeleton-robots/2025-05-13T16:40:48+08:00https://flcube.com/genentech-to-invest-over-700-million-in-north-carolina-drug-manufacturing-facility/2025-05-13T16:27:54+08:00https://flcube.com/huadong-medicine-presents-dr10624-study-results-for-obesity-and-hypertriglyceridemia-at-easl-2025/2025-05-13T16:22:34+08:00https://flcube.com/teva-announces-8-workforce-reduction-to-achieve-700-million-cost-saving-goal/2025-05-13T16:16:51+08:00https://flcube.com/formosa-pharmaceuticals-signs-licensing-deal-with-laboratorios-saval-for-app13007/2025-05-13T16:08:02+08:00https://flcube.com/hybio-partners-with-icarbonx-to-develop-triple-agonist-for-metabolic-diseases/2025-05-13T15:59:34+08:00https://flcube.com/tenacia-partners-with-tsh-biopharm-for-ztalmy-commercialization-in-taiwan/2025-05-13T15:45:53+08:00https://flcube.com/beigenes-sonrotoclax-gains-nmpa-priority-review-for-mcl-treatment/2025-05-13T15:38:25+08:00https://flcube.com/united-imaging-healthcare-gains-fda-approval-for-uangio-aviva-interventional-x-ray-system/2025-05-13T15:31:43+08:00https://flcube.com/trump-executive-order-seeks-to-align-us-prescription-drug-prices-with-global-standards/2025-05-13T15:26:26+08:00https://flcube.com/fosun-pharmas-fcn-159-granted-breakthrough-therapy-designation-for-pediatric-lch/2025-05-13T15:21:52+08:00https://flcube.com/merck-sharp-dohme-launches-recarbrio-in-china-for-bacterial-pneumonia-and-infections/2025-05-13T15:02:33+08:00https://flcube.com/roche-invests-550-million-in-indianapolis-diagnostics-facility-for-cgm-systems/2025-05-13T14:48:30+08:00https://flcube.com/remegens-disitamab-vedotin-phase-iii-study-meets-pfs-and-os-endpoints/2025-05-13T12:37:05+08:00https://flcube.com/eastenova-biotechnology-makes-hong-kong-ipo-debut-with-regenerative-medicine-focus/2025-05-13T12:29:48+08:00https://flcube.com/astrazenecas-trixeo-aerosphere-wins-uk-approval-for-copd/2025-05-13T11:31:49+08:00https://flcube.com/grand-pharma-completes-patient-enrollment-for-tlx591-cdx-phase-iii-trial/2025-05-13T11:23:19+08:00https://flcube.com/hengrui-pharmaceuticals-gains-nmpa-clearance-for-shr-1316-sc-in-es-sclc-trial/2025-05-12T17:08:16+08:00https://flcube.com/fosun-pharmas-lbp-shc4-receives-fda-approval-for-androgenic-alopecia-study/2025-05-12T16:55:00+08:00https://flcube.com/microports-talos-stent-gains-marketing-approval-in-argentina/2025-05-12T16:46:37+08:00https://flcube.com/hainan-unveils-20-measures-to-boost-pharmaceutical-industry-reform-and-quality/2025-05-12T16:35:48+08:00https://flcube.com/minghui-pharmaceutical-signs-licensing-deal-with-qilu-for-b7-h3-adc-development/2025-05-12T16:21:17+08:00https://flcube.com/enchannel-medical-secures-rmb-600-million-in-series-b-funding-for-electrophysiological-products/2025-05-12T16:11:48+08:00https://flcube.com/hansoh-pharmas-ameile-wins-fourth-nmpa-approval-for-nsclc-treatment/2025-05-12T16:02:43+08:00https://flcube.com/eli-lilly-and-purdue-expand-partnership-with-250-million-investment/2025-05-12T15:56:22+08:00https://flcube.com/carsgen-therapeutics-ct0596-shows-promising-results-in-early-clinical-study/2025-05-12T15:49:42+08:00https://flcube.com/cspc-receives-fda-approval-for-syh2046-in-heart-failure-after-acute-myocardial-infarction/2025-05-12T15:04:54+08:00https://flcube.com/ucb-gets-japanese-approval-for-new-administration-routes-of-rystiggo-in-gmg/2025-05-12T14:58:46+08:00https://flcube.com/shanghai-escugen-partners-with-conjugatebio-on-ezwi-fit-platform-for-adc-development/2025-05-12T14:53:57+08:00https://flcube.com/innocare-pharmas-mesutoclax-granted-breakthrough-therapy-designation-for-r-r-mcl/2025-05-12T14:39:16+08:00https://flcube.com/astrazeneca-breaks-ground-on-new-small-molecule-drug-plant-in-wuxi/2025-05-12T12:09:17+08:00https://flcube.com/iaso-biotherapeutics-fucaso-granted-orphan-drug-designation-by-sfda-for-multiple-myeloma/2025-05-12T12:03:17+08:00https://flcube.com/lepu-medicals-mwn109-gets-nmpa-clinical-approval-for-diabetes-and-obesity/2025-05-12T11:49:47+08:00https://flcube.com/remegens-disitamab-vedotin-receives-nmpa-approval-for-her2-breast-cancer-with-liver-metastasis/2025-05-12T11:41:38+08:00https://flcube.com/nmpa-grants-hengrui-pharmaceuticals-approval-for-adebrelimab-combination-trials/2025-05-12T11:07:06+08:00https://flcube.com/xtalpi-holdings-plans-acquisition-of-re-medical-for-rmb-250-million/2025-05-12T10:59:34+08:00https://flcube.com/sino-medical-sciences-gains-mexican-approval-for-coronary-balloon-catheters/2025-05-12T10:44:59+08:00https://flcube.com/abogens-abo2102-mrna-cancer-vaccine-gets-us-clinical-trial-approval/2025-05-09T18:51:05+08:00https://flcube.com/jjs-tremfya-approved-for-ulcerative-colitis-in-china/2025-05-09T18:45:05+08:00https://flcube.com/chinas-cde-reveals-93rd-batch-of-reference-preparations-for-gqce/2025-05-09T17:59:04+08:00https://flcube.com/nhc-issues-guidelines-for-geriatric-medicine-departments-construction-and-management/2025-05-09T16:03:20+08:00https://flcube.com/takeda-reports-2-8-revenue-growth-in-fiscal-2024-driven-by-product-sales/2025-05-09T15:02:21+08:00https://flcube.com/zai-lab-reports-q1-2025-revenue-growth-and-pipeline-progress/2025-05-09T14:44:21+08:00https://flcube.com/shanghai-bdgenes-bd111-gene-therapy-advances-to-phase-ii-clinical-trials/2025-05-09T14:37:47+08:00https://flcube.com/prudential-hong-kong-collaborates-with-foshan-fosun-chancheng-hospital-for-direct-payment-services/2025-05-09T14:33:06+08:00https://flcube.com/sanyou-medical-partners-with-cgbio-to-launch-regenerative-medicine-joint-venture/2025-05-09T14:24:08+08:00https://flcube.com/hengrui-pharma-files-for-new-dalpiciclib-indication-in-early-breast-cancer/2025-05-09T13:59:17+08:00https://flcube.com/gilead-sciences-announces-11-billion-investment-in-us-expansion/2025-05-09T13:52:18+08:00https://flcube.com/pfizer-partners-with-hsitp-to-boost-life-sciences-innovation-in-greater-bay-area/2025-05-09T12:37:20+08:00https://flcube.com/insilico-medicine-files-for-ipo-to-leverage-ai-in-drug-discovery/2025-05-09T12:32:07+08:00https://flcube.com/pfizers-zavicefta-approved-by-chinas-nmpa-for-severe-infections-in-all-ages/2025-05-09T12:11:28+08:00https://flcube.com/amgens-tepezza-approved-in-uk-for-thyroid-eye-disease-treatment/2025-05-09T12:05:17+08:00https://flcube.com/guangzhou-regenverse-therapeutics-raises-rmb-100-million-in-pre-series-a-financing/2025-05-08T21:00:28+08:00https://flcube.com/novo-nordisk-reports-18-yoy-revenue-growth-in-q1-2025/2025-05-08T19:28:52+08:00https://flcube.com/sino-biopharmaceutical-and-jd-healthcare-forge-comprehensive-strategic-partnership/2025-05-08T16:21:11+08:00https://flcube.com/adicon-holdings-acquires-suzhou-youqin-medical-laboratory-and-yuande-weikang/2025-05-08T16:15:01+08:00https://flcube.com/oricell-partners-with-umoja-biopharma-to-develop-in-vivo-car-t-cell-therapies/2025-05-08T16:07:15+08:00https://flcube.com/beigenes-q1-2025-revenues-soar-49-yoy-driven-by-brukinsa-global-sales/2025-05-08T15:46:52+08:00https://flcube.com/european-commission-approves-jjs-tremfya-for-crohns-disease-treatment/2025-05-08T14:51:49+08:00https://flcube.com/amgen-reports-9-revenue-growth-in-q1-2025-driven-by-double-digit-product-sales/2025-05-08T14:38:33+08:00https://flcube.com/astrazeneca-and-daiichi-sankyo-announce-positive-destiny-breast11-trial-results-for-enhertu/2025-05-08T14:27:47+08:00https://flcube.com/siemens-healthineers-reports-q2-2025-revenue-up-6-8-to-eur-5-909-billion/2025-05-08T12:09:37+08:00https://flcube.com/grand-pharma-receives-nmpa-review-for-phase-iii-trial-of-tlx591-in-prostate-cancer/2025-05-08T11:48:38+08:00https://flcube.com/biogen-reports-8-yoy-sales-growth-in-q1-2025-driven-by-rare-disease-therapies/2025-05-07T14:35:38+08:00https://flcube.com/zhongsheng-pharmas-ray1225-shows-positive-results-in-phase-ii-trials-for-weight-loss-and-blood-glucose-reduction/2025-05-07T14:26:28+08:00https://flcube.com/alchemab-therapeutics-licenses-atlx-1282-to-eli-lilly-for-als-treatment/2025-05-07T14:20:28+08:00https://flcube.com/chinas-nmpa-releases-draft-guidelines-for-development-risk-management-plan/2025-05-07T14:13:21+08:00https://flcube.com/astrazenecas-calquence-gains-eu-approval-for-mantle-cell-lymphoma/2025-05-07T14:07:03+08:00https://flcube.com/huadong-medicines-hdm2005-receives-nmpa-approval-for-dlbcl-clinical-trial/2025-05-07T11:56:06+08:00https://flcube.com/fresenius-medical-care-reports-1-revenue-growth-in-q1-2025/2025-05-07T11:49:40+08:00https://flcube.com/innovent-biologics-completes-first-dosing-in-phase-ii-study-for-efdamrofusp-alfa-in-dme/2025-05-07T11:43:26+08:00https://flcube.com/endocell-secures-rmb-200-million-in-financing-to-advance-islet-regeneration-technology/2025-05-07T11:32:44+08:00https://flcube.com/beijing-wantais-hiv-urine-self-test-kit-gains-who-prequalification/2025-05-07T10:56:25+08:00https://flcube.com/formosa-pharmaceuticals-licenses-clobetasol-propionate-to-apotex-for-mexico/2025-05-07T10:41:20+08:00https://flcube.com/shuangcheng-pharmas-generic-bivalirudin-approved-by-australias-tga/2025-05-07T10:21:53+08:00https://flcube.com/everest-medicines-nefecon-receives-full-approval-from-nmpa-for-igan-treatment/2025-05-07T09:58:33+08:00https://flcube.com/novartis-to-acquire-regulus-therapeutics-for-up-to-1-7-billion/2025-05-06T17:40:07+08:00https://flcube.com/cspcs-jmt202-receives-fda-ind-approval-for-hypertriglyceridemia-trials/2025-05-06T17:14:19+08:00https://flcube.com/guilin-sanjins-bc006-monoclonal-antibody-gains-nmpa-approval-for-ipf-trials/2025-05-06T16:47:14+08:00https://flcube.com/innovent-biologics-presents-positive-ibi302-results-for-namd-at-arvo-2025/2025-05-06T16:30:24+08:00https://flcube.com/accuredit-therapeutics-art001-shows-promising-results-in-attr-treatment/2025-05-06T16:22:37+08:00https://flcube.com/novo-nordisks-once-daily-wegovy-nda-accepted-for-fda-review/2025-05-06T16:00:53+08:00https://flcube.com/nanjing-perlove-medical-equipment-files-ipo-application-in-hong-kong/2025-05-06T15:49:50+08:00https://flcube.com/sanofis-opella-becomes-independent-consumer-healthcare-company-after-cdr-deal/2025-05-06T15:42:06+08:00https://flcube.com/johnson-johnsons-imaavy-gains-fda-approval-for-generalized-myasthenia-gravis/2025-05-06T15:16:26+08:00https://flcube.com/chengdu-origen-announces-first-patient-dosing-of-kh658-in-wet-amd-trial/2025-05-06T15:10:48+08:00https://flcube.com/chinas-13-ministries-release-guidance-to-optimize-primary-healthcare-institutions/2025-05-06T14:54:32+08:00https://flcube.com/astrazenecas-breztri-aerosphere-meets-primary-endpoints-in-phase-iii-asthma-trials/2025-05-06T14:48:05+08:00https://flcube.com/eli-lilly-reports-45-yoy-sales-growth-in-q1-2025-driven-by-mounjaro-and-zepbound/2025-05-06T14:42:42+08:00https://flcube.com/eucerin-partners-with-guangzhou-united-family-hospital-for-dermatology-services/2025-05-06T14:32:38+08:00https://flcube.com/alphamab-and-cspc-announce-positive-interim-results-for-kn026-in-her2-gastric-cancer-trial/2025-05-06T14:12:39+08:00https://flcube.com/innovent-biologics-initiates-first-in-human-dosing-of-ibi3020-in-phase-i-trial/2025-04-30T22:20:12+08:00https://flcube.com/dizal-pharmaceutical-reports-strong-revenue-growth-in-2024-and-q1-2025/2025-04-30T22:10:59+08:00https://flcube.com/ipsen-and-shanghai-pharmaceutical-partner-to-expand-diphereline-coverage-in-china/2025-04-30T21:56:35+08:00https://flcube.com/novartis-q1-2025-results-net-sales-up-15-yoy-strong-growth-in-key-brands/2025-04-30T21:48:17+08:00https://flcube.com/merck-sharp-dohme-announces-1-billion-biologics-center-in-wilmington-delaware/2025-04-30T21:33:02+08:00https://flcube.com/eli-lilly-partners-with-creyon-bio-to-develop-rna-targeted-therapies/2025-04-30T21:27:11+08:00https://flcube.com/abbvies-rinvoq-gains-fda-approval-for-giant-cell-arteritis/2025-04-30T12:43:13+08:00https://flcube.com/bayer-ag-launches-phase-i-study-of-225ac-gpc3-for-advanced-hepatocellular-carcinoma/2025-04-30T12:34:52+08:00https://flcube.com/itcure-and-obio-technology-partner-to-advance-gene-editing-and-vlp-delivery-systems/2025-04-30T12:30:05+08:00https://flcube.com/fosun-pharma-partners-with-fakeeh-care-group-to-advance-biopharmaceuticals-in-saudi-arabia/2025-04-30T12:21:37+08:00https://flcube.com/fosun-pharma-reports-q1-2025-revenues-of-rmb-9-42-billion-net-profits-of-rmb-765-million/2025-04-30T12:15:26+08:00https://flcube.com/roches-ventana-trop2-device-receives-fda-breakthrough-designation/2025-04-30T12:04:31+08:00https://flcube.com/hengrui-pharmaceuticals-receives-nmpa-clearance-for-hrs-5635-in-chronic-hbv/2025-04-30T11:57:32+08:00https://flcube.com/fosun-pharmas-henlius-strikes-deal-with-sandoz-for-global-rights-to-hlx13-biosimilar/2025-04-30T11:48:26+08:00https://flcube.com/beigene-wins-uspto-ruling-invalidating-pharmacyclics-patent-claims/2025-04-30T11:35:16+08:00https://flcube.com/astrazenecas-q1-2025-results-10-revenue-growth-oncology-segment-shines/2025-04-30T11:25:56+08:00https://flcube.com/pfizers-q1-2025-results-revenues-down-6-yoy-amid-paxlovid-ira-impact/2025-04-30T11:03:07+08:00https://flcube.com/united-imaging-healthcare-reports-9-73-revenue-decline-in-2024-financials/2025-04-29T21:18:59+08:00https://flcube.com/innovent-biologics-expands-clinical-partnership-with-immvirx-to-include-hepatocellular-carcinoma/2025-04-29T21:06:42+08:00https://flcube.com/boehringer-ingelheims-zongertinib-shows-promising-results-in-her2-mutant-nsclc-trial/2025-04-29T20:59:49+08:00https://flcube.com/kangpu-biopharmaceuticals-receives-nmpa-approval-for-kpg-818-phase-iib-study-in-sle/2025-04-29T15:04:33+08:00https://flcube.com/wuxi-apptec-reports-21-0-yoy-revenue-growth-in-q1-2025/2025-04-29T14:58:00+08:00https://flcube.com/frontera-therapeutics-gene-therapy-ft-017-gains-clinical-trial-approvals-for-hcm/2025-04-29T14:51:21+08:00https://flcube.com/johnson-johnsons-tar-200-shows-promising-results-in-phase-iib-sunrise-1-study-for-bladder-cancer/2025-04-29T14:45:47+08:00https://flcube.com/regenerons-lynozyfic-gains-ec-conditional-approval-for-relapsed-multiple-myeloma/2025-04-29T14:39:09+08:00https://flcube.com/nmpa-issues-new-quality-management-standards-for-online-medical-device-sales/2025-04-29T14:28:48+08:00https://flcube.com/beigenes-sonrotoclax-nda-accepted-by-nmpa-for-cll-sll-treatment/2025-04-29T14:22:47+08:00https://flcube.com/nhsa-launches-intelligent-supervision-reform-pilot-in-designated-medical-institutions/2025-04-29T14:13:51+08:00https://flcube.com/shanghai-pharmaceuticals-posts-modest-q1-revenue-growth-sees-profit-decline/2025-04-29T12:34:46+08:00https://flcube.com/our-united-corporation-files-for-ipo-in-hong-kong-stock-exchange/2025-04-29T12:28:11+08:00https://flcube.com/henlius-biotechs-hlx22-receives-clinical-trial-approval-in-germany-for-her2-positive-cancers/2025-04-29T12:17:58+08:00https://flcube.com/genscript-to-acquire-additional-stake-in-probio-cayman-for-usd-225-1-million/2025-04-29T12:12:04+08:00https://flcube.com/cspc-pharmaceutical-reports-7-8-revenue-decline-in-2024-amid-vbp-impact/2025-04-29T12:05:20+08:00https://flcube.com/innovent-biologics-posts-51-8-yoy-revenue-growth-in-2024-financial-report/2025-04-29T11:46:32+08:00https://flcube.com/hengrui-pharmaceuticals-gains-nmpa-clinical-clearance-for-camrelizumab-in-acral-melanoma/2025-04-28T15:24:35+08:00https://flcube.com/shouyao-holdings-gets-ethics-approval-for-sy-5933-phase-ib-ii-study-in-kras-g12c-mutated-tumors/2025-04-28T15:16:04+08:00https://flcube.com/sihuan-pharmas-polycaprolactone-microsphere-filler-gains-nmpa-approval/2025-04-28T15:13:30+08:00https://flcube.com/shouyao-holdings-unveils-rmb787-million-investment-in-beijing-biopark-rd-and-gmp-facility/2025-04-28T15:07:28+08:00https://flcube.com/biokins-bl-b01d1-secures-nmpa-green-light-for-two-phase-ii-clinical-trials-in-gynecological-cancers/2025-04-28T14:58:23+08:00https://flcube.com/boehringer-ingelheim-biopharmaceuticals-china-completes-pmda-gmp-inspection-for-japan-market-supply/2025-04-28T14:45:49+08:00https://flcube.com/centrymeds-cmde005-bispecific-antibody-receives-fda-clinical-approval-for-egfr-positive-tumors/2025-04-28T13:01:52+08:00https://flcube.com/pfizers-inlyta-receives-nmpa-approval-for-first-line-renal-cell-carcinoma-combination-therapy/2025-04-28T12:45:35+08:00https://flcube.com/anglikang-pharmaceutical-receives-nmpa-clinical-clearance-for-alk-n001-in-advanced-solid-tumors/2025-04-28T12:40:50+08:00https://flcube.com/grand-pharmas-acornmed-utlife-uc-urothelial-carcinoma-assay-first-prescription-administered-in-china/2025-04-28T11:55:41+08:00https://flcube.com/sihuan-pharmaceutical-wins-nmpa-approval-for-polylactic-acid-facial-filler/2025-04-28T11:45:15+08:00https://flcube.com/roches-q1-2025-results-pharma-sales-drive-8-growth-amidst-flat-diagnostics/2025-04-28T11:01:20+08:00https://flcube.com/bms-q1-2025-results-opdivo-sales-up-12-despite-overall-revenue-decline/2025-04-28T10:54:43+08:00https://flcube.com/merck-q1-2025-results-keytruda-sales-grow-6-despite-gardasil-dip-in-china/2025-04-27T18:39:31+08:00https://flcube.com/hengrui-pharmaceuticals-receives-nmpa-clearance-for-phase-ii-trial-of-shr-4849-shr-8068-and-adebrelimab-in-advanced-solid-tumors/2025-04-27T18:21:49+08:00https://flcube.com/innocare-pharmas-orelabrutinib-gains-nmpa-approval-for-first-line-cll-sll-treatment/2025-04-27T18:14:12+08:00https://flcube.com/chipscreen-biosciences-cuts-private-placement-proceeds-to-rmb-950-million/2025-04-27T18:08:42+08:00https://flcube.com/shanghai-junshi-biosciences-loqtorzi-receives-nmpa-approval-for-melanoma-treatment/2025-04-27T18:01:44+08:00https://flcube.com/innovent-biologics-aoyixin-wins-nmpa-approval-for-first-line-nsclc-treatment/2025-04-27T17:55:06+08:00https://flcube.com/cspc-pharmaceutical-group-gains-nmpa-approval-for-syh2068-sirna-clinical-trials/2025-04-27T17:47:36+08:00https://flcube.com/grand-pharma-group-and-sirtex-medical-us-launch-commercial-partnership-in-medical-innovation/2025-04-27T17:39:22+08:00https://flcube.com/shanghai-henlius-and-alvogen-korea-ink-licensing-deal-for-hansizhuang-serplulimab/2025-04-27T17:26:51+08:00https://flcube.com/digital-intelligent-transformation-of-chinas-pharmaceutical-industry-2025-2030-plan-unveiled/2025-04-27T17:18:06+08:00https://flcube.com/zhejiang-jolly-pharma-invests-in-lingyi-biotech-for-gene-therapy-development/2025-04-27T17:03:19+08:00https://flcube.com/johnson-johnsons-rybrevant-gains-nmpa-approval-for-expanded-lung-cancer-indication/2025-04-27T16:54:16+08:00https://flcube.com/ltz-therapeutics-secures-40m-series-a-to-advance-immunotherapy-pipeline/2025-04-27T16:43:42+08:00https://flcube.com/amgen-announces-900m-investment-to-expand-ohio-manufacturing/2025-04-27T16:37:50+08:00https://flcube.com/johnson-johnsons-tremfya-approved-by-ec-for-ulcerative-colitis-treatment/2025-04-27T16:32:45+08:00https://flcube.com/keymed-biosciences-gains-nmpa-approval-for-phase-i-ii-study-of-cm518d1/2025-04-27T16:26:06+08:00https://flcube.com/akesos-ivonescimab-approved-by-nmpa-for-first-line-pd-l1-positive-nsclc/2025-04-27T16:08:01+08:00https://flcube.com/hefei-lifeon-gains-nmpa-approval-for-nexletol-clinical-trials-in-china/2025-04-26T00:51:49+08:00https://flcube.com/fujian-cosunter-gains-nmpa-clearance-for-phase-ii-hbv-study-of-gst-hg131-and-gst-hg141/2025-04-26T00:39:26+08:00https://flcube.com/anhui-ankes-allogeneic-car-t-therapy-utaa09-approved-for-r-r-b-all-trials/2025-04-25T23:31:33+08:00https://flcube.com/juventas-cell-therapys-cnct-19-gains-nmpa-approval-for-refractory-lupus-nephritis/2025-04-25T17:47:48+08:00https://flcube.com/tyk-medicines-submits-pre-nda-package-for-asandeutertinib-in-nsclc-brain-metastasis/2025-04-25T17:37:16+08:00https://flcube.com/microport-scientifics-mri-conditional-alizea-hybrid-pacing-system-secures-ce-certification/2025-04-25T17:33:00+08:00https://flcube.com/abbvie-files-bla-for-trenibote-in-moderate-to-severe-glabellar-lines-treatment/2025-04-25T17:25:20+08:00https://flcube.com/genfleets-kras-g12d-inhibitor-gfh375-vs-7375-gains-fda-trial-approval/2025-04-25T17:18:09+08:00https://flcube.com/innate-pharma-and-sanofi-restructure-2016-research-agreement-on-cd123-anket-drug/2025-04-25T17:12:30+08:00https://flcube.com/medtronic-submits-510k-applications-for-interoperable-diabetes-management-system/2025-04-25T17:02:51+08:00https://flcube.com/thermo-fisher-announces-2-billion-us-investment-to-strengthen-life-sciences-infrastructure/2025-04-25T16:54:41+08:00https://flcube.com/merck-kgaa-nears-completion-of-3-5-billion-acquisition-of-springworks-therapeutics/2025-04-25T16:45:16+08:00https://flcube.com/cn-bio-and-pharmaron-partner-to-validate-and-expand-ooc-technology-applications/2025-04-25T16:41:23+08:00https://flcube.com/gan-lee-pharmaceuticals-reports-417-million-usd-revenue-and-80-75-profit-surge-in-2024/2025-04-25T16:31:26+08:00https://flcube.com/hepalink-secures-sahpra-approval-for-ivenoxin-in-south-africa/2025-04-25T16:24:35+08:00https://flcube.com/akesos-penpulimab-gains-fda-approval-for-nasopharyngeal-carcinoma-treatment/2025-04-25T12:51:24+08:00https://flcube.com/sanofi-reports-q1-sales-growth-driven-by-dupixent-and-new-product-launches/2025-04-25T12:42:53+08:00https://flcube.com/baheal-partners-with-jiluntai-for-commercialization-of-technetium-99m-labeled-imaging-agent/2025-04-24T17:18:09+08:00https://flcube.com/shineco-inc-announces-acquisition-of-infiniclone-for-regenerative-medicine-expansion/2025-04-24T17:05:31+08:00https://flcube.com/shenzhen-core-medical-closes-series-d-round-to-advance-miniaturized-artificial-hearts/2025-04-24T16:54:13+08:00https://flcube.com/doer-biologics-begins-phase-ii-study-of-dr10624-for-steatotic-liver-disease/2025-04-24T16:48:45+08:00https://flcube.com/boehringer-ingelheim-partners-with-tessellate-bio-on-alt-cancer-therapies/2025-04-24T16:10:46+08:00https://flcube.com/genentech-collaborates-with-repertoire-immune-medicines-on-autoimmune-disease-therapies/2025-04-24T16:01:53+08:00https://flcube.com/astrazeneca-expands-ai-partnership-with-tempus-ai-and-pathos-ai-for-oncology-research/2025-04-24T15:48:35+08:00https://flcube.com/boston-scientific-reports-20-9-revenue-growth-in-q1-2025-financial-results/2025-04-24T15:38:27+08:00https://flcube.com/roche-launches-navify-chest-pain-triage-algorithm-with-ce-mark/2025-04-24T15:32:14+08:00https://flcube.com/trump-administration-considers-tying-us-drug-prices-to-international-benchmarks/2025-04-24T15:25:00+08:00https://flcube.com/pingan-good-doctor-reports-q1-2025-revenue-growth-and-net-profit-turnaround/2025-04-24T12:13:49+08:00https://flcube.com/microport-medbot-gains-nmpa-clearance-for-toumais-remote-surgery-across-departments/2025-04-24T12:02:03+08:00https://flcube.com/qyuns-therapeutics-signs-global-licensing-deal-with-caldera-for-autoimmune-bsab/2025-04-24T11:37:39+08:00https://flcube.com/roche-unveils-50-billion-five-year-us-investment-plan-to-expand-manufacturing-and-rd/2025-04-23T18:13:31+08:00https://flcube.com/china-medical-system-announces-spin-off-of-dermavon-for-hkex-ipo/2025-04-23T18:07:17+08:00https://flcube.com/bmss-cobenfy-shows-promise-in-phase-iii-arise-trial-for-schizophrenia/2025-04-23T17:45:03+08:00https://flcube.com/cspc-gains-nmpa-approval-for-phase-iii-trial-of-prusogliptin-metformin-fdc/2025-04-23T17:38:05+08:00https://flcube.com/cspc-pharmaceutical-gains-fda-ind-clearance-for-jmt203-in-cancer-cachexia/2025-04-23T17:22:24+08:00https://flcube.com/grand-pharma-secures-nmpa-approval-for-fluticasone-nasal-spray/2025-04-23T17:14:16+08:00https://flcube.com/biokin-receives-nmpa-approval-for-cd33-adc-in-aml-trial/2025-04-23T17:03:46+08:00https://flcube.com/fujifilm-diosynth-secures-3-billion-us-manufacturing-pact-with-regeneron/2025-04-23T16:42:32+08:00https://flcube.com/hotgen-biotech-injects-rmb-300-million-into-subsidiary-sungen-bio-for-biologic-rd/2025-04-23T16:33:22+08:00https://flcube.com/nmpa-issues-91st-batch-of-reference-standards-for-generic-drug-quality-evaluation/2025-04-23T15:58:37+08:00https://flcube.com/united-innomed-closes-rmb-100-million-series-b-funding-for-heart-failure-devices/2025-04-23T15:51:40+08:00https://flcube.com/novocure-wins-ce-mark-for-optune-lua-in-metastatic-nsclc-treatment/2025-04-23T14:57:39+08:00https://flcube.com/jw-therapeutics-enters-licensing-pact-with-juno-therapeutics-for-slvv-process/2025-04-23T14:44:33+08:00https://flcube.com/imbioray-gains-nmpa-approval-for-phase-iitrial-of-ibr854-in-advanced-rcc/2025-04-23T14:28:46+08:00https://flcube.com/ascletis-pharma-announces-positive-phase-ib-results-for-asc30-in-obesity-treatment/2025-04-23T14:17:36+08:00https://flcube.com/delonix-partners-with-wuxi-vaccines-to-advance-omv-plus-platform-for-bacterial-vaccines/2025-04-23T14:05:44+08:00https://flcube.com/akesos-ivonescimab-shows-strong-results-in-phase-iii-trial-for-sq-nsclc/2025-04-23T13:47:45+08:00https://flcube.com/bms-secures-nmpa-approval-for-opdivo-in-resectable-nsclc-neoadjuvant-therapy/2025-04-22T18:41:12+08:00https://flcube.com/astrazenecas-ultomiris-approved-in-china-for-generalized-myasthenia-gravis/2025-04-22T18:37:05+08:00https://flcube.com/zai-labs-augtyro-nda-accepted-by-chinas-nmpa-for-ntrk-fusion-solid-tumors/2025-04-22T18:32:48+08:00https://flcube.com/viatris-submits-marketing-application-for-effexor-sr-in-japan-for-generalized-anxiety-disorder/2025-04-22T18:23:33+08:00https://flcube.com/dizal-pharma-secures-rmb-1-796-billion-private-placement-to-advance-rd-and-facilities/2025-04-22T18:09:23+08:00https://flcube.com/bio-thera-solutions-gains-nmpa-clinical-approval-for-bat7111-in-advanced-solid-tumors/2025-04-22T18:02:01+08:00https://flcube.com/ascentage-pharmas-oncology-drugs-lisaftoclax-and-olverembatinib-gain-csco-guidelines-inclusion/2025-04-22T17:54:56+08:00https://flcube.com/gan-lees-gzr102-receives-nmpa-clinical-trial-clearance-for-type-2-diabetes/2025-04-22T17:48:31+08:00https://flcube.com/chinas-medical-insurance-payment-reform-achieves-nationwide-coverage-faces-challenges-ahead/2025-04-22T17:35:22+08:00https://flcube.com/regenerons-eylea-hd-receives-fda-complete-response-letter-despite-priority-review/2025-04-22T17:08:39+08:00https://flcube.com/hengrui-gains-nmpa-approval-for-phase-iii-study-of-shr-8068-in-pd-l1-negative-nsclc/2025-04-22T17:01:51+08:00https://flcube.com/kelun-biotech-gains-fda-clearance-for-phase-i-trial-of-adc-skb518/2025-04-22T16:53:57+08:00https://flcube.com/grand-pharmas-gpn02006-shows-promising-hcc-diagnostic-results-in-trial/2025-04-22T16:26:25+08:00https://flcube.com/shanghai-operation-robot-secures-rmb-100-million-series-c-funding-for-ai-driven-surgical-robot-development/2025-04-22T16:13:05+08:00https://flcube.com/novo-nordisk-partners-with-jd-healthcare-to-advance-obesity-and-diabetes-management/2025-04-22T14:33:55+08:00https://flcube.com/novo-nordisks-wegovy-gets-nmpa-label-update-for-cardiovascular-risk-reduction/2025-04-22T14:27:11+08:00https://flcube.com/broncus-medical-secures-nmpa-approval-for-broncablate-in-lung-cancer-treatment/2025-04-22T14:20:10+08:00https://flcube.com/rona-therapeutics-wins-nmpa-ind-approval-for-sirna-hypertension-drug-rn1871/2025-04-22T13:54:49+08:00https://flcube.com/shanghai-pharmaceuticals-partners-with-organon-to-market-womens-health-products-in-china/2025-04-22T12:10:49+08:00https://flcube.com/hutchmed-completes-patient-enrollment-for-orpathys-in-gastric-cancer-trial/2025-04-22T11:47:10+08:00https://flcube.com/shanghai-healthcare-administration-pushes-for-11th-round-of-vbp/2025-04-21T20:19:05+08:00https://flcube.com/akesos-ebdarokimab-receives-nmpa-approval-for-moderate-to-severe-plaque-psoriasis/2025-04-21T17:01:11+08:00https://flcube.com/vivolights-multimodal-coronary-oct-system-gains-fda-clearance/2025-04-21T16:35:21+08:00https://flcube.com/belief-biomed-gains-nmpa-clinical-trial-approval-for-dmd-gene-therapy-bbm-d101/2025-04-21T16:26:38+08:00https://flcube.com/sanofis-dupixent-approved-by-fda-for-chronic-spontaneous-urticaria/2025-04-21T15:40:59+08:00https://flcube.com/biogens-high-dose-spinraza-regimen-accepted-for-cde-review-in-china/2025-04-21T15:34:00+08:00https://flcube.com/sichuan-biokin-gains-nmpa-approval-for-phase-ii-trials-of-bl-b01d1-in-combination-therapies/2025-04-21T15:28:40+08:00https://flcube.com/walvax-biotech-gains-nmpa-clinical-clearance-for-20-valent-pneumococcal-vaccine/2025-04-21T15:10:53+08:00https://flcube.com/asieris-pharmaceuticals-reports-strong-2024-financial-results-for-urogenital-cancer-drugs/2025-04-21T15:02:59+08:00https://flcube.com/shandong-lukang-plans-private-placement-to-raise-rmb1-2-billion-for-drug-development/2025-04-21T14:42:23+08:00https://flcube.com/dizals-golidocitinib-receives-csco-class-1-recommendation-for-ptcl-treatment/2025-04-21T12:22:40+08:00https://flcube.com/humanwell-healthcare-gains-nmpa-approval-for-hws116-clinical-trials-in-advanced-solid-tumors/2025-04-21T12:12:09+08:00https://flcube.com/medtronic-wins-fda-approval-for-simplera-sync-sensor-in-minimed-780g-system/2025-04-21T11:54:12+08:00https://flcube.com/suzhou-zelgen-gains-nmpa-approval-for-zg006-in-small-cell-lung-cancer-study/2025-04-21T11:48:50+08:00https://flcube.com/hengrui-pharmaceuticals-gains-nmpa-approval-for-phase-ib-ii-trials-of-hrs-1167-and-shr-4658/2025-04-21T11:43:32+08:00https://flcube.com/astrazenecas-truqap-granted-nmpa-approval-for-breast-cancer-treatment/2025-04-21T11:30:19+08:00https://flcube.com/novo-nordisks-sogroya-approved-for-use-in-boao-lecheng-medical-zone/2025-04-21T11:20:04+08:00https://flcube.com/regenerons-eylea-hd-receives-fda-priority-review-for-macular-edema-treatment/2025-04-18T18:55:23+08:00https://flcube.com/brl-medicine-secures-ind-approval-for-brl-301-car-t-therapy-in-r-r-b-nhl/2025-04-18T18:49:58+08:00https://flcube.com/sanofi-licenses-first-in-class-bsabs-from-earendil-labs-for-autoimmune-and-ibd-treatment/2025-04-18T18:36:17+08:00https://flcube.com/bayer-commissions-pennsylvania-facility-expansion-after-44-million-investment/2025-04-18T18:27:32+08:00https://flcube.com/takedas-adzynma-beigenes-sonrotoclax-and-avistones-andatinib-set-for-priority-review-in-china/2025-04-18T18:24:06+08:00https://flcube.com/velavigo-and-ollin-biosciences-ink-licensing-deal-for-first-in-class-bsab-vbs-102/2025-04-18T18:13:47+08:00https://flcube.com/eli-lillys-orforglipron-meets-primary-endpoint-in-phase-iii-achieve-1-trial-for-type-2-diabetes/2025-04-18T18:00:36+08:00https://flcube.com/3sbios-707-bispecific-antibody-receives-btd-for-first-line-nsclc-in-china/2025-04-18T17:53:04+08:00https://flcube.com/neushen-therapeutics-closes-series-a-funding-for-cns-disorder-drug-development/2025-04-18T17:39:47+08:00https://flcube.com/la-prairie-holistic-healths-functional-nutrient-product-approved-in-hainan-pilot-zone/2025-04-18T15:43:12+08:00https://flcube.com/gsks-arexvy-rsv-vaccine-receives-favorable-acip-vote-for-adults-aged-50-59/2025-04-18T15:34:31+08:00https://flcube.com/gene-cradle-gains-nmpa-approval-for-phase-iii-trial-of-gc101-in-type-ii-5q-spinal-muscular-atrophy/2025-04-18T15:24:16+08:00https://flcube.com/medtronics-implantable-defibrillator-system-gains-nmpa-approval-in-china/2025-04-18T15:14:05+08:00https://flcube.com/zhaoke-ophthalmology-enrolls-first-patient-for-cyclosporine-a-eye-gel-phase-iii-study/2025-04-18T15:08:04+08:00https://flcube.com/illumina-and-tempus-ai-collaborate-to-advance-next-generation-sequencing-in-clinical-practice/2025-04-18T14:57:49+08:00https://flcube.com/junion-therapeutics-secures-rmb-100-million-series-a-financing-for-weight-loss-device/2025-04-18T14:36:46+08:00https://flcube.com/eli-lilly-collaborates-with-bighat-biosciences-to-engineer-advanced-therapeutic-antibodies/2025-04-18T14:17:23+08:00https://flcube.com/shanghai-henlius-initiates-phase-ii-study-of-hlx22-in-her2-low-breast-cancer/2025-04-18T13:52:41+08:00https://flcube.com/gsks-blenrep-approved-by-uk-mhra-for-multiple-myeloma-treatment/2025-04-18T13:35:14+08:00https://flcube.com/salubris-pharmas-yolt-101-gene-editing-drug-accepted-for-nmpa-review/2025-04-18T13:27:50+08:00https://flcube.com/hansohs-hs-20093-adc-earns-btd-for-advanced-nsclc-from-chinas-nmpa/2025-04-18T13:15:31+08:00https://flcube.com/akeso-biopharma-partners-with-virogin-to-test-ivonescimab-and-vg201-in-colorectal-cancer-trial-2/2025-04-17T21:48:25+08:00https://flcube.com/chengdu-kanghong-gains-nmpa-approval-for-kh815-in-advanced-solid-tumors/2025-04-17T21:38:13+08:00https://flcube.com/avistones-vebreltinib-and-plb1004-receive-cde-breakthrough-therapy-designation-for-nsclc/2025-04-17T21:29:11+08:00https://flcube.com/apollomics-partner-avistone-wins-conditional-approval-for-c-met-inhibitor-in-china/2025-04-17T21:24:47+08:00https://flcube.com/bain-capital-to-acquire-tanabe-pharma-in-jpy-510-billion-deal/2025-04-17T21:23:43+08:00https://flcube.com/beijing-avistone-pharmaceuticals-raises-rmb-1-billion-in-series-b-funding-to-accelerate-drug-development/2025-04-17T21:22:41+08:00https://flcube.com/shanghai-pharmaceuticals-rmb-4-66-billion-ma-fund-completes-amac-registration/2025-04-17T21:18:09+08:00https://flcube.com/zhaoke-ophthalmology-signs-distribution-agreements-with-thailands-interpharma-for-myopia-and-presbyopia-treatments/2025-04-17T19:53:57+08:00https://flcube.com/eisai-and-biogen-win-eu-approval-for-leqembi-in-early-alzheimers-disease/2025-04-17T19:47:37+08:00https://flcube.com/jiangsu-wuzhong-pharma-faces-forced-delisting-after-csrc-investigation/2025-04-17T19:40:48+08:00https://flcube.com/sichuan-biokins-bl-m09d1-adc-receives-nmpa-clinical-trial-clearance-for-solid-tumors/2025-04-17T19:33:15+08:00https://flcube.com/da-ren-tang-sells-stake-in-tianjin-shike-to-haleon-for-rmb-1-623-billion/2025-04-17T19:17:36+08:00https://flcube.com/akeso-biopharma-partners-with-virogin-to-test-ivonescimab-and-vg201-in-colorectal-cancer-trial/2025-04-17T18:59:46+08:00https://flcube.com/berry-genomics-collaborates-with-beijing-childrens-hospital-on-newborn-birth-defects-screening-project/2025-04-17T18:51:47+08:00https://flcube.com/trump-orders-hhs-to-reduce-drug-prices-revamp-medicare-negotiation-program/2025-04-17T15:14:33+08:00https://flcube.com/galderma-launches-sculptra-in-china-as-first-regenerative-biostimulator/2025-04-16T16:49:49+08:00https://flcube.com/easton-pharmas-ep-9001a-shows-promising-results-in-phase-ib-for-bone-metastasis-cancer-pain/2025-04-16T16:42:17+08:00https://flcube.com/edwards-lifesciences-gains-eu-ce-mark-for-sapien-m3-mitral-valve-system/2025-04-16T15:13:51+08:00https://flcube.com/innocare-pharmas-zurletrectinib-nda-accepted-by-chinas-cde-for-trk-fusion-cancers/2025-04-16T15:08:01+08:00https://flcube.com/nhc-releases-standardized-family-doctor-service-packages-for-key-demographic-groups/2025-04-16T14:56:35+08:00https://flcube.com/kosell-medtech-partners-with-wenzhou-medical-university-on-k-sheath-system/2025-04-16T14:51:53+08:00https://flcube.com/sichuan-biokin-secures-four-phase-ii-approvals-for-bl-b01d1-in-combination-therapies/2025-04-16T11:47:49+08:00https://flcube.com/hansoh-pharmaceutical-gains-clinical-approval-for-kras-g12d-targeted-drug-hs-10529/2025-04-16T11:43:38+08:00https://flcube.com/accuredit-therapeutics-reports-positive-24-week-data-for-art002-in-hefh-patients/2025-04-16T11:37:03+08:00https://flcube.com/cyprumed-signs-non-exclusive-license-agreement-with-msd-for-oral-peptide-delivery-tech/2025-04-16T11:24:29+08:00https://flcube.com/us-commerce-department-launches-section-232-probe-on-pharma-imports-and-national-security/2025-04-16T10:44:41+08:00https://flcube.com/johnson-johnson-reports-q1-2025-revenue-growth-led-by-innovative-medicines-and-medtech/2025-04-16T10:32:44+08:00https://flcube.com/bms-faces-phase-iii-setback-for-camzyos-in-non-obstructive-hcm-study/2025-04-15T15:18:09+08:00https://flcube.com/beijing-wantai-launches-phase-iii-trial-for-9-valent-hpv-vaccine-in-chinese-males/2025-04-15T15:13:11+08:00https://flcube.com/jiangsu-nhwa-initiates-phase-i-trial-for-nh280105-an-oral-lp-pla%e2%82%82-inhibitor-for-alzheimers-disease/2025-04-15T14:58:21+08:00https://flcube.com/hengrui-pharmaceuticals-gains-nmpa-clearance-for-phase-ii-study-of-hrs-7058-in-solid-tumors/2025-04-15T14:46:03+08:00https://flcube.com/pfizer-halts-development-of-danuglipron-due-to-drug-induced-liver-injury-case/2025-04-15T14:35:58+08:00https://flcube.com/roches-columvi-approved-by-ec-for-relapsed-dlbcl-treatment-in-europe/2025-04-15T14:30:06+08:00https://flcube.com/hengrui-pharmaceuticals-gains-nmpa-approval-for-shr-1819-in-allergic-rhinitis-study/2025-04-15T14:12:51+08:00https://flcube.com/cspc-pharmaceutical-gains-fda-approval-for-sys6041-adc-in-advanced-solid-tumors/2025-04-15T14:02:30+08:00https://flcube.com/boehringer-ingelheim-partners-with-cue-biopharma-to-advance-cue-501-for-autoimmune-diseases/2025-04-15T13:44:55+08:00https://flcube.com/peijia-medicals-taurustrio-tav-system-accepted-for-nmpa-review-in-china/2025-04-15T13:35:18+08:00https://flcube.com/hightide-therapeutics-htd1801-shows-positive-phase-iii-results-in-type-2-diabetes-treatment/2025-04-15T13:29:25+08:00https://flcube.com/zhuhai-beihai-biotech-gains-nmpa-clinical-clearance-for-innovative-peptide-drug-conjugate-bh259/2025-04-15T13:23:07+08:00https://flcube.com/novlead-biotech-secures-series-c-financing-to-expand-no-inhalation-therapy-device-production/2025-04-15T13:05:00+08:00https://flcube.com/chromatin-bioscience-collaborates-with-astellas-pharma-to-design-cell-selective-synthetic-promoters/2025-04-15T12:59:31+08:00https://flcube.com/apollomics-partners-with-launxp-for-vebreltinib-in-asian-nsclc-treatment/2025-04-15T11:39:12+08:00https://flcube.com/convalife-and-xlement-launch-ai-powered-joint-lab-for-drug-development-innovation/2025-04-15T11:23:25+08:00https://flcube.com/anlong-biopharmaceutical-and-sun-novo-partner-to-advance-sirna-technology-in-cardiovascular-treatments/2025-04-15T11:10:30+08:00https://flcube.com/bioray-biopharmaceutical-expands-to-turkey-with-three-key-drugs-marking-international-milestone/2025-04-15T10:59:39+08:00https://flcube.com/msds-gardasil-9-approved-in-china-for-males-aged-16-to-26/2025-04-14T15:51:20+08:00https://flcube.com/nhc-urges-hospitals-to-establish-healthy-weight-management-clinics-by-june/2025-04-14T14:06:25+08:00https://flcube.com/mabwell-and-dp-technology-collaborate-to-build-biopharma-ai-platform-for-drug-development/2025-04-14T13:58:27+08:00https://flcube.com/bristol-myers-squibb-wins-fda-approval-for-opdivo-yervoy-combo-in-first-line-hcc-treatment/2025-04-14T13:48:34+08:00https://flcube.com/jiangxi-institute-of-biological-products-files-for-hong-kong-ipo-amid-strong-market-position/2025-04-14T11:57:57+08:00https://flcube.com/zhaoke-ophthalmology-launches-phase-ii-study-for-brimochol-pf-in-presbyopia-treatment/2025-04-14T11:46:54+08:00https://flcube.com/cspc-pharmaceutical-gains-nmpa-approval-for-clinical-trial-of-syh2046-in-heart-failure/2025-04-14T11:28:02+08:00https://flcube.com/amgens-imdelltra-shows-positive-phase-iii-results-in-small-cell-lung-cancer/2025-04-14T11:21:14+08:00https://flcube.com/shanghai-microport-ep-medtech-secures-nmpa-fast-track-designation-for-easyecho-catheter/2025-04-14T11:17:10+08:00https://flcube.com/jiangsu-hengrui-secures-nmpa-approval-for-clinical-trials-of-shr-3792-and-hrs-9190/2025-04-14T10:57:41+08:00https://flcube.com/johnson-johnson-launches-rybrevant-in-china-for-egfr-exon-20-insertion-mutation-lung-cancer/2025-04-14T10:52:53+08:00https://flcube.com/tasly-pharma-gains-nmpa-green-light-for-car-t-therapy-clinical-study-in-recurrent-glioblastoma/2025-04-14T10:37:56+08:00https://flcube.com/cr-boya-gains-nmpa-approval-for-clinical-trials-of-subcutaneous-human-immunoglobulin/2025-04-14T10:29:48+08:00https://flcube.com/novartis-announces-usd-23-billion-investment-to-expand-u-s-manufacturing-and-rd-hubs/2025-04-11T17:55:34+08:00https://flcube.com/juventas-cell-therapy-secures-china-clinical-trial-approval-for-inaticabtagene-autoleucel-in-aiha/2025-04-11T17:50:19+08:00https://flcube.com/belief-biomed-and-takeda-win-nmpa-approval-for-chinas-first-hemophilia-b-gene-therapy/2025-04-11T17:30:36+08:00https://flcube.com/zai-labs-partner-argenx-secures-fda-approval-for-vygart-hytrulo-prefilled-syringe-in-gmg-and-cidp/2025-04-11T17:16:33+08:00https://flcube.com/pierre-fabre-and-redridge-bio-partner-on-biparatopic-antibody-development-for-precision-oncology/2025-04-11T16:50:08+08:00https://flcube.com/intco-medical-and-jd-healthcare-partner-to-innovate-internet-healthcare-service-models/2025-04-11T16:09:12+08:00https://flcube.com/kingstronbios-prostyle-a-valve-gains-nmpa-approval-setting-new-benchmark-in-transcatheter-aortic-valve-replacement/2025-04-11T15:28:52+08:00https://flcube.com/iregene-therapeutics-secures-rmb-100-million-in-series-b-financing-to-advance-ipsc-technology/2025-04-11T15:13:41+08:00https://flcube.com/iregenes-nouvsight001-gains-orphan-drug-designation-for-retinitis-pigmentosa-treatment/2025-04-11T15:04:39+08:00https://flcube.com/iregenes-pioneering-cell-therapy-nouvneu001-administered-in-wuhan-for-parkinsons-disease/2025-04-11T15:04:38+08:00https://flcube.com/novo-nordisk-invests-brl-6-4-billion-in-brazilian-manufacturing-expansion-for-obesity-drugs/2025-04-11T15:00:32+08:00https://flcube.com/jemincare-group-announces-nmpa-approval-of-generic-clenil-for-asthma-treatment/2025-04-11T14:45:33+08:00https://flcube.com/nona-biosciences-and-atossa-therapeutics-forge-partnership-to-advance-breast-cancer-therapies/2025-04-11T14:22:09+08:00https://flcube.com/bayers-vitrakvi-fully-approved-by-fda-for-ntrk-fusion-solid-tumors/2025-04-11T13:54:03+08:00https://flcube.com/luye-pharma-launches-rotigotine-luye-in-uk-for-parkinsons-and-restless-leg-syndrome/2025-04-11T12:32:43+08:00https://flcube.com/astellas-pharma-partners-with-shanghai-pharma-on-zolbetuximab-commercialization/2025-04-11T12:23:18+08:00https://flcube.com/ck-life-sciences-reports-promising-preclinical-results-for-trop2-targeted-cancer-vaccine/2025-04-11T11:54:40+08:00https://flcube.com/kangtai-biologicals-pentavalent-rotavirus-vaccine-enters-phase-iii-trials/2025-04-10T16:33:22+08:00https://flcube.com/zelgen-biopharmas-zg005-approved-for-gastrointestinal-tumor-trials-in-china/2025-04-10T16:15:29+08:00https://flcube.com/hemacells-xj-mk-002-gains-fda-orphan-drug-designation-for-giant-platelet-syndrome/2025-04-10T16:07:40+08:00https://flcube.com/iview-therapeutics-iview-1201-gains-fda-orphan-drug-designation-for-fungal-keratitis/2025-04-10T15:58:36+08:00https://flcube.com/hansoh-pharmas-ibrexafungerp-approved-for-vulvovaginal-candidiasis-in-china/2025-04-10T15:51:36+08:00https://flcube.com/hengrui-pharmaceuticals-ivarmacitinib-approved-for-atopic-dermatitis/2025-04-10T15:43:51+08:00https://flcube.com/beijing-starmabs-sm2275-receives-fda-ind-approval-for-dual-target-cancer-therapy/2025-04-10T14:51:48+08:00https://flcube.com/ge-healthcare-appoints-jeannette-bankes-as-president-and-ceo-of-patient-care-solutions/2025-04-10T14:26:02+08:00https://flcube.com/wantai-bios-tuberculosis-test-kit-joins-unops-stoptb-procurement-list/2025-04-10T14:21:34+08:00https://flcube.com/b-brauns-duplex-system-approved-by-fda-for-piperacillin-and-tazobactam/2025-04-10T14:10:18+08:00https://flcube.com/sino-biopharmas-tqb3019-gains-nmpa-approval-for-hematological-malignancies/2025-04-10T14:02:34+08:00https://flcube.com/peijia-medicals-yonflow-stent-approved-by-chinas-nmpa/2025-04-10T12:16:36+08:00https://flcube.com/gaush-meditechs-corneal-confocal-microscope-approved-in-jiangsu/2025-04-10T12:08:03+08:00https://flcube.com/simcere-pharmaceutical-gains-nmpa-approval-for-fgfr2b-targeted-adc-sim0686/2025-04-10T12:00:14+08:00https://flcube.com/sinopep-allsino-partners-with-gulf-pharmaceutical-for-semaglutide-api-supply/2025-04-10T11:52:51+08:00https://flcube.com/u-s-tariffs-on-pharmaceuticals-and-their-impact-on-chinas-medical-indust/2025-04-09T21:28:56+08:00https://flcube.com/shanghai-kehua-bioengineering-launches-xian-medical-complex-project/2025-04-09T18:05:56+08:00https://flcube.com/sichuan-biokin-launches-phase-iii-trial-for-bl-b01d1-in-urothelial-carcinoma/2025-04-09T18:00:47+08:00https://flcube.com/abbvies-rinvoq-approved-in-eu-for-giant-cell-arteritis/2025-04-09T17:46:04+08:00https://flcube.com/bristol-myers-squibbs-opdivo-yervoy-combo-approved-for-msi-h-colorectal-cancer/2025-04-09T17:40:53+08:00https://flcube.com/yifan-pharma-secures-nmpa-approval-for-generic-sedapain/2025-04-09T17:31:41+08:00https://flcube.com/yunnan-baiyaos-inr102-gains-nmpa-clinical-trial-clearance-for-prostate-cancer/2025-04-09T17:26:24+08:00https://flcube.com/huidagenes-hfcas12max-licensed-to-vita-therapeutics-for-neuromuscular-cell-therapy/2025-04-09T16:59:50+08:00https://flcube.com/nmpa-optimizes-drug-manufacturing-license-process-with-digital-qr-codes/2025-04-09T16:51:29+08:00https://flcube.com/bayer-submits-eylea-8-mg-for-rvo-macular-edema-approval-in-eu/2025-04-09T16:34:15+08:00https://flcube.com/aidea-pharma-terminates-covid-19-drug-collaboration-with-pharmablock/2025-04-09T16:24:52+08:00https://flcube.com/daiichi-sankyo-and-astrazenecas-datroway-approved-in-eu-for-breast-cancer/2025-04-09T16:13:50+08:00https://flcube.com/idt-and-shanghai-bioscience-forge-partnership-to-drive-local-innovation-in-china/2025-04-09T16:00:58+08:00https://flcube.com/bio-thera-solutions-reports-5-44-revenue-growth-in-2024-driven-by-biosimilar-sales/2025-04-09T15:53:53+08:00https://flcube.com/winsunny-pharmas-fy101-gains-nmpa-clinical-approval-for-hyperlipidemia/2025-04-09T15:33:10+08:00https://flcube.com/highlife-sass-tmvr-system-receives-fda-breakthrough-device-designation/2025-04-09T15:24:52+08:00https://flcube.com/zhifei-biological-gains-bangladesh-approval-for-dysentery-vaccine-trial/2025-04-09T15:13:34+08:00https://flcube.com/hengrui-pharmaceuticals-vunakizumab-approved-for-ankylosing-spondylitis/2025-04-09T15:06:45+08:00https://flcube.com/cspc-pharmaceuticals-jmt108-gains-fda-approval-for-advanced-malignant-tumor-trials/2025-04-09T15:00:04+08:00https://flcube.com/amgens-uplizna-approved-by-fda-for-igg4-related-disease/2025-04-08T17:38:57+08:00https://flcube.com/jjs-rybrevant-sc-formulation-approved-by-ec-for-nsclc-treatment/2025-04-08T17:28:21+08:00https://flcube.com/tj-biopharma-partners-with-biogen-on-felzartamab-phase-iii-studies-in-china/2025-04-08T17:04:50+08:00https://flcube.com/jjs-darzalex-sc-formulation-approved-for-newly-diagnosed-multiple-myeloma/2025-04-08T16:55:04+08:00https://flcube.com/shenzhen-unveils-comprehensive-policy-package-to-boost-biopharma-innovation/2025-04-08T16:11:22+08:00https://flcube.com/aim-vaccines-serum-free-rabies-vaccine-accepted-for-review-by-nmpa/2025-04-08T15:59:53+08:00https://flcube.com/sinomab-biosciences-sm17-shows-promising-results-in-phase-ib-atopic-dermatitis-study/2025-04-08T15:54:32+08:00https://flcube.com/luye-pharmas-toludesvenlafaxine-approved-for-marketing-in-macau/2025-04-08T15:43:34+08:00https://flcube.com/shanxi-yanghe-medical-technology-faces-production-halt-over-gmp-violation/2025-04-08T15:34:20+08:00https://flcube.com/hansoh-pharmaceutical-secures-dual-nmpa-approvals-for-oncology-pipeline-expansion/2025-04-08T15:22:27+08:00https://flcube.com/huadong-medicines-dr30206-approved-for-clinical-trials-in-gastrointestinal-tumors/2025-04-08T15:16:08+08:00https://flcube.com/beijing-unveils-measures-to-accelerate-innovative-drug-development-and-regulatory-efficiency/2025-04-08T15:08:32+08:00https://flcube.com/novo-nordisk-partners-with-tencent-healthcare-for-weight-management-initiative-in-china/2025-04-08T14:53:03+08:00https://flcube.com/siemens-set-to-acquire-dotmatics-for-5-1-billion-to-boost-life-sciences-rd/2025-04-08T14:48:39+08:00https://flcube.com/lynmou-medical-secures-series-a-funding-for-endoscope-expansion/2025-04-08T14:20:44+08:00https://flcube.com/phanes-therapeutics-gains-cde-approval-for-peluntamig-phase-ii-trial-in-sclc-and-nec/2025-04-08T14:11:29+08:00https://flcube.com/hengrui-pharmaceuticals-licenses-shr7280-to-merck-for-assisted-reproduction/2025-04-08T14:04:27+08:00https://flcube.com/suzhou-ribo-life-science-completes-enrollment-for-phase-iia-study-of-fxi-targeted-sirna-drug-rbd4059/2025-04-08T12:57:23+08:00https://flcube.com/nanjing-king-friend-bios-biosimilar-victoza-approved-by-fda/2025-04-07T18:09:44+08:00https://flcube.com/bio-sincerity-pharma-tech-gains-nmpa-approval-for-bios-0618-in-obstructive-sleep-apnea/2025-04-07T18:01:33+08:00https://flcube.com/duality-biotherapeutics-makes-hong-kong-ipo-debut-with-adc-pipeline/2025-04-07T17:53:15+08:00https://flcube.com/santens-tapcom-approved-by-chinas-nmpa-for-glaucoma-treatment/2025-04-07T17:45:38+08:00https://flcube.com/peijia-medicals-reachtactile-robot-assists-first-human-tavr-trial/2025-04-07T17:40:35+08:00https://flcube.com/enhertu-approved-by-ec-for-earlier-line-treatment-of-hr-her2-low-breast-cancer/2025-04-07T17:28:10+08:00https://flcube.com/sino-biopharmaceuticals-tqb2101-receives-nmpa-approval-for-phase-i-trial-in-advanced-malignancies/2025-04-07T17:21:57+08:00https://flcube.com/hengrui-pharmaceuticals-gains-nmpa-approval-for-hrs-6719-in-solid-tumors/2025-04-07T17:13:49+08:00https://flcube.com/sanofis-rilzabrutinib-granted-orphan-drug-designation-for-rare-diseases/2025-04-07T17:01:13+08:00https://flcube.com/sunshine-guojians-ssgj-627-gains-nmpa-approval-for-ulcerative-colitis-trial/2025-04-07T16:29:56+08:00https://flcube.com/sarepta-and-roche-seek-to-resume-elevidys-trials-after-ema-halt/2025-04-07T16:21:47+08:00https://flcube.com/bayers-vividion-therapeutics-starts-phase-i-study-for-ras-pi3k%ce%b1-inhibitor/2025-04-07T16:09:18+08:00https://flcube.com/abl-bio-and-gsk-partner-on-neurodegenerative-disease-therapies-with-grabody-b-platform/2025-04-07T15:48:59+08:00https://flcube.com/beigene-halts-ociperlimab-clinical-program-for-lung-cancer/2025-04-07T15:07:06+08:00https://flcube.com/eli-lilly-secures-global-license-for-sangamos-stac-bbb-gene-therapy-technology/2025-04-07T14:47:27+08:00https://flcube.com/microport-endovasculars-talos-stent-approved-in-brazil-for-aortic-dissection/2025-04-07T14:38:09+08:00https://flcube.com/fujian-keruis-generic-sirolimus-gel-approved-by-chinas-nmpa/2025-04-07T14:30:34+08:00https://flcube.com/johnson-johnson-completes-acquisition-of-intra-cellular-therapies/2025-04-03T19:00:07+08:00https://flcube.com/yuewei-medtech-secures-rmb100-million-in-series-a-funding-for-cardiac-device-development/2025-04-03T18:54:19+08:00https://flcube.com/boehringer-ingelheim-reports-6-1-sales-growth-in-2024-bolstered-by-key-pharmaceuticals/2025-04-03T18:46:16+08:00https://flcube.com/ge-healthcare-partners-with-probo-medical-to-distribute-ultrasound-devices/2025-04-03T18:43:31+08:00https://flcube.com/henlius-biotechs-hlx04-o-shows-positive-results-in-wamd-phase-iii-trial/2025-04-03T18:34:22+08:00https://flcube.com/mabwell-biosciences-7mw3711-adc-receives-clinical-trial-approval-in-china/2025-04-03T18:29:21+08:00https://flcube.com/sinovac-partners-with-cpma-to-advance-vaccine-preventable-disease-initiatives/2025-04-03T18:11:44+08:00https://flcube.com/novartis-vanrafia-gets-fda-accelerated-approval-for-igan/2025-04-03T18:06:36+08:00https://flcube.com/sanofi-and-cathay-capital-launch-rmb-2-billion-pharma-innovation-fund-in-china/2025-04-03T18:00:01+08:00https://flcube.com/shionogi-partners-with-link-medical-for-cefiderocol-development-in-australia-and-new-zealand/2025-04-03T17:44:23+08:00https://flcube.com/wuxi-xdc-partners-with-mabsoft-to-advance-innovative-adc-development/2025-04-03T17:37:48+08:00https://flcube.com/guojian-qingke-biomedical-gains-nmpa-approval-for-3d-mscs-in-stroke-trials/2025-04-03T17:26:30+08:00https://flcube.com/gan-lee-pharmaceuticals-secures-pakistan-approval-for-insulin-glargine-cartridge/2025-04-03T17:01:21+08:00https://flcube.com/biogens-biib080-receives-fda-fast-track-designation-for-alzheimers/2025-04-03T16:44:34+08:00https://flcube.com/nmpa-reduces-influenza-vaccine-batch-release-time-to-45-working-days/2025-04-03T16:24:02+08:00https://flcube.com/pfizer-and-flagship-pioneering-collaborate-on-ai-driven-drug-development/2025-04-03T16:09:53+08:00https://flcube.com/nurix-therapeutics-expands-sanofi-partnership-with-undisclosed-tpd-program/2025-04-03T16:00:23+08:00https://flcube.com/jiangxi-rimag-lists-ct-chest-lesion-data-on-shanghai-data-exchange/2025-04-03T15:43:32+08:00https://flcube.com/novartis-fabhalta-approved-in-china-for-c3-glomerulopathy/2025-04-03T15:37:53+08:00https://flcube.com/immorna-closes-series-a-and-a-rounds-near-100m-for-mrna-development/2025-04-02T21:32:59+08:00https://flcube.com/medytox-shifts-strategy-for-china-market-entry-with-next-generation-botulinum-toxin/2025-04-02T21:32:41+08:00https://flcube.com/fosun-pharmaceutical-gets-fda-green-light-for-hlx42-adc-clinical-study/2025-04-02T21:32:22+08:00https://flcube.com/huadong-medicine-ends-collaboration-on-vtvs-ttp273-for-diabetes-treatment/2025-04-02T21:31:47+08:00https://flcube.com/blue-sail-medical-secures-rmb-900-million-investment-for-rd-and-capacity-expansion/2025-04-02T21:31:10+08:00https://flcube.com/celltrions-infliximab-biosimilar-shows-promising-long-term-efficacy-and-safety-in-cd-and-uc/2025-04-02T21:30:23+08:00https://flcube.com/hengrui-medicine-advances-clinical-trial-for-pd-l1-inhibitor-combo-in-cldn18-2-positive-tumors/2025-04-02T21:30:02+08:00https://flcube.com/johnson-johnsons-xarelto-demonstrates-reduced-bleeding-risk-in-atrial-fibrillation-patients-post-pci/2025-04-02T21:28:31+08:00https://flcube.com/biogen-gains-fda-breakthrough-status-for-felzartamab-in-kidney-transplant-rejection-treatment/2025-04-02T21:28:16+08:00https://flcube.com/boehringer-ingelheim-china-and-shanghai-pharmaceuticals-holding-co-launch-strategic-partnership-for-linagliptin/2025-04-02T21:27:43+08:00https://flcube.com/fujian-cosunters-covid-19-therapy-gst-hg171-ritonavir-approved-in-macau/2025-04-02T21:27:27+08:00https://flcube.com/eli-lilly-in-advanced-talks-to-acquire-scorpion-therapeutics-for-2-5-billion/2025-04-02T21:26:43+08:00https://flcube.com/chinas-moc-lists-us-firms-pvh-and-illumina-as-unreliable-entities/2025-04-02T21:26:27+08:00https://flcube.com/beijing-biostars-utidelone-gains-fda-approval-for-global-phase-ii-iii-study/2025-04-02T21:26:06+08:00https://flcube.com/astrazenecas-2024-financials-beat-expectations-with-21-revenue-growth/2025-04-02T21:25:28+08:00https://flcube.com/fosun-pharmaceuticals-xs-03-gets-nmpa-green-light-for-crc-study/2025-04-02T21:25:03+08:00https://flcube.com/organons-2024-financial-report-shows-steady-growth-in-womens-health-and-biosimilars/2025-04-02T21:24:08+08:00https://flcube.com/roche-and-jd-healthcare-collaborate-on-influenza-prevention-with-xofluza-baloxavir-marboxil/2025-04-02T21:23:26+08:00https://flcube.com/inventisbio-announces-positive-phase-ii-results-for-d-2570-in-psoriasis-treatment/2025-04-02T21:23:02+08:00https://flcube.com/merck-sharp-dohme-expands-durham-facility-with-1b-investment-for-vaccine-production/2025-04-02T21:22:34+08:00https://flcube.com/astrazeneca-to-acquire-esobiotec-for-up-to-1-billion-to-boost-cell-therapy-portfolio/2025-04-02T21:22:13+08:00https://flcube.com/nmpa-seeks-public-input-on-drug-trial-data-protection-measures/2025-04-02T21:21:50+08:00https://flcube.com/astrazeneca-and-daiichi-sankyo-initiate-destiny-gastric05-study-for-enhertu-in-metastatic-gastric-cancer/2025-04-02T21:21:37+08:00https://flcube.com/shionogi-submits-rolling-nda-for-ensitrelvir-in-us-for-covid-19-prophylaxis/2025-04-02T17:48:44+08:00https://flcube.com/chinas-national-health-commission-outlines-key-tasks-for-primary-healthcare-reform-in-2025/2025-04-02T17:13:47+08:00https://flcube.com/pfizer-expands-abrysvo-rsv-vaccine-indication-to-include-ages-18-59-in-eu/2025-04-02T17:04:38+08:00https://flcube.com/accuredits-artbase-a1-base-editor-authorized-by-uspto/2025-04-02T16:59:00+08:00https://flcube.com/organon-acquires-u-s-rights-to-tofidence-from-biogen/2025-04-02T16:50:29+08:00https://flcube.com/zhifei-bios-trivalent-influenza-vaccine-approved-for-clinical-trials-in-china/2025-04-02T16:39:32+08:00https://flcube.com/chempartner-plans-share-issuance-to-raise-up-to-316-3-million-yuan/2025-04-02T16:21:51+08:00https://flcube.com/peijia-medical-and-dsm-firmenich-collaborate-on-polymer-heart-valve-innovation/2025-04-02T16:14:30+08:00https://flcube.com/henlius-and-organons-hlx11-biosimilar-clears-ema-validation-hurdle/2025-04-02T14:23:46+08:00https://flcube.com/huadong-medicines-semaglutide-injection-accepted-for-review-by-chinas-nmpa/2025-04-02T14:07:42+08:00https://flcube.com/medtronic-partners-with-methinks-ai-to-enhance-stroke-care-in-emerging-markets/2025-04-02T12:47:07+08:00https://flcube.com/hengrui-pharmaceuticals-secures-clinical-trial-approval-for-hrs-9813-in-ipf/2025-04-02T12:34:45+08:00https://flcube.com/sino-medical-sciences-secures-malaysian-approval-for-coronary-balloon-catheter/2025-04-01T18:55:23+08:00https://flcube.com/luye-pharmas-weekly-rivastigmine-patch-approved-in-japan-for-alzheimers/2025-04-01T18:47:00+08:00https://flcube.com/beigenes-tevimbra-recommended-for-eu-approval-in-small-cell-lung-cancer/2025-04-01T18:32:59+08:00https://flcube.com/otsuka-files-fda-application-for-sibeprenlimab-in-igan-treatment/2025-04-01T18:26:57+08:00https://flcube.com/basecare-medical-reports-44-revenue-growth-in-2024-ivf-sector/2025-04-01T18:20:01+08:00https://flcube.com/ucbs-rystiggo-approved-in-china-for-generalized-myasthenia-gravis/2025-04-01T18:08:18+08:00https://flcube.com/renji-hospital-partners-with-raffles-medical-group-to-boost-shanghais-medical-tourism/2025-04-01T17:41:07+08:00https://flcube.com/china-proposes-new-measures-to-optimize-high-end-medical-device-regulation/2025-04-01T15:43:12+08:00https://flcube.com/ge-healthcare-takes-full-ownership-of-japans-nihon-medi-physics/2025-04-01T15:17:28+08:00https://flcube.com/hengrui-pharmaceuticals-ivarmacitinib-approved-for-rheumatoid-arthritis-in-china/2025-04-01T15:06:32+08:00https://flcube.com/chinese-firms-nanjing-fs-and-hunan-huize-form-alliance-for-full-process-pharma-services/2025-04-01T14:00:23+08:00https://flcube.com/huapont-life-sciences-gains-nmpa-approval-for-generic-daivobet/2025-04-01T13:50:12+08:00https://flcube.com/chinese-ivd-firm-annoroad-gene-targets-global-expansion-with-ipo/2025-04-01T13:14:05+08:00https://flcube.com/ascletis-pharmas-asc30-shows-positive-results-in-us-phase-ib-obesity-study/2025-04-01T13:02:31+08:00https://flcube.com/abbisko-therapeutics-secures-85m-from-merck-for-pimicotinib-global-rights/2025-04-01T12:51:57+08:00https://flcube.com/chia-tai-tianqing-launches-npp-for-urgent-cancer-treatment-in-hong-kong/2025-03-31T18:33:58+08:00https://flcube.com/innovent-biologics-ibi363-granted-breakthrough-therapy-designation-for-melanoma/2025-03-31T18:29:14+08:00https://flcube.com/nhc-data-reveals-digital-leap-for-class-3-hospitals-amid-drug-cost-crackdown/2025-03-31T18:18:34+08:00https://flcube.com/hengruis-hrs-5965-granted-breakthrough-therapy-designation-for-iga-nephropathy/2025-03-31T18:08:08+08:00https://flcube.com/sanofis-dupixent-approved-in-japan-for-chronic-obstructive-pulmonary-disease/2025-03-31T18:02:57+08:00https://flcube.com/pacific-shuanglin-bio-pharmacy-partners-with-xtalpi-for-blood-product-innovation/2025-03-31T17:55:04+08:00https://flcube.com/novartis-pluvicto-gains-expanded-fda-approval-for-prostate-cancer-treatment/2025-03-31T17:37:47+08:00https://flcube.com/emas-chmp-issues-negative-opinion-on-lillys-kisunla-for-alzheimers/2025-03-31T17:27:29+08:00https://flcube.com/chinas-iac-drafts-commercial-health-insurance-drug-list-a-series-to-bridge-nrdl-coverage-gaps/2025-03-31T16:53:11+08:00https://flcube.com/china-scraps-outpatient-prepayment-in-public-hospitals-by-2025-healthcare-reform-shifts-financial-burden/2025-03-31T16:39:34+08:00https://flcube.com/ubrigene-appoints-dr-joy-zhou-to-lead-cell-therapy-development/2025-03-31T16:25:35+08:00https://flcube.com/bmss-opdivo-yervoy-combo-approved-by-nmpa-for-first-line-hcc-treatment/2025-03-31T16:16:25+08:00https://flcube.com/roches-ocrevus-approved-by-chinas-nmpa-for-multiple-sclerosis-treatment/2025-03-31T16:09:34+08:00https://flcube.com/shanghai-bio-heart-launches-sakura-scb-study-for-drug-coated-balloon-in-japan/2025-03-31T16:04:02+08:00https://flcube.com/astrazenecas-imfinzi-approved-by-fda-for-bladder-cancer-treatment/2025-03-31T15:49:14+08:00https://flcube.com/microport-endovascular-reports-1-61-revenue-growth-in-2024-with-strong-profit-increase/2025-03-31T13:58:39+08:00https://flcube.com/luye-pharma-group-reports-2024-revenue-dip-despite-growth-in-product-sales/2025-03-31T13:50:42+08:00https://flcube.com/hengrui-pharmaceuticals-reports-22-63-revenue-growth-in-2024-with-strong-innovative-drug-sales/2025-03-31T13:32:42+08:00https://flcube.com/sanofis-qfitlia-approved-by-fda-for-hemophilia-a-and-b-prophylaxis/2025-03-31T13:26:30+08:00https://flcube.com/brii-biosciences-presents-elebsiran-phase-ii-data-at-apasl-2025-meeting/2025-03-31T13:12:29+08:00https://flcube.com/akeso-biopharma-reports-53-revenue-decline-in-2024-despite-growth-in-product-sales/2025-03-31T13:03:29+08:00https://flcube.com/iaso-biotherapeutics-fucaso-approved-in-macao-for-relapsed-multiple-myeloma/2025-03-31T12:55:11+08:00https://flcube.com/eli-lilly-launches-kisunla-in-china-for-early-alzheimers-treatment/2025-03-31T12:47:57+08:00https://flcube.com/laekna-submits-revised-protocol-for-lae102-obesity-trial-with-eli-lilly/2025-03-31T12:25:46+08:00https://flcube.com/eclincloud-secures-new-funding-to-accelerate-ai-innovation-in-clinical-research/2025-03-30T11:45:55+08:00https://flcube.com/china-tightens-medical-device-quality-oversight-2025-inspection-plan-unveiled/2025-03-29T21:55:09+08:00https://flcube.com/policy-analysis-shanghais-2025-pharmaceutical-procurement-regulation-and-market-implications/2025-03-29T21:43:37+08:00https://flcube.com/guangdong-accelerates-centralized-procurement-for-apixaban-and-key-therapeutics/2025-03-29T21:25:28+08:00https://flcube.com/china-unveils-2025-medical-device-inspection-strategy-to-tighten-quality-control/2025-03-29T21:13:04+08:00https://flcube.com/eisai-transfers-pariet-rights-in-china-to-cbc-group-controlled-peak-pharma/2025-03-29T16:24:15+08:00https://flcube.com/sinovac-biotechs-sna02-48-gains-clinical-approval-for-tetanus-prevention/2025-03-29T15:28:18+08:00https://flcube.com/shanghai-designates-backup-suppliers-and-specialized-drug-formulations-in-gy-yd2024-2-procurement/2025-03-29T00:53:18+08:00https://flcube.com/abbott-laboratories-volt-pfa-system-receives-eu-ce-mark-for-atrial-fibrillation-treatment/2025-03-28T17:07:30+08:00https://flcube.com/alcon-laboratories-acquires-majority-stake-in-aurion-biotech-to-advance-eye-disease-cell-therapy/2025-03-28T16:58:51+08:00https://flcube.com/genmabs-tivdak-approved-in-japan-for-advanced-cervical-cancer-treatment/2025-03-28T16:51:21+08:00https://flcube.com/cstone-pharmaceuticals-reports-2024-results-with-license-fee-growth-offsetting-drug-sales-decline/2025-03-28T16:33:27+08:00https://flcube.com/transthera-and-akeso-biopharma-collaborate-on-hcc-study-with-tinengotinib-and-bispecific-antibodies/2025-03-28T16:26:37+08:00https://flcube.com/nmpa-approves-qingfengs-suraxavir-marboxil-for-influenza-a-and-b-treatment/2025-03-28T16:13:42+08:00https://flcube.com/medtronic-launches-digital-innovation-base-in-beijings-biopark/2025-03-28T15:58:28+08:00https://flcube.com/huadong-medicine-gains-nmpa-approval-for-hdm3019-rheumatoid-arthritis-trial/2025-03-28T15:45:56+08:00https://flcube.com/lees-pharmaceutical-holdings-ltd-reports-32-9-revenue-growth-in-2023/2025-03-28T15:38:53+08:00https://flcube.com/remegens-2024-revenue-soars-58-54-on-strong-product-sales-and-rd-growth/2025-03-28T15:28:53+08:00https://flcube.com/jw-therapeutics-sees-9-revenue-decline-in-2024-amid-commercial-strategy-shift/2025-03-28T15:15:56+08:00https://flcube.com/ascentage-pharmas-revenue-soars-342-in-2024-on-strong-drug-sales-and-partnerships/2025-03-28T15:10:23+08:00https://flcube.com/shanghai-pharmaceuticals-reports-5-75-revenue-growth-in-2024-with-innovation-initiatives/2025-03-28T15:03:59+08:00https://flcube.com/yichang-hecs-yiqibuvir-approved-by-nmpa-for-chronic-hcv-infection/2025-03-28T14:04:39+08:00https://flcube.com/luye-pharmas-shandong-boan-bio-reports-17-5-revenue-growth-in-2024/2025-03-28T13:02:43+08:00https://flcube.com/microport-cardioflow-medtech-reports-7-5-revenue-growth-in-2024-driven-by-global-expansion/2025-03-28T12:29:15+08:00https://flcube.com/hengrui-pharmaceuticals-gets-nmpa-green-light-for-hrs-1738-and-hrs-5817-clinical-trials/2025-03-28T11:49:18+08:00https://flcube.com/microport-medbot-reports-strong-2024-growth-for-toumai-and-skywalker-robots/2025-03-28T11:20:46+08:00https://flcube.com/inventisbios-kras-g12c-inhibitor-d-1553-earns-cde-breakthrough-therapy-status/2025-03-27T18:38:37+08:00https://flcube.com/canbridge-pharmaceuticals-presents-positive-phase-i-data-for-can106-at-eha-congress/2025-03-27T18:36:52+08:00https://flcube.com/zai-labs-repotrectinib-earns-two-breakthrough-therapy-designations-in-china-for-ros1-nsclc/2025-03-27T18:34:35+08:00https://flcube.com/oncusp-therapeutics-licenses-multitudes-cdh6-adc-for-global-development/2025-03-27T18:32:39+08:00https://flcube.com/ascentage-pharmas-lisaftoclax-shows-promising-results-in-phase-i-trial-for-non-hodgkin-lymphoma-2/2025-03-27T18:30:57+08:00https://flcube.com/kangpu-biopharmaceuticals-begins-phase-iia-trial-of-kpg-818-for-systemic-lupus-erythematosus/2025-03-27T18:28:50+08:00https://flcube.com/shanghai-microport-medbot-completes-worlds-furthest-remote-robot-surgery-via-5g/2025-03-27T18:25:07+08:00https://flcube.com/pfizers-lorbrena-receives-first-prescription-in-china-for-nsclc-treatment/2025-03-27T18:22:18+08:00https://flcube.com/healzen-therapeutics-and-hisun-partner-on-first-in-class-protein-degradation-product/2025-03-27T18:19:23+08:00https://flcube.com/ascentage-pharmas-lisaftoclax-shows-promising-results-in-phase-i-trial-for-non-hodgkin-lymphoma/2025-03-27T18:11:19+08:00https://flcube.com/pfizers-ritlecitinib-earns-cde-breakthrough-designation-for-ulcerative-colitis/2025-03-27T18:09:05+08:00https://flcube.com/ascletis-pharma-appoints-john-p-gargiulo-as-chief-business-officer-to-lead-growth/2025-03-27T18:06:40+08:00https://flcube.com/meta-pharmaceuticals-secures-14-8-million-to-advance-immuno-metabolism-drug-development/2025-03-27T18:04:31+08:00https://flcube.com/beijing-winsunny-pharma-plans-ipo-to-boost-drug-development-and-production/2025-03-27T17:59:23+08:00https://flcube.com/ferring-and-i-mab-expand-olamkicept-collaboration-for-inflammatory-diseases/2025-03-27T17:58:00+08:00https://flcube.com/soaring-costs-of-cynomolgus-monkeys-impact-chinas-biologic-drug-development/2025-03-27T17:55:32+08:00https://flcube.com/shanghai-henlius-partners-with-organon-for-global-biosimilar-commercialization/2025-03-27T17:54:10+08:00https://flcube.com/beigenes-brukinsa-faces-three-month-fda-approval-delay-for-cll-sll-indication/2025-03-27T17:51:33+08:00https://flcube.com/junshi-biosciences-receives-nmpa-approval-for-fourth-generation-egfr-inhibitor-wj13404/2025-03-27T17:43:39+08:00https://flcube.com/innovent-biologics-receives-bpom-approval-for-bevagen-in-indonesia/2025-03-27T17:38:00+08:00https://flcube.com/innovent-biologics-ibi306-accepted-for-review-by-chinas-nmpa-for-hypercholesterolemia/2025-03-27T17:34:53+08:00https://flcube.com/nhsa-releases-draft-proposals-for-nrdl-annual-renewal-process/2025-03-27T17:32:43+08:00https://flcube.com/clover-biopharmaceuticals-begins-phase-iii-trial-for-covid-19-booster-scb-2019/2025-03-27T17:27:32+08:00https://flcube.com/sanofis-mrna-chlamydia-vaccine-gains-fda-fast-track-designation/2025-03-27T17:15:03+08:00https://flcube.com/fangzhou-inc-partners-with-tencent-health-to-advance-ai-driven-healthcare-solutions/2025-03-27T17:05:26+08:00https://flcube.com/merck-sharp-dohmes-capvaxive-approved-by-european-commission-for-pneumococcal-prevention/2025-03-27T16:48:28+08:00https://flcube.com/jiangsu-hengrui-pharmaceuticals-receives-nmpa-approval-for-shr-9803-and-shr-a2102-clinical-trials/2025-03-27T16:31:18+08:00https://flcube.com/servier-and-black-diamond-therapeutics-ink-global-deal-for-solid-tumor-targeted-therapy-bdtx-4933/2025-03-27T15:33:37+08:00https://flcube.com/bio-thera-solutions-inks-licensing-deal-with-dr-reddys-for-biosimilar-commercialization/2025-03-27T15:24:29+08:00https://flcube.com/shanghai-junshi-biosciences-loqtorzi-approved-in-singapore-for-nasopharyngeal-carcinoma/2025-03-27T15:07:29+08:00https://flcube.com/zhejiang-funow-medicine-launches-triple-cream-for-melasma-treatment-in-china/2025-03-27T14:56:14+08:00https://flcube.com/luye-pharmas-ba1302-receives-fda-orphan-drug-designation-for-lung-and-pancreatic-cancer/2025-03-27T14:43:02+08:00https://flcube.com/insilico-medicine-collaborates-with-mabwell-bio-to-enhance-adc-rd-with-ai/2025-03-27T14:37:48+08:00https://flcube.com/bayer-inks-licensing-deal-for-suzhou-puhes-prmt5-inhibitor-bay-3713372/2025-03-27T14:32:48+08:00https://flcube.com/astrazenecas-calquence-approved-by-nmpa-for-cll-sll-treatment/2025-03-27T14:15:15+08:00https://flcube.com/shanghai-zj-bio-techs-hcv-nucleic-acid-test-kit-receives-nmpa-approval/2025-03-27T14:02:41+08:00https://flcube.com/shanghai-raas-plans-rmb4-2-billion-acquisition-of-nanyue-biopharming-to-boost-plasma-resources/2025-03-27T13:46:29+08:00https://flcube.com/sichuan-huiyu-pharmaceutical-wins-marketing-approvals-in-italy-portugal-saudi-arabia/2025-03-27T13:27:36+08:00https://flcube.com/alphamab-oncology-doses-first-patient-in-phase-i-trial-for-pd-l1-ox40-bispecific-antibody-kn052/2025-03-27T00:04:26+08:00https://flcube.com/walvax-biotechnology-halts-ev71-vaccine-development-amid-changing-disease-trends/2025-03-26T23:59:00+08:00https://flcube.com/jiangsu-hengrui-medicines-hetrombopag-olamine-receives-fda-orphan-drug-designation-for-itp/2025-03-26T23:55:03+08:00https://flcube.com/wuxi-apptec-faces-shareholder-divestment-of-up-to-3-stake/2025-03-26T23:51:59+08:00https://flcube.com/zai-lab-ltd-makes-fcrn-antagonist-efgartigimod-available-for-myasthenia-gravis-treatment/2025-03-26T23:47:04+08:00https://flcube.com/bristol-myers-squibb-launches-reblozyl-in-china-for-%ce%b2-thalassemia-treatment/2025-03-26T23:44:01+08:00https://flcube.com/china-nt-pharma-group-company-ltd-inks-licensing-deal-for-monoclonal-antibodies/2025-03-26T23:41:26+08:00https://flcube.com/clover-biopharmaceuticals-initiates-scb-219m-clinical-study-for-cit-treatment/2025-03-26T23:39:32+08:00https://flcube.com/changchun-high-new-technologys-jinnamab-approved-for-aosd-clinical-study-by-us-fda/2025-03-26T23:37:42+08:00https://flcube.com/yabao-pharmaceuticals-ybsw015-gets-australian-ethical-approval-for-covid-19-trial/2025-03-26T22:24:26+08:00https://flcube.com/suzhou-zelgens-jak-inhibitor-jacktinib-gets-nmpa-green-light-for-covid-19-trial/2025-03-26T22:21:59+08:00https://flcube.com/sichuan-keluns-kl340399-wins-nmpa-approval-for-solid-tumor-trials/2025-03-26T22:18:14+08:00https://flcube.com/winhealth-pharma-and-ferring-partner-to-co-promote-pentasa-in-china/2025-03-26T22:16:07+08:00https://flcube.com/wuxi-atu-partners-with-wugen-to-accelerate-nk-cell-therapy-development/2025-03-26T22:10:17+08:00https://flcube.com/jiangsu-hengrui-medicines-shr4640-receives-nmpa-approval-for-gout-trial/2025-03-26T20:39:25+08:00https://flcube.com/beijing-aosaikangs-askg315-receives-nmpa-approval-for-solid-tumor-trial/2025-03-26T20:37:20+08:00https://flcube.com/jacobson-pharma-leads-hkd-6-million-jv-for-specialty-drug-distribution/2025-03-26T20:35:03+08:00https://flcube.com/hansoh-pharmaceuticals-ameile-accepted-for-uk-regulatory-review/2025-03-26T20:25:03+08:00https://flcube.com/megarobo-secures-usd-300-million-in-series-c-round-led-by-goldman-sachs/2025-03-26T20:22:57+08:00https://flcube.com/china-issues-monkeypox-diagnosis-guidelines-amid-global-outbreaks/2025-03-26T20:20:59+08:00https://flcube.com/quoin-pharmaceuticals-partners-with-winhealth-for-rare-disease-treatments-in-greater-china/2025-03-26T20:16:21+08:00https://flcube.com/us-bipartisan-bill-seeks-to-regulate-investments-in-chinese-high-tech-firms/2025-03-26T20:10:38+08:00https://flcube.com/hangzhou-tongee-medical-closes-rmb-100-million-series-b-round-for-gastric-bypass-stent/2025-03-26T18:58:01+08:00https://flcube.com/scotland-reports-first-case-of-ashep-ua-in-children-who-issues-guidelines/2025-03-26T18:53:41+08:00https://flcube.com/walvaxs-mrna-vaccine-awcorna-shows-superior-immune-response-in-phase-iii-trial/2025-03-26T18:50:34+08:00https://flcube.com/tianhe-2-supercomputer-aids-drug-discovery-with-deep-learning-biosynthetic-tool/2025-03-26T18:44:44+08:00https://flcube.com/shanghai-pharmaceuticals-licenses-benapenem-and-plazomicin-from-xuanzhu-bio-for-greater-china/2025-03-26T18:43:19+08:00https://flcube.com/sichuan-meidas-phentolamine-gains-priority-review-for-pheochromocytoma-treatment/2025-03-26T18:40:29+08:00https://flcube.com/mabwells-6mw3511-accepted-by-nmpa-for-advanced-solid-tumor-treatment/2025-03-26T18:36:42+08:00https://flcube.com/nmpa-approves-164-medical-devices-in-may-2022-including-medtronic-and-boston-scientific-products/2025-03-26T18:34:29+08:00https://flcube.com/boao-lecheng-sees-surge-in-drug-use-and-medical-tourism-amid-global-partnerships/2025-03-26T18:32:35+08:00https://flcube.com/takedas-obizur-accepted-by-chinas-nmpa-for-acquired-hemophilia-a-treatment/2025-03-26T18:30:38+08:00https://flcube.com/sirnaomics-stp705-shows-promising-results-in-skin-cancer-trial/2025-03-26T18:28:02+08:00https://flcube.com/joincare-pharmaceutical-plans-usd-300-400-million-gdr-issue-for-global-expansion/2025-03-26T18:25:57+08:00https://flcube.com/hitgen-inc-forms-strategic-partnership-for-new-drug-research-and-development/2025-03-26T18:22:20+08:00https://flcube.com/merck-kgaa-partners-with-roche-to-commercialize-tepmetko-in-china/2025-03-26T18:09:30+08:00https://flcube.com/china-resources-medical-holdings-reports-2024-revenue-of-rmb9-86-billion-amid-net-profit-surge/2025-03-26T16:25:52+08:00https://flcube.com/gsks-blujepa-approved-by-fda-for-uncomplicated-urinary-tract-infections/2025-03-26T16:04:55+08:00https://flcube.com/guangzhou-doublle-bioproduct-receives-ind-approval-for-e101-in-type-2-diabetes/2025-03-26T15:58:49+08:00https://flcube.com/wuxi-biologics-reports-9-6-revenue-growth-in-2024-expanding-crdmo-services/2025-03-26T15:49:04+08:00https://flcube.com/sanofis-tolebrutinib-accepted-for-fda-review-in-non-relapsing-secondary-progressive-multiple-sclerosis/2025-03-26T15:42:28+08:00https://flcube.com/fosun-pharmas-2024-revenue-reaches-rmb-41-1-billion-amid-rd-investment/2025-03-26T15:33:01+08:00https://flcube.com/burning-rock-reports-q4-revenue-growth-amid-improved-profitability/2025-03-26T15:27:00+08:00https://flcube.com/chinas-2025-pharmacopoeia-edition-approved-set-for-october-1-implementation/2025-03-26T15:18:29+08:00https://flcube.com/alphamab-oncology-reports-192-58-revenue-surge-led-by-envafolimab/2025-03-26T14:59:21+08:00https://flcube.com/shanghai-henlius-biotech-receives-nmpa-approval-for-hlx79-in-glomerulonephritis-trial/2025-03-26T14:44:26+08:00https://flcube.com/chia-tai-tianqings-tqb2210-approved-for-advanced-malignant-tumor-study/2025-03-26T14:36:24+08:00https://flcube.com/cansino-biologics-partners-with-saudi-spimaco-to-boost-meningococcal-vaccine-access/2025-03-26T14:27:46+08:00https://flcube.com/everest-medicines-reports-surge-in-revenue-advances-core-products-and-rd-pipeline/2025-03-26T12:14:12+08:00https://flcube.com/jiangsu-hengrui-pharmaceuticals-inks-global-license-deal-with-merck-for-hrs-5346/2025-03-26T12:00:23+08:00https://flcube.com/sichuan-kelun-biotech-gains-nmpa-approval-for-skb107-bone-metastasis-trial/2025-03-26T11:46:07+08:00https://flcube.com/abbisko-therapeutics-receives-nmpa-approval-for-ach-drug-absk061/2025-03-26T11:34:17+08:00https://flcube.com/fapon-biotech-partners-with-sansure-to-develop-next-generation-diagnostic-solutions/2025-03-26T11:19:36+08:00https://flcube.com/boehringer-ingelheim-venture-fund-and-hong-kong-science-park-launch-co-incubation-plan/2025-03-25T23:45:08+08:00https://flcube.com/innovent-biologics-tyvyt-approved-for-first-line-esophageal-squamous-cell-carcinoma/2025-03-25T23:42:40+08:00https://flcube.com/chinas-seventh-national-volume-based-procurement-round-kicks-off-with-revised-rules/2025-03-25T23:39:55+08:00https://flcube.com/shenzhen-axbio-closes-usd-100-million-series-b-round-for-sequencing-tech-expansion/2025-03-25T23:34:25+08:00https://flcube.com/boston-scientific-launches-expect-airway-ultrasound-needle-in-china-for-lung-cancer-diagnosis/2025-03-25T23:27:42+08:00https://flcube.com/iomics-biosciences-secures-rmb-100-million-for-proteomics-and-spatialomics-expansion/2025-03-25T23:25:21+08:00https://flcube.com/innocare-and-keymed-biosciences-ccr8-targeted-mab-cm369-accepted-by-nmpa/2025-03-25T23:23:33+08:00https://flcube.com/cde-releases-58th-and-59th-batches-of-chemical-generic-reference-preparations/2025-03-25T23:12:15+08:00https://flcube.com/shenzhens-lwpoct-secures-rmb-100-million-in-series-a-round-for-cdmo-expansion/2025-03-25T23:09:44+08:00https://flcube.com/henlius-biotech-begins-global-phase-iii-trial-for-denosumab-biosimilar-hlx14/2025-03-25T23:03:46+08:00https://flcube.com/cellular-biomedicine-groups-c-car039-receives-nmpa-approval-for-b-cell-nhl-study/2025-03-25T23:01:34+08:00https://flcube.com/global-cord-blood-corps-cellenkos-gets-fda-nod-for-myelofibrosis-trial/2025-03-25T22:59:42+08:00https://flcube.com/beijing-introduces-white-list-system-for-biomedical-rd-item-imports/2025-03-25T22:54:13+08:00https://flcube.com/ocumension-therapeutics-ot-401-approved-for-chronic-non-infectious-uveitis-in-china/2025-03-25T22:52:19+08:00https://flcube.com/astrazeneca-expands-in-china-with-qingdao-partnership-and-manufacturing-base/2025-03-25T22:50:17+08:00https://flcube.com/cstone-pharmaceuticals-ayvakit-included-in-taiwans-national-health-insurance/2025-03-25T22:47:43+08:00https://flcube.com/eureka-biotechnology-secures-rmb-100-million-for-cell-and-gene-therapy-solutions/2025-03-25T22:45:25+08:00https://flcube.com/therorna-secures-over-rmb-280-million-in-series-a-round-to-accelerate-circrna-tech-development/2025-03-25T22:39:43+08:00https://flcube.com/qingdao-huaren-pharmaceutical-gains-ce-marks-for-monkeypox-and-covid-19-detection-kits/2025-03-25T22:35:32+08:00https://flcube.com/ssy-groups-blonanserin-and-paracetamol-approved-by-chinas-nmpa/2025-03-25T22:32:25+08:00https://flcube.com/shanghai-shineyo-medical-device-secures-rmb-100-million-in-series-a-round/2025-03-25T22:30:09+08:00https://flcube.com/rakuten-medical-taiwan-administers-first-dose-of-asp-1929-in-phase-ii-trial/2025-03-25T21:59:25+08:00https://flcube.com/beigenes-tislelizumab-accepted-for-review-in-gastric-cancer-treatment/2025-03-25T21:53:47+08:00https://flcube.com/zelgens-jakitinib-phase-iii-study-meets-primary-endpoint-for-myelofibrosis/2025-03-25T21:52:01+08:00https://flcube.com/nanjing-cro-caremo-secures-rmb-150-million-in-series-a-round/2025-03-25T21:49:56+08:00https://flcube.com/lees-pharmaceutical-wins-nmpa-approval-for-als-drug-teglutik/2025-03-25T21:44:07+08:00https://flcube.com/winsan-medical-acquires-52-stake-in-goodfeel-dental-clinic-for-rmb-156-million/2025-03-25T21:06:50+08:00https://flcube.com/innocare-pharmas-icp-189-first-dosed-in-china-shp2-inhibitor-trial/2025-03-25T21:03:17+08:00https://flcube.com/china-nt-pharma-group-inks-licensing-deal-for-orticumab-in-asia/2025-03-25T21:01:28+08:00https://flcube.com/mega-genomics-limited-makes-hong-kong-ipo-debut-at-hkd-18-per-share/2025-03-25T20:46:57+08:00https://flcube.com/venus-medtechs-venusp-valve-used-compassionately-in-us-for-pulmonary-regurgitation/2025-03-25T20:41:25+08:00https://flcube.com/merck-kgaas-erbitux-approved-in-china-for-head-and-neck-cancer-treatment/2025-03-25T20:39:29+08:00https://flcube.com/cspcs-jmt103-accepted-for-review-in-china-targets-rankl-related-deficiencies/2025-03-25T20:37:32+08:00https://flcube.com/grand-pharma-launches-sir-spheres-for-liver-cancer-treatment-in-china/2025-03-25T20:34:32+08:00https://flcube.com/organons-china-head-shi-wang-departs-to-lead-sanofi-greater-china/2025-03-25T18:48:42+08:00https://flcube.com/antengene-receives-australian-tga-approval-for-atg-018-clinical-trial/2025-03-25T18:45:46+08:00https://flcube.com/helixon-secures-rmb-500-million-in-series-a-round-to-advance-ai-driven-drug-development/2025-03-25T18:43:37+08:00https://flcube.com/jumbo-drug-banks-jdb153-enters-phase-i-trial-for-advanced-solid-tumors/2025-03-25T18:39:07+08:00https://flcube.com/remegens-telitacicept-begins-global-phase-iii-trial-for-severe-sle/2025-03-25T18:31:39+08:00https://flcube.com/suzhou-teligene-ltd-plans-ipo-on-shanghai-star-market-for-cancer-drug-development/2025-03-25T18:29:32+08:00https://flcube.com/brightgene-bio-medical-technology-gains-nmpa-approval-for-oseltamivir-dry-suspension/2025-03-25T18:25:37+08:00https://flcube.com/kexing-pharmaceuticals-oral-covid-19-drug-shen26-accepted-for-clinical-trial-review/2025-03-25T18:21:14+08:00https://flcube.com/sunshine-guojian-pharmaceutical-signs-licensing-deal-for-cipterbin-adc-development/2025-03-25T18:17:30+08:00https://flcube.com/takeda-pharmaceuticals-teduglutide-filed-for-marketing-approval-in-china/2025-03-25T18:04:18+08:00https://flcube.com/guangzhou-baiyunshan-halts-spinning-off-of-guangzhou-pharmaceutical-amid-hk-capital-shifts/2025-03-25T18:02:17+08:00https://flcube.com/frontier-biotechs-albuvirtide-shows-promising-hiv-treatment-results-in-phase-iii-trial/2025-03-25T17:52:56+08:00https://flcube.com/astrazeneca-officially-launches-fasenra-for-severe-eosinophilic-asthma-in-china/2025-03-25T17:04:22+08:00https://flcube.com/united-laboratories-inks-global-licensing-deal-with-novo-nordisk-for-obesity-drug/2025-03-25T16:56:50+08:00https://flcube.com/fapon-biotech-partners-with-tencent-healthcare-to-boost-ivd-and-medical-device-fields/2025-03-25T16:47:58+08:00https://flcube.com/joint-biosciences-ovv-01-receives-fda-fast-track-designation-for-soft-tissue-sarcoma-trial/2025-03-25T16:43:21+08:00https://flcube.com/sino-biopharmaceuticals-culmerciclib-shows-positive-results-in-phase-iii-breast-cancer-trial/2025-03-25T16:30:40+08:00https://flcube.com/clover-biopharmaceuticals-receives-termination-notice-from-gavi-for-covid-19-vaccine-agreement/2025-03-25T16:11:06+08:00https://flcube.com/simcere-pharmaceutical-group-reports-steady-revenue-amid-rd-investment-shift/2025-03-25T14:30:49+08:00https://flcube.com/henlius-biotech-reports-6-1-revenue-growth-with-strong-oncology-product-sales/2025-03-25T14:26:23+08:00https://flcube.com/sichuan-kelun-biotech-reports-25-5-revenue-growth-with-key-drug-approvals/2025-03-25T14:19:19+08:00https://flcube.com/chinas-nhsa-releases-2024-healthcare-security-bulletin-highlighting-insurance-coverage-and-reimbursement/2025-03-25T14:09:55+08:00https://flcube.com/7th-national-vbp-round-venue-moved-to-nanjing-from-shanghai/2025-03-25T13:59:47+08:00https://flcube.com/sino-biopharmaceuticals-tq-b3101-accepted-by-nmpa-for-ros1-nsclc-treatment/2025-03-25T13:57:24+08:00https://flcube.com/ascletis-pharma-presents-asc22-phase-iib-results-for-chronic-hepatitis-b-at-ilc-2022/2025-03-25T13:55:07+08:00https://flcube.com/cosunter-pharmas-hbv-surface-antigen-inhibitor-gst-hg121-approved-for-phase-i-trial/2025-03-25T13:52:39+08:00https://flcube.com/sanyou-biopharmaceuticals-and-dragon-sail-form-strategic-partnership-for-global-biopharma-services/2025-03-25T13:49:48+08:00https://flcube.com/nmpa-approves-senscures-cryoablation-catheter-and-kangduos-laparoscopic-surgery-system/2025-03-25T13:46:05+08:00https://flcube.com/westlake-therapeutics-secures-rmb-100-million-in-series-a-funding-for-red-cell-therapy-pipeline/2025-03-25T13:28:55+08:00https://flcube.com/phenovision-bio-secures-angel-funding-for-spatial-multi-omics-technology-platform/2025-03-25T13:21:30+08:00https://flcube.com/gsk-launches-nucala-in-china-for-eosinophilic-granulomatosis-with-polyangiitis/2025-03-25T13:16:19+08:00https://flcube.com/genor-biopharma-and-abogen-biosciences-collaborate-on-cancer-mrna-therapies/2025-03-25T13:13:40+08:00https://flcube.com/jenscare-scientifics-ken-valve-receives-nmpa-marketing-approval/2025-03-25T13:08:49+08:00https://flcube.com/sineugene-therapeutics-snug01-receives-fda-clearance-for-als-clinical-study/2025-03-25T12:52:23+08:00https://flcube.com/gsks-nucala-accepted-for-ema-review-for-copd-treatment/2025-03-25T12:44:26+08:00https://flcube.com/opella-and-jd-healthcare-collaborate-to-enhance-fatty-liver-awareness-in-china/2025-03-25T12:39:34+08:00https://flcube.com/chongqing-zhifei-acquires-51-stake-in-chenan-bio-for-rmb593-million/2025-03-25T12:31:44+08:00https://flcube.com/shanghai-ark-biopharmaceuticals-ak0901-meets-phase-iii-endpoints-in-adhd-trial/2025-03-25T11:37:02+08:00https://flcube.com/wuxi-xdc-reports-90-8-revenue-surge-expanding-in-adc-market/2025-03-25T11:11:01+08:00https://flcube.com/suzhou-xueji-biotechs-xj-mk-002-gets-fda-orphan-drug-designation-for-camt/2025-03-25T10:56:21+08:00https://flcube.com/beijing-sungen-biomedicals-sgc001-receives-fda-fast-track-designation-for-ami-treatment/2025-03-25T10:45:36+08:00https://flcube.com/lundbeck-initiates-talisman-study-on-multiple-system-atrophy-in-china-and-eu/2025-03-25T01:20:49+08:00https://flcube.com/ocon-healthcare-partners-with-bio-genuine-for-china-marketing-rights-and-womens-health-product-development/2025-03-25T01:18:44+08:00https://flcube.com/expeclinlab-raises-rmb-185-million-to-boost-clinical-mass-spectrometry-business/2025-03-25T01:07:06+08:00https://flcube.com/beijing-luzhu-biotechnology-secures-series-c-funding-for-meningococcal-vaccine-development/2025-03-25T01:01:34+08:00https://flcube.com/eli-lillys-donanemab-receives-tacit-approval-for-alzheimers-clinical-trial-in-china/2025-03-25T00:59:28+08:00https://flcube.com/hainan-lecheng-partners-with-fosun-pharma-on-innovative-medical-devices-and-diagnostics/2025-03-25T00:57:30+08:00https://flcube.com/recbios-r520a-mrna-covid-19-vaccine-receives-clinical-approval-in-the-philippines/2025-03-25T00:54:35+08:00https://flcube.com/pfizers-besponsa-first-prescribed-in-china-for-leukemia-treatment/2025-03-25T00:50:22+08:00https://flcube.com/kelun-pharmaceutical-receives-usd-30-million-from-msd-for-licensing-deal/2025-03-25T00:48:19+08:00https://flcube.com/immuneonco-biopharmaceuticals-files-for-hkse-ipo-with-comprehensive-tumor-immunotherapy-pipeline/2025-03-25T00:46:07+08:00https://flcube.com/clover-biopharmaceuticals-scb-2019-covid-19-vaccine-shows-strong-immune-response-in-third-shot-study/2025-03-25T00:44:17+08:00https://flcube.com/harbour-biomed-receives-fda-approval-for-hbm7008-clinical-trials/2025-03-25T00:42:32+08:00https://flcube.com/sinovac-biotechs-coronavac-receives-conditional-registration-from-south-african-regulator/2025-03-25T00:40:54+08:00https://flcube.com/joysbio-develops-rapid-test-for-sars-cov-2-omicron-subvariants-ba-4-and-ba-5/2025-03-25T00:38:58+08:00https://flcube.com/antengene-and-beigene-collaborate-on-selinexor-and-tislelizumab-combination-trial-for-lymphoma/2025-03-25T00:33:56+08:00https://flcube.com/cansino-biologics-partners-with-grand-life-sciences-to-commercialize-tetanus-vaccine-in-greater-china/2025-03-25T00:00:02+08:00https://flcube.com/allianthera-biopharma-starts-global-phase-i-trial-for-atb102-in-inflammatory-bowel-diseases/2025-03-24T22:58:36+08:00https://flcube.com/jiangsu-hengrui-pharmaceuticals-ivarmacitinib-receives-nmpa-approval-for-ankylosing-spondylitis/2025-03-24T22:50:15+08:00https://flcube.com/oriomics-liver-cancer-screening-reagent-earns-fda-breakthrough-device-designation/2025-03-24T22:42:11+08:00https://flcube.com/kexing-biopharm-partners-with-biomap-on-ai-driven-macromolecular-drug-development/2025-03-24T22:35:25+08:00https://flcube.com/cstone-pharmaceuticals-files-for-ema-approval-of-sugemalimab-for-unresectable-stage-iii-nsclc/2025-03-24T22:28:55+08:00https://flcube.com/abbisko-therapeutics-and-allist-pharmaceuticals-partner-on-kras-g12c-nsclc-combination-therapy/2025-03-24T22:23:47+08:00https://flcube.com/eli-lilly-launches-lilly-gateway-laboratory-in-china-to-boost-biotech-innovation/2025-03-24T22:12:39+08:00https://flcube.com/clover-biopharmaceuticals-receives-fda-approval-for-scb-1019-rsv-vaccine-trial/2025-03-24T22:07:38+08:00https://flcube.com/aim-vaccines-mrna-based-shingles-vaccine-receives-fda-approval-for-clinical-study/2025-03-24T21:53:47+08:00https://flcube.com/nmpa-updates-rules-on-domestic-production-of-imported-medical-devices/2025-03-24T21:44:26+08:00https://flcube.com/broncus-medicals-broncqct-approved-by-zhejiang-administration-for-china-market-entry/2025-03-24T21:38:15+08:00https://flcube.com/lifetech-scientifics-lambre-plus-laa-closure-system-gains-us-medical-insurance-coverage/2025-03-24T21:31:16+08:00https://flcube.com/hansoh-pharmaceutical-reports-21-revenue-growth-boosted-by-innovative-drugs/2025-03-24T18:47:48+08:00https://flcube.com/johnson-johnson-pledges-usd55-billion-for-us-expansion-focusing-on-manufacturing-and-rd/2025-03-24T18:42:07+08:00https://flcube.com/fda-issues-second-crl-to-hengruis-camrelizumab-combo-due-to-manufacturing-issues/2025-03-24T18:37:09+08:00https://flcube.com/abbvie-sues-genmab-over-alleged-trade-secret-misappropriation-in-adc-development/2025-03-24T18:31:13+08:00https://flcube.com/shanghai-junshi-biosciences-loqtorzi-approved-for-hepatocellular-carcinoma-treatment/2025-03-24T18:22:35+08:00https://flcube.com/shanghai-pharmaceuticals-subsidiary-fined-usd23-million-for-anti-monopoly-violations/2025-03-24T18:13:34+08:00https://flcube.com/hutchmeds-tazverik-receives-conditional-approval-from-chinas-nmpa-for-lymphoma-treatment/2025-03-24T18:03:12+08:00https://flcube.com/shenzhen-kangtai-partners-with-astrazeneca-to-establish-vaccine-jv-in-beijing/2025-03-24T17:53:13+08:00https://flcube.com/syneron-bio-collaborates-with-astrazeneca-to-develop-macrocyclic-peptides-for-chronic-diseases/2025-03-24T17:42:56+08:00https://flcube.com/hainan-poly-pharm-faces-delisting-after-csrc-imposes-strict-penalties-for-financial-misconduct/2025-03-24T17:34:59+08:00https://flcube.com/astrazeneca-unveils-usd2-5-billion-beijing-rd-center-plan-amid-strategic-china-partnerships/2025-03-24T17:12:41+08:00https://flcube.com/innovent-biologics-doses-first-patient-with-ibi354-in-hericare-ovarian01-study/2025-03-24T17:04:03+08:00https://flcube.com/everest-medicines-evm14-mrna-cancer-vaccine-clears-us-fda-ind-application/2025-03-24T16:57:43+08:00https://flcube.com/harbour-biomed-partners-with-astrazeneca-on-multi-specific-antibody-development/2025-03-24T16:50:58+08:00https://flcube.com/cspc-pharmaceutical-group-gains-nmpa-approval-for-sys6040-clinical-trial/2025-03-24T16:45:54+08:00https://flcube.com/duality-biotherapeutics-clears-hkex-hearing-set-for-ipo-with-2-7b-valuation/2025-03-24T00:11:25+08:00https://flcube.com/china-biopharmaceutical-leads-ai-integration-with-deepseek-r1/2025-03-23T11:39:50+08:00https://flcube.com/driving-innovation-in-traditional-chinese-medicine-a-policy-backed-renaissance/2025-03-22T13:32:32+08:00https://flcube.com/ge-healthcare-unveils-invenia-abus-premium-for-enhanced-dense-breast-screening/2025-03-21T17:45:59+08:00https://flcube.com/daiichi-sankyo-launches-datroway-in-japan-for-hr-positive-her2-negative-breast-cancer/2025-03-21T17:41:26+08:00https://flcube.com/porton-pharma-solutions-porton-advanced-partners-with-eureka-therapeutics-on-t-cell-therapies/2025-03-21T17:31:32+08:00https://flcube.com/triasteks-3d-printed-t20g-receives-us-clinical-approval-for-noac-treatment/2025-03-21T17:24:42+08:00https://flcube.com/johnson-johnsons-tremfya-gains-fda-approval-for-crohns-disease-treatment/2025-03-21T17:17:24+08:00https://flcube.com/menarini-group-partners-with-visualdx-to-enhance-bpdcn-identification-using-ai-ml-tools/2025-03-21T16:35:38+08:00https://flcube.com/elevation-oncology-halts-eo-3021-development-after-poor-phase-1-data/2025-03-21T16:02:54+08:00https://flcube.com/changchun-high-new-technology-industries-receives-us-trial-approval-for-gensci120-in-rheumatoid-arthritis/2025-03-21T15:36:28+08:00https://flcube.com/novartis-fabhalta-approved-by-fda-for-c3-glomerulopathy-treatment/2025-03-21T14:55:05+08:00https://flcube.com/sino-biopharmaceuticals-2024-revenue-up-10-2-on-strong-innovative-drug-sales/2025-03-21T14:29:24+08:00https://flcube.com/arcutis-biotherapeutics-zoryve-cream-nears-fda-approval-for-pediatric-atopic-dermatitis/2025-03-21T14:08:07+08:00https://flcube.com/sanofi-to-acquire-dr-0201-for-600-million-to-advance-myeloid-cell-engager/2025-03-21T14:01:32+08:00https://flcube.com/kexing-biopharm-and-hinova-forge-alliance-to-expand-global-market-reach/2025-03-21T13:32:07+08:00https://flcube.com/kintor-pharmaceuticals-kx-826-shows-promising-results-in-alopecia-phase-iii-trial/2025-03-21T13:23:52+08:00https://flcube.com/junshi-biosciences-receives-nmpa-approval-for-js212-in-advanced-solid-tumors/2025-03-21T13:06:10+08:00https://flcube.com/hengruis-trastuzumab-rezetecan-nears-8th-breakthrough-therapy-designation/2025-03-21T00:02:53+08:00https://flcube.com/fosuns-henlius-receives-fda-orphan-drug-designation-for-her2-targeting-hlx22/2025-03-20T23:47:56+08:00https://flcube.com/paratek-pharmaceuticals-to-acquire-optinose-for-330-million/2025-03-20T23:27:01+08:00https://flcube.com/boji-medicals-huasheng-transfers-glucosamine-sulfate-capsules-technology-to-panlong/2025-03-20T23:16:44+08:00https://flcube.com/oxford-biotherapeutics-partners-with-roche-on-cancer-therapeutics-discovery/2025-03-20T22:56:35+08:00https://flcube.com/joyo-pharmas-jyp0035-receives-clinical-trial-approval-for-breast-cancer-treatment/2025-03-20T22:45:29+08:00https://flcube.com/cde-announces-92nd-batch-of-reference-preparations-for-generic-drug-evaluation/2025-03-20T21:36:01+08:00https://flcube.com/hutchmeds-2024-financial-report-shows-dip-in-revenue-amid-oncology-product-growth/2025-03-20T21:23:21+08:00https://flcube.com/servier-and-black-diamond-therapeutics-ink-global-deal-for-bdtx-4933/2025-03-20T17:45:53+08:00https://flcube.com/ascletis-pharma-doses-first-patient-in-chinas-phase-ii-trial-for-hiv-1-treatment-with-asc22/2025-03-19T22:09:23+08:00https://flcube.com/jixing-pharmaceuticals-aficamten-receives-cde-approval-for-phase-iii-hcm-study/2025-03-19T22:05:21+08:00https://flcube.com/bdgene-advances-crispr-based-bd111-for-herpes-keratitis-with-ind-filing/2025-03-19T22:02:18+08:00https://flcube.com/microport-neurotech-lists-in-hong-kong-with-43-3-million-ipo/2025-03-19T22:00:35+08:00https://flcube.com/bayers-kerendia-approved-by-chinas-nmpa-for-diabetic-kidney-disease/2025-03-19T21:58:49+08:00https://flcube.com/hengrui-medicines-shr3680-approved-for-high-burden-metastatic-prostate-cancer/2025-03-19T21:56:09+08:00https://flcube.com/legend-biotech-collaborates-with-trinity-college-dublin-on-car-t-therapies-for-solid-tumors/2025-03-19T21:52:51+08:00https://flcube.com/anchordx-and-west-china-hospital-collaborate-on-lung-cancer-early-diagnosis/2025-03-19T21:48:36+08:00https://flcube.com/akeso-biopharmas-cadonilimab-approved-for-cervical-cancer-treatment/2025-03-19T21:46:29+08:00https://flcube.com/lanova-medicines-secures-series-b-funding-to-advance-oncology-pipeline/2025-03-19T21:41:25+08:00https://flcube.com/genfleet-collaborates-with-biolinerx-to-develop-motixafortide-for-pancreatic-cancer-in-china/2025-03-19T21:37:51+08:00https://flcube.com/henlius-and-palleon-partner-on-her2-targeted-antibody-sialidase-fusion-protein/2025-03-19T21:34:41+08:00https://flcube.com/telix-pharmaceuticals-gains-brazilian-approval-for-prostate-cancer-diagnostic-agent-tlx591-cdx/2025-03-19T16:20:08+08:00https://flcube.com/distinct-healthcare-files-for-hong-kong-ipo-to-expand-integrated-medical-services/2025-03-19T16:13:30+08:00https://flcube.com/pfizer-restructures-china-operations-to-boost-growth-and-innovation/2025-03-19T16:07:34+08:00https://flcube.com/cdes-2024-annual-drug-review-report-shows-continued-growth-in-regulatory-filings/2025-03-19T15:59:15+08:00https://flcube.com/everest-medicines-initiates-jiashan-plant-for-etrasimod-tablet-production/2025-03-19T15:54:32+08:00https://flcube.com/ge-healthcare-and-nvidia-expand-partnership-to-advance-autonomous-x-ray-and-ultrasound-technologies/2025-03-19T15:47:22+08:00https://flcube.com/tonghua-dongbao-initiates-phase-iii-trial-for-insulin-degludec-liraglutide-combo-in-type-2-diabetes/2025-03-19T15:39:49+08:00https://flcube.com/formosa-pharmaceuticals-inks-licensing-pact-with-cipla-for-app13007-in-11-countries/2025-03-19T15:32:38+08:00https://flcube.com/accuredit-therapeutics-receives-fda-orphan-drug-designation-for-attr-treatment/2025-03-19T15:15:39+08:00https://flcube.com/johnson-johnsons-nipocalimab-receives-fda-fast-track-designation-for-sjogrens-disease/2025-03-19T15:05:12+08:00https://flcube.com/medbanks-reports-2024-financial-results-amid-business-reorganization/2025-03-19T14:45:36+08:00https://flcube.com/astrazenecas-imfinzi-approved-in-eu-for-limited-stage-small-cell-lung-cancer/2025-03-19T14:35:00+08:00https://flcube.com/hutchmed-and-innovent-announce-positive-results-for-fruquintinib-and-sintilimab-in-renal-cell-carcinoma-trial/2025-03-19T13:28:14+08:00https://flcube.com/celregen-therapeutics-secures-rmb100-million-for-ipsc-regenerative-medicine-platform/2025-03-19T11:01:15+08:00https://flcube.com/ge-healthcare-launches-altix-ai-i-edition-for-enhanced-cardiac-procedures/2025-03-18T15:46:39+08:00https://flcube.com/wuxi-apptec-reports-steady-revenue-growth-amid-diversified-business-expansion/2025-03-18T15:40:03+08:00https://flcube.com/eisai-launches-jpy16-billion-tender-for-econavista-to-expand-dementia-care-ecosystem/2025-03-18T15:22:45+08:00https://flcube.com/bayers-kerendia-gets-fda-priority-review-for-heart-failure-with-preserved-ejection-fraction/2025-03-18T15:07:52+08:00https://flcube.com/hmzs-biopharmaceutical-blacklisted-after-failing-to-monitor-production-process/2025-03-18T15:02:08+08:00https://flcube.com/icecure-medical-secures-chinese-patent-for-cryogenic-system-connector/2025-03-18T14:44:30+08:00https://flcube.com/fibrogen-reports-decline-in-sales-pushes-ahead-with-roxadustat-and-new-drug-development/2025-03-18T14:35:58+08:00https://flcube.com/taiho-pharmaceutical-to-acquire-araris-biotech-for-usd-400-million-expanding-adc-portfolio/2025-03-18T14:30:03+08:00https://flcube.com/livzon-pharmaceutical-receives-approval-for-clinical-trials-of-adjuvanted-influenza-vaccine-lzsn2401/2025-03-18T14:17:50+08:00https://flcube.com/lifetech-scientifics-aortic-stent-system-approved-by-chinas-nmpa/2025-03-18T14:11:35+08:00https://flcube.com/pomdoctor-files-for-nasdaq-ipo-to-expand-chronic-disease-management-services/2025-03-18T14:05:38+08:00https://flcube.com/rona-therapeutics-initiates-phase-ii-study-for-rn0361-in-severe-hypertriglyceridemia/2025-03-18T13:58:55+08:00https://flcube.com/hengrui-pharmaceuticals-receives-nmpa-clearance-for-hrs-6213-in-solid-tumor-diagnosis/2025-03-18T13:51:27+08:00https://flcube.com/alphamab-oncologys-jskn033-receives-breakthrough-therapy-designation-for-platinum-resistant-ovarian-cancer/2025-03-18T13:38:38+08:00https://flcube.com/astrazeneca-licenses-alteogens-alt-b4-for-subcutaneous-cancer-therapies/2025-03-17T18:31:25+08:00https://flcube.com/merck-co-s-winrevair-approved-for-pulmonary-arterial-hypertension-in-hainan/2025-03-17T18:22:06+08:00https://flcube.com/visirna-therapeutics-announces-positive-phase-iii-results-for-plozasiran-in-fcs-treatment/2025-03-17T18:16:57+08:00https://flcube.com/robo-medicals-innovative-gastrointestinal-endoscopic-instrument-gains-nmpa-approval/2025-03-17T18:11:36+08:00https://flcube.com/basilea-pharmaceutica-marks-milestone-as-cresemba-sales-soar-in-asia-pacific/2025-03-17T18:00:50+08:00https://flcube.com/phenomenex-inaugurates-china-rd-center-to-advance-danahers-launching-china-strategy/2025-03-17T17:49:41+08:00https://flcube.com/bmss-breyanzi-approved-by-ec-for-relapsed-or-refractory-follicular-lymphoma/2025-03-17T17:42:06+08:00https://flcube.com/accropeutics-closes-rmb100-million-series-b-round-to-advance-inflammatory-disease-pipeline/2025-03-17T17:03:57+08:00https://flcube.com/life-molecular-imaging-launches-neuraceq-in-hong-kong-for-alzheimers-detection/2025-03-17T16:27:40+08:00https://flcube.com/frontera-therapeutics-receives-nmpa-approval-for-ft-003-in-diabetic-retinopathy-study/2025-03-17T16:17:11+08:00https://flcube.com/inari-medical-wins-nmpa-approval-for-thrombectomy-stent-system-in-china/2025-03-17T15:40:32+08:00https://flcube.com/jiangsu-hengrui-pharmaceuticals-tegileridine-approved-for-postoperative-pain-management/2025-03-17T15:30:28+08:00https://flcube.com/doma-biopharmaceuticals-her3-muc1-targeted-adc-dm002-receives-nmpa-clinical-approval/2025-03-17T15:18:18+08:00https://flcube.com/microport-endovascular-medtechs-cratos-system-approved-for-aortic-dissection-treatment/2025-03-17T13:49:22+08:00https://flcube.com/akeso-biopharmas-penpulimab-approved-for-first-line-npc-treatment/2025-03-17T13:40:23+08:00https://flcube.com/innovent-biologics-sycume-approved-by-chinas-nmpa-for-thyroid-eye-disease/2025-03-17T12:10:58+08:00https://flcube.com/simcere-pharmaceuticals-adc189-nda-accepted-for-influenza-treatment/2025-03-17T12:04:03+08:00https://flcube.com/rona-therapeutics-secures-25m-pre-b-round-to-advance-sirna-therapies/2025-03-16T22:15:31+08:00https://flcube.com/tonghua-golden-horse-pharmaceutical-embraces-ai-with-deepseek-r1-for-drug-innovation/2025-03-16T21:59:43+08:00https://flcube.com/deepseeks-rise-in-the-pharmaceutical-industry-a-new-era-of-ai-driven-transformation/2025-03-15T22:35:14+08:00https://flcube.com/pharmavan-and-kefeng-changjian-sign-pact-to-accelerate-spt-07a-development/2025-03-15T12:25:16+08:00https://flcube.com/roches-itovebi-approved-in-china-for-pik3ca-mutated-breast-cancer/2025-03-14T17:55:41+08:00https://flcube.com/quantum-hi-tech-and-ecnu-establish-ai-driven-drug-manufacturing-lab/2025-03-14T17:49:53+08:00https://flcube.com/biocity-and-msd-enter-clinical-collaboration-for-bc3195-and-keytruda-combination-trial/2025-03-14T17:39:40+08:00https://flcube.com/shanghai-fosun-pharmaceutical-transfers-unicorn-ii-holdings-stake-to-warburg-pincus-subsidiary/2025-03-14T17:20:25+08:00https://flcube.com/salipro-biotech-and-boehringer-ingelheim-collaborate-on-drug-development-for-membrane-proteins/2025-03-14T17:10:17+08:00https://flcube.com/cspc-pharmaceutical-group-receives-fda-approval-for-syh2051-clinical-trial/2025-03-14T16:58:12+08:00https://flcube.com/gaush-meditechs-anterion-ophthalmic-detector-receives-nmpa-market-approval/2025-03-14T16:34:59+08:00https://flcube.com/bio-thera-solutions-bat2506-biosimilar-accepted-for-review-by-chinas-nmpa/2025-03-14T16:11:13+08:00https://flcube.com/otsuka-and-lundbeck-win-eu-approval-for-rxulti-in-adolescent-schizophrenia/2025-03-14T15:54:58+08:00https://flcube.com/shanghai-fosun-pharmaceutical-gains-nmpa-approval-for-xh-s003-in-pnh-treatment/2025-03-14T15:46:21+08:00https://flcube.com/trinomab-biotech-launches-xintituo-for-tetanus-treatment-in-zhuhai/2025-03-14T15:29:19+08:00https://flcube.com/tasly-pharmas-nr-20201-receives-nmpa-approval-for-acute-ischemic-stroke-trial/2025-03-14T15:03:24+08:00https://flcube.com/jiangsu-aideas-ad108-receives-nmpa-approval-for-acute-ischemic-stroke/2025-03-14T14:48:40+08:00https://flcube.com/insilico-medicine-closes-usd110-million-series-e-round-to-advance-ai-driven-drug-pipeline/2025-03-14T14:25:24+08:00https://flcube.com/sanyou-medical-raises-rmb214-million-for-stake-in-smtp-technology/2025-03-14T14:11:06+08:00https://flcube.com/gaush-meditech-receives-nmpa-approval-for-femtosecond-laser-corneal-refractive-surgery-system/2025-03-14T02:06:41+08:00https://flcube.com/ipsen-appoints-olivia-brown-as-global-head-of-neurotoxins-effective-april-1st/2025-03-14T02:00:05+08:00https://flcube.com/china-medical-systems-cms-d003-receives-nmpa-approval-for-clinical-study-in-ohcm/2025-03-14T01:54:30+08:00https://flcube.com/zai-lab-submits-tivdak-bla-to-chinas-nmpa-for-cervical-cancer-treatment/2025-03-14T01:47:35+08:00https://flcube.com/haisco-pharmaceuticals-hsk44459-receives-nmpa-approval-for-psoriasis-and-atopic-dermatitis-trials/2025-03-14T01:37:27+08:00https://flcube.com/johnson-johnson-medtech-gains-fda-clearance-for-monarch-quest-with-ai-algorithms/2025-03-14T01:31:02+08:00https://flcube.com/arvinas-and-pfizer-announce-positive-phase-iii-results-for-vepdegestrant-in-er-her2-breast-cancer/2025-03-14T01:25:21+08:00https://flcube.com/harbour-biomed-launches-elance-therapeutics-to-tackle-obesity-treatment-challenges/2025-03-14T01:17:56+08:00https://flcube.com/pierre-fabre-partners-with-redridge-bio-on-bpa-drug-development-for-oncology-and-dermatology/2025-03-14T01:09:30+08:00https://flcube.com/visen-pharmaceuticals-ipo-launches-on-hong-kong-stock-exchange-amid-growth-in-endocrine-therapies/2025-03-14T01:01:23+08:00https://flcube.com/roche-and-zealand-pharma-collaborate-to-develop-petrelintide-for-weight-management/2025-03-14T00:56:53+08:00https://flcube.com/china-issues-guidelines-for-informatization-of-compact-county-level-medical-communities/2025-03-14T00:48:17+08:00https://flcube.com/cde-releases-91st-batch-of-reference-preparations-for-generic-drug-evaluation/2025-03-14T00:42:49+08:00https://flcube.com/chinas-nhsa-issues-guidelines-for-neurological-medical-services-pricing/2025-03-14T00:36:57+08:00https://flcube.com/grand-pharmaceutical-group-reports-strong-2024-financials-with-12-8-revenue-growth/2025-03-14T00:31:58+08:00https://flcube.com/ping-an-healthcare-reports-2024-financial-turnaround-with-growth-in-healthcare-services/2025-03-14T00:28:12+08:00https://flcube.com/jiuzhitangs-stem-cell-therapy-for-autism-receives-nmpa-clinical-trial-approval/2025-03-13T11:44:00+08:00https://flcube.com/newdel-biotech-secures-a-round-funding-to-accelerate-delai-driven-drug-discovery/2025-03-12T15:36:40+08:00https://flcube.com/sun-novo-partners-with-youjia-biomedical-to-develop-antibody-oligonucleotide-conjugate-for-metabolic-diseases/2025-03-12T15:23:58+08:00https://flcube.com/novartis-cosentyx-approved-by-nmpa-for-moderate-to-severe-hidradenitis-suppurativa/2025-03-12T14:52:02+08:00https://flcube.com/legend-biotech-reports-strong-q4-and-full-year-2024-financial-results/2025-03-12T14:40:22+08:00https://flcube.com/ono-pharmaceutical-licenses-ionis-sapablursen-for-global-development-in-polycythemia-vera/2025-03-12T14:22:35+08:00https://flcube.com/boehringer-ingelheim-launches-one-medicine-platform-with-veevas-development-cloud/2025-03-12T13:58:48+08:00https://flcube.com/biogen-initiates-transcend-study-for-felzartamab-in-late-amr-kidney-transplant-patients/2025-03-12T13:45:00+08:00https://flcube.com/mindrank-ltd-receives-fda-clearance-for-mrank-106-clinical-study-in-solid-tumors/2025-03-12T13:36:54+08:00https://flcube.com/aim-vaccine-co-ltd-announces-market-filing-for-innovative-serum-free-rabies-vaccine/2025-03-12T13:25:31+08:00https://flcube.com/towardpi-medical-secures-rmb500-million-in-series-e-round-for-ophthalmic-equipment-expansion/2025-03-12T13:14:51+08:00https://flcube.com/wuxi-xdc-and-abtis-partner-to-advance-antibody-drug-conjugate-innovation/2025-03-12T11:06:14+08:00https://flcube.com/ascletis-pharmas-asc47-shows-positive-results-in-phase-ib-study-for-weight-loss/2025-03-12T10:51:51+08:00https://flcube.com/astrazenecas-imfinzi-approved-by-nmpa-for-early-stage-nsclc-treatment/2025-03-11T15:20:23+08:00https://flcube.com/huihe-healthcares-k-clip-wins-chinese-approval-for-tricuspid-regurgitation-treatment/2025-03-11T15:13:36+08:00https://flcube.com/harbour-biomed-appoints-michael-d-patten-as-chief-strategy-officer-to-lead-global-growth/2025-03-11T15:01:51+08:00https://flcube.com/genmabs-hexabody-cd38-clinical-development-halted-after-jj-opt-out/2025-03-11T14:54:12+08:00https://flcube.com/sichuan-kelun-biotechs-sacituzumab-tirumotecan-wins-new-nmpa-approval-for-nsclc/2025-03-11T14:47:33+08:00https://flcube.com/illumina-responds-to-chinese-mofcom-notice-amid-sequencing-instrument-export-ban/2025-03-11T14:39:32+08:00https://flcube.com/huadong-medicine-seeks-regular-approval-for-elahere-in-ovarian-cancer-treatment/2025-03-11T14:32:01+08:00https://flcube.com/hansoh-pharmaceuticals-ameile-wins-new-nmpa-approval-for-advanced-nsclc-treatment/2025-03-11T14:24:45+08:00https://flcube.com/imeik-technology-development-co-ltd-acquires-majority-stake-in-regen-biotech-via-joint-venture/2025-03-11T14:18:48+08:00https://flcube.com/lundbecks-amlenetug-receives-orphan-drug-designation-in-japan-for-multiple-system-atrophy/2025-03-11T14:04:50+08:00https://flcube.com/shenzhen-genemind-biosciences-partners-with-precisiongenes-for-molecular-diagnostic-innovation/2025-03-11T00:26:56+08:00https://flcube.com/juvensis-therapeutics-secures-rmb100-million-for-heart-gene-therapy-development/2025-03-11T00:21:03+08:00https://flcube.com/jiangsu-hengrui-pharmaceuticals-receives-nmpa-approval-for-hrs-4029-in-acute-ischemic-stroke/2025-03-11T00:03:24+08:00https://flcube.com/innocare-pharma-presents-positive-phase-ii-results-of-icp-488-in-psoriasis-at-aad-meeting/2025-03-10T23:50:24+08:00https://flcube.com/nona-biosciences-launches-hu-matrix-ai-driven-engine-for-accelerated-antibody-drug-discovery/2025-03-10T23:13:23+08:00https://flcube.com/sichuan-biokin-pharmaceutical-plans-rmb3-9-billion-private-placement-for-novel-drug-rd/2025-03-10T23:02:40+08:00https://flcube.com/litedds-lit0922-approved-for-phase-i-trial-in-marker-expressing-advanced-solid-tumors/2025-03-10T22:29:31+08:00https://flcube.com/jiangsu-hengrui-pharmaceuticals-receives-nmpa-approval-for-shr-4602-clinical-study-in-advanced-solid-tumors/2025-03-10T18:53:21+08:00https://flcube.com/jiangsu-cowin-biotech-obtains-nmpa-license-for-gene-methylation-detection-kit/2025-03-10T18:47:25+08:00https://flcube.com/bristol-myers-squibbs-opdivo-yervoy-combo-approved-by-eu-for-hepatocellular-carcinoma/2025-03-10T17:34:13+08:00https://flcube.com/roche-launches-genentech-innovation-center-in-boston-to-accelerate-drug-development/2025-03-10T17:12:59+08:00https://flcube.com/sansure-biotech-plans-rmb130-million-investment-in-shenzhen-genemind-for-gene-sequencing-expansion/2025-03-10T16:17:43+08:00https://flcube.com/abbvies-skyrizi-approved-by-chinas-nmpa-for-moderate-to-severe-crohns-disease/2025-03-10T16:09:51+08:00https://flcube.com/sun-pharma-to-acquire-checkpoint-therapeutics-for-usd355-million-focusing-on-cancer-immunotherapy/2025-03-10T16:03:15+08:00https://flcube.com/pfizers-elrexfio-receives-conditional-nmpa-approval-for-relapsed-multiple-myeloma/2025-03-10T15:47:37+08:00https://flcube.com/microport-scientific-corp-reports-10-revenue-growth-and-58-net-loss-decrease-in-2024/2025-03-10T15:42:13+08:00https://flcube.com/sonoscape-medical-corp-wins-first-ai-powered-prenatal-ultrasound-approval-in-china/2025-03-10T15:32:21+08:00https://flcube.com/tyk-medicines-inc-s-ty-9591-shows-superiority-over-osimertinib-in-egfr-mutated-lung-cancer-with-brain-metastasis/2025-03-10T15:17:17+08:00https://flcube.com/aim-vaccine-co-ltd-receives-nmpa-approval-for-human-diploid-rabies-vaccine-trial/2025-03-10T10:56:21+08:00https://flcube.com/newco-model-chinas-innovative-drug-companies-new-transaction-mode-in-capital-winter/2025-03-09T19:10:01+08:00https://flcube.com/hangzhou-chance-pharmaceuticals-secures-new-funding-for-inhalation-powder-aerosol-development/2025-03-09T00:37:00+08:00https://flcube.com/sino-biopharmaceutical-licenses-nanjing-delovas-qp001-for-mainland-china-rights/2025-03-07T23:13:42+08:00https://flcube.com/fosun-pharmaceuticals-foritinib-accepted-for-review-by-chinas-nmpa-for-nsclc-treatment/2025-03-07T23:01:11+08:00https://flcube.com/fosun-pharmaceuticals-handayuan-seeks-nmpa-approval-for-expanded-indications-in-autoimmune-treatments/2025-03-07T22:52:24+08:00https://flcube.com/fosun-pharmaceuticals-humira-biosimilar-gains-new-indications-with-nmpa-approval/2025-03-07T22:51:52+08:00https://flcube.com/boehringer-ingelheim-appeals-cnipas-invalidation-of-jardiance-patents/2025-03-07T22:50:53+08:00https://flcube.com/everest-medicines-begins-clinical-trial-for-personalized-mrna-cancer-vaccine-evm16/2025-03-07T22:38:32+08:00https://flcube.com/sinocelltech-group-receives-nmpa-approval-for-sctt11-clinical-study-in-thyroid-eye-disease/2025-03-07T22:30:02+08:00https://flcube.com/johnson-johnson-terminate-phase-iii-ventura-program-for-aticaprant-in-adjunctive-treatment-of-mdd/2025-03-07T22:14:48+08:00https://flcube.com/major-policy-directions-in-chinas-healthcare-arena-a-comprehensive-breakdown/2025-03-07T22:01:30+08:00https://flcube.com/gan-lee-pharmaceuticals-joins-brazils-pdp-for-localized-insulin-production/2025-03-07T21:53:21+08:00https://flcube.com/insilico-medicines-ai-discovered-drug-rentosertib-approved-for-clinical-trials/2025-03-07T21:34:24+08:00https://flcube.com/4c-medical-lands-175m-series-d-to-advance-altavalve-tmvr-system/2025-03-07T18:50:57+08:00https://flcube.com/microport-cardioflow-medtechs-altavalve-receives-fda-breakthrough-designation-for-mitral-regurgitation-treatment/2025-03-07T18:48:38+08:00https://flcube.com/merck-kgaa-reports-2024-revenue-growth-despite-challenges-in-life-sciences/2025-03-07T18:42:12+08:00https://flcube.com/astellas-pharma-and-yaskawa-establish-jv-for-cell-therapy-product-manufacturing-platform/2025-03-07T18:38:10+08:00https://flcube.com/johnson-johnson-officially-launches-spravato-in-china-for-depression-treatment/2025-03-07T18:28:41+08:00https://flcube.com/abbisko-therapeutics-absk131-receives-clinical-trial-approval-from-chinas-nmpa/2025-03-07T18:22:20+08:00https://flcube.com/cryofocus-medtechs-malignant-stenosis-cryoablation-system-approved-by-nmpa-for-chinese-market/2025-03-07T18:15:25+08:00https://flcube.com/suzhou-genassists-gen6050x-receives-fda-clearance-for-duchenne-muscular-dystrophy-treatment/2025-03-07T16:05:10+08:00https://flcube.com/bioray-biopharmaceuticals-br111-receives-nmpa-clearance-for-clinical-trials-in-ror1-positive-malignancies/2025-03-07T00:37:07+08:00https://flcube.com/cstone-pharmaceuticals-cs5001-enters-phase-ib-trial-for-diffuse-large-b-cell-lymphoma/2025-03-06T22:59:43+08:00https://flcube.com/roches-gazyva-receives-fda-review-acceptance-for-lupus-nephritis-treatment/2025-03-06T21:35:36+08:00https://flcube.com/ascentage-pharmas-olverembatinib-receives-third-btd-in-china-for-ph-all-treatment/2025-03-06T21:27:54+08:00https://flcube.com/immuneoncos-timdarpacept-imm01-and-imm2510-receive-nmpa-approval-for-clinical-study-in-advanced-malignant-tumors/2025-03-06T21:19:14+08:00https://flcube.com/cspc-pharmas-jmt108-receives-nmpa-clinical-approval-for-advanced-malignant-tumors/2025-03-06T20:34:26+08:00https://flcube.com/sandozs-q4-2024-results-show-strong-biosimilar-growth/2025-03-06T20:24:32+08:00https://flcube.com/peijia-medical-completes-first-two-implants-of-trilogy-thv-system-in-taiwan/2025-03-06T18:53:29+08:00https://flcube.com/huadong-medicines-v30-optical-radiofrequency-device-receives-nmpa-review-approval/2025-03-06T18:47:48+08:00https://flcube.com/jiangsu-nhwa-pharmaceutical-invests-in-neurothree-to-develop-cns-therapies/2025-03-06T18:35:08+08:00https://flcube.com/bayer-posts-steady-q4-growth-pharmaceutical-sales-lead-the-way/2025-03-06T18:24:46+08:00https://flcube.com/novocare-pharmacy-offers-reduced-cost-wegovy-for-cash-paying-patients/2025-03-06T18:18:17+08:00https://flcube.com/antengenes-xpovio-receives-marketing-approval-in-indonesia/2025-03-06T18:09:24+08:00https://flcube.com/sino-medical-sciences-ht-supreme-stent-system-gains-vietnamese-marketing-approval/2025-03-06T18:01:37+08:00https://flcube.com/yifan-pharma-secures-rights-to-bayers-stivarga-and-nexavar-in-china/2025-03-06T17:45:59+08:00https://flcube.com/rongcan-biotechs-mrna-hpv-vaccine-receives-fda-clinical-approval/2025-03-06T15:43:42+08:00https://flcube.com/insilico-medicine-and-tenacia-partner-on-ai-driven-cns-therapies/2025-03-06T14:34:31+08:00https://flcube.com/lexenpharm-and-sun-novo-partner-on-long-acting-asthma-and-copd-drugs/2025-03-06T01:10:15+08:00https://flcube.com/baheal-pharmaceutical-gains-exclusive-rights-to-roches-mabthera-in-china/2025-03-06T01:00:42+08:00https://flcube.com/zhejiang-huahais-hb0034-meets-primary-endpoint-in-gpp-study/2025-03-06T00:43:42+08:00https://flcube.com/cstone-pharmaceuticals-and-steincares-ink-licensing-deal-for-pd-l1-inhibitor-in-latin-america/2025-03-06T00:27:32+08:00https://flcube.com/fosun-pharmas-24-valent-pneumococcal-vaccine-receives-nmpa-approval-for-phase-i-trial/2025-03-06T00:02:51+08:00https://flcube.com/bio-thera-solutions-inks-licensing-deal-with-world-medicine-for-bat2206/2025-03-05T23:01:51+08:00https://flcube.com/hainan-poly-pharms-us-partner-slate-run-pharmaceuticals-collaborates-with-premier-on-contrast-agents/2025-03-05T19:03:12+08:00https://flcube.com/gensaic-and-novo-nordisk-team-up-to-develop-cardiometabolic-therapies/2025-03-05T18:42:35+08:00https://flcube.com/msd-china-reorganizes-to-boost-mature-product-lines/2025-03-05T15:45:51+08:00https://flcube.com/suzhou-abogens-rsv-mrna-vaccine-ind-approved-by-chinas-cde/2025-03-05T15:34:16+08:00https://flcube.com/cde-launches-spark-project-to-boost-pediatric-antitumor-drug-rd/2025-03-05T15:27:50+08:00https://flcube.com/beigenes-tevimbra-receives-fda-approval-for-escc-treatment/2025-03-05T15:00:38+08:00https://flcube.com/corestar-biotech-secures-series-a-funding-for-poct-rd-expansion/2025-03-04T23:11:58+08:00https://flcube.com/great-robotics-raises-rmb-100m-for-surgical-robot-development/2025-03-04T23:06:23+08:00https://flcube.com/visum-pharma-series-b-financing-to-advance-rd-and-gmp-workshop-construction/2025-03-04T23:01:28+08:00https://flcube.com/yunnan-jianzhijia-plans-acquisition-of-hebei-tangren-pharmacy-in-usd-309-million-deal/2025-03-04T22:51:12+08:00https://flcube.com/sun-pharma-loses-vbp-bid-for-bicalutamide-in-china-due-to-quality-failures/2025-03-04T22:46:43+08:00https://flcube.com/allist-pharmaceuticals-furmonertinib-receives-nmpa-approval-for-first-line-nsclc-treatment/2025-03-04T22:44:28+08:00https://flcube.com/dakang-medical-secures-rmb-400m-in-series-e-round-for-hemodialysis-center-expansion/2025-03-04T22:42:03+08:00https://flcube.com/ascentage-pharmas-apg-5918-receives-fda-approval-for-first-in-human-study/2025-03-04T22:33:37+08:00https://flcube.com/luzhu-bio-files-for-hong-kong-ipo-after-rmb-4-42-billion-valuation/2025-03-04T22:31:33+08:00https://flcube.com/youwe-bios-series-b-financing-to-advance-microneedle-technology-commercialization/2025-03-04T22:28:40+08:00https://flcube.com/nhsa-updates-nrdl-with-focus-on-expert-review-and-simplified-renewals/2025-03-04T22:22:40+08:00https://flcube.com/astrazeneca-and-daiichi-sankyos-enhertu-shows-positive-results-in-phase-iii-study/2025-03-04T22:04:38+08:00https://flcube.com/genentechs-tnkase-approved-by-fda-for-acute-ischemic-stroke-treatment/2025-03-04T21:41:35+08:00https://flcube.com/eisais-lecanemab-rejected-by-australias-tga-for-early-alzheimers-treatment/2025-03-04T18:54:28+08:00https://flcube.com/boston-scientific-to-acquire-sonivie-boosting-hypertension-treatment-portfolio/2025-03-04T18:45:27+08:00https://flcube.com/fapon-biopharmas-fp008-receives-fda-approval-for-clinical-trials/2025-03-04T18:37:56+08:00https://flcube.com/kyorin-pharmaceutical-licenses-krp-m223-to-novartis-for-global-development/2025-03-04T18:29:53+08:00https://flcube.com/gsks-depemokimab-accepted-for-fda-review-as-ultra-long-acting-biologic/2025-03-04T16:50:12+08:00https://flcube.com/juvestar-and-raziel-therapeutics-launch-phase-iii-study-for-rzl-012-in-china/2025-03-04T16:44:00+08:00https://flcube.com/waters-and-kehuas-lc-ms-systems-gain-nmpa-approval-for-ivd-use/2025-03-04T16:10:53+08:00https://flcube.com/zai-labs-augtyro-receives-tfda-approval-for-ros1-positive-nsclc-and-ntrk-fusion-solid-tumors/2025-03-04T15:58:44+08:00https://flcube.com/shanghai-bioscience-completes-rmb-100m-financing-round-led-by-huagai-capital/2025-03-04T15:50:30+08:00https://flcube.com/huadong-medicines-saiyuexin-receives-nmpa-approval-for-pediatric-psoriasis-treatment/2025-03-04T14:53:06+08:00https://flcube.com/bayer-healthcare-and-jd-healthcare-partner-on-womens-health-ecosystem/2025-03-04T14:45:53+08:00https://flcube.com/huadong-medicines-hdm1005-receives-nmpa-approval-for-clinical-trials/2025-03-04T14:38:06+08:00https://flcube.com/bio-hearts-iberis-rdn-system-completes-first-commercial-surgery-in-germany/2025-03-04T14:30:41+08:00https://flcube.com/geneseeq-and-mgi-tech-form-global-partnership-for-oncology-solutions/2025-03-04T13:05:24+08:00https://flcube.com/tonghua-dongbaos-tongboli-under-gmp-inspection-in-egypt/2025-03-04T12:53:14+08:00https://flcube.com/united-laboratories-ubt251-receives-fda-green-light-for-phase-ii-ckd-study/2025-03-04T12:32:14+08:00https://flcube.com/cstone-pharmaceuticals-doses-first-patient-in-cs2009-phase-i-study-for-solid-tumors/2025-03-04T11:20:35+08:00https://flcube.com/nmpa-releases-plans-to-support-hk-and-macau-drug-device-production-in-mainland-cities/2025-03-03T22:00:32+08:00https://flcube.com/bio-thera-solutions-bat8010-receives-nmpa-approval-for-solid-tumor-clinical-trials/2025-03-03T21:58:39+08:00https://flcube.com/kelun-pharmas-skb264-adc-receives-breakthrough-therapy-designation-for-tnbc/2025-03-03T21:56:15+08:00https://flcube.com/burning-rock-biotech-launches-prevent-study-for-early-cancer-detection/2025-03-03T21:34:03+08:00https://flcube.com/harbour-biomeds-partner-nk-celltech-raises-rmb-100m-in-series-a-financing/2025-03-03T21:31:51+08:00https://flcube.com/nmpa-releases-55th-batch-of-reference-drugs-for-generic-evaluation/2025-03-03T21:29:43+08:00https://flcube.com/beigenes-tislelizumab-shows-survival-benefit-in-esophageal-cancer-study/2025-03-03T21:28:23+08:00https://flcube.com/nmpa-releases-work-plans-for-temporary-import-of-urgently-needed-drugs/2025-03-03T21:09:54+08:00https://flcube.com/huadong-medicines-biosimilar-ozempic-semaglutide-wins-nmpa-clinical-trial-approval/2025-03-03T21:08:10+08:00https://flcube.com/jixing-pharmaceuticals-enrolls-first-patient-in-etripamil-phase-iii-study-for-psvt/2025-03-03T21:04:56+08:00https://flcube.com/takedas-obizur-prioritized-for-review-in-acquired-hemophilia-a-treatment/2025-03-03T21:02:02+08:00https://flcube.com/genscript-biotechs-probio-subsidiary-receives-usd-37-25m-investment-from-zhenjiang-gaoxin/2025-03-03T19:04:24+08:00https://flcube.com/zhiyi-bio-raises-rmb-100m-in-series-b-round-for-lbp-pipeline-development/2025-03-03T19:01:20+08:00https://flcube.com/brii-biosciences-exercises-option-for-vir-3434-in-greater-china/2025-03-03T18:59:28+08:00https://flcube.com/innovent-biologics-doses-first-patient-in-ibi112-phase-ii-study-for-ulcerative-colitis/2025-03-03T18:56:46+08:00https://flcube.com/vivavision-biotech-and-dragon-sail-pharmaceutical-partner-on-ophthalmology-r-d/2025-03-03T18:54:27+08:00https://flcube.com/junshi-biosciences-receives-fda-approval-for-pi3k-%ce%b1-inhibitor-rp903-in-breast-cancer-study/2025-03-03T18:52:32+08:00https://flcube.com/innocare-pharmas-guangzhou-plant-approved-for-orelabrutinib-commercial-production/2025-03-03T18:49:22+08:00https://flcube.com/hengrui-medicines-generic-tacrolimus-wins-nmpa-approval-for-transplant-rejection-prevention/2025-03-03T18:47:17+08:00https://flcube.com/medtronic-kanghui-and-changzhou-high-tech-zone-partner-on-science-park/2025-03-03T18:45:07+08:00https://flcube.com/nhc-releases-technical-guidelines-for-drug-clinical-evaluation/2025-03-03T18:43:09+08:00https://flcube.com/hitgen-and-haichang-bio-partner-to-develop-anti-cancer-rnai-drugs/2025-03-03T18:41:27+08:00https://flcube.com/hainan-medical-products-administration-issues-guidelines-for-imported-drug-management/2025-03-03T18:38:49+08:00https://flcube.com/abbisko-therapeutics-doses-first-patient-in-absk061-phase-i-study-for-solid-tumors/2025-03-03T18:36:50+08:00https://flcube.com/ascletis-pharma-doses-first-patient-in-asc22-hiv-study-with-chidamide/2025-03-03T18:34:46+08:00https://flcube.com/fosun-pharmaceutical-and-reneuron-renew-ctx-cell-therapy-deal-for-china/2025-03-03T18:31:40+08:00https://flcube.com/eurofins-discoverx-opens-shanghai-office-to-expand-asia-pacific-operations/2025-03-03T18:26:20+08:00https://flcube.com/solasia-pharma-reduces-china-operations-transfers-drug-rights-to-lees/2025-03-03T18:22:04+08:00https://flcube.com/abbvie-enters-obesity-field-with-gubras-gub014295-licensing-deal/2025-03-03T18:11:55+08:00https://flcube.com/zeiss-groups-visumax-800-with-smile-pro-software-approved-by-chinas-nmpa/2025-03-03T17:57:32+08:00https://flcube.com/laeknas-lae120-receives-fda-approval-for-solid-tumor-clinical-trials/2025-03-03T17:51:18+08:00https://flcube.com/synerks-snk-2726-gets-fda-green-light-for-phase-i-hypertension-study/2025-03-03T17:45:04+08:00https://flcube.com/omron-healthcare-and-china-jo-jo-drugstores-launch-atrial-fibrillation-screening-zone/2025-03-03T17:39:04+08:00https://flcube.com/work-medical-and-chartwell-med-partner-on-investment-tools-for-healthcare-projects/2025-03-03T17:32:48+08:00https://flcube.com/innovent-biologics-doses-first-patient-in-ibi363-melanoma-study-vs-keytruda/2025-03-03T17:18:54+08:00https://flcube.com/eyebright-medtech-plans-private-placement-to-expand-contact-lens-production/2025-03-03T17:09:49+08:00https://flcube.com/sinocelltechs-finotonlimab-gets-nmpa-approval-for-liver-cancer-treatment/2025-03-03T17:00:51+08:00https://flcube.com/danatlas-raises-rmb-150m-to-advance-synthetic-lethality-drug-pipeline/2025-03-03T16:33:36+08:00https://flcube.com/magnet-biomedicine-and-eli-lilly-partner-on-molecular-glue-therapeutics/2025-03-03T16:21:30+08:00https://flcube.com/astrazeneca-and-amgens-tezspire-shows-positive-results-in-phase-iii-study/2025-03-03T16:10:12+08:00https://flcube.com/baidu-health-partners-with-jolly-pharma-to-boost-digital-drug-marketing/2025-03-03T15:59:16+08:00https://flcube.com/duality-biotherapeutics-updates-ipo-filing-with-hkse-under-chapter-18a-rules/2025-03-03T15:50:45+08:00https://flcube.com/dartsbio-licenses-potential-first-in-class-bsab-ds005-to-duality-biologics/2025-03-03T15:30:49+08:00https://flcube.com/duality-biologics-licenses-adc-platform-to-denmarks-adcendo-for-mesenchymal-tumor-program/2025-03-03T15:30:04+08:00https://flcube.com/biontech-and-duality-biologics-ink-exclusive-license-agreement-for-adc-assets/2025-03-03T15:30:03+08:00https://flcube.com/adcendo-aps-expands-partnership-with-duality-biologics-for-two-additional-adcs/2025-03-03T15:30:02+08:00https://flcube.com/biontechs-db-1303-adc-shows-promising-results-in-solid-tumor-phase-i-iia-trial/2025-03-03T15:30:01+08:00https://flcube.com/biotherus-inc-and-biontech-se-enter-global-license-agreement-for-cancer-therapies/2025-03-03T15:30:00+08:00https://flcube.com/biontech-expands-partnership-with-duality-biologics-for-global-rights-to-adc-db-1305/2025-03-03T15:30:00+08:00https://flcube.com/biontech-and-dualitys-db-1305-earns-fast-track-status-for-platinum-resistant-cancers/2025-03-03T15:29:59+08:00https://flcube.com/duality-biologics-db-1303-on-track-for-breakthrough-designation-for-her2-endometrial-cancer/2025-03-03T15:29:58+08:00https://flcube.com/duality-biologics-eyes-hong-kong-ipo-bolstering-adc-pipeline-and-global-clinical-trials/2025-03-03T15:29:57+08:00https://flcube.com/duality-biologics-initiates-global-clinical-trial-for-db-1419-in-advanced-solid-tumors/2025-03-03T15:29:56+08:00https://flcube.com/duality-biotherapeutics-bdca2-adc-db-2304-phase-i-trial-registered-on-clinicaltrials-gov/2025-03-03T15:29:56+08:00https://flcube.com/adcendo-aps-secures-oversubscribed-usd135-million-series-b-financing-to-advance-adc-pipeline/2025-03-03T15:29:55+08:00https://flcube.com/gsk-plc-enters-exclusive-option-agreement-with-duality-biologics-for-adc-candidate-db-1324/2025-03-03T15:29:54+08:00https://flcube.com/gsk-plc-partners-with-muna-therapeutics-to-discover-alzheimers-disease-treatment-targets/2025-03-03T15:29:53+08:00https://flcube.com/duality-biologics-db-1311-adc-shows-promising-results-in-global-phase-1-2a-trial/2025-03-03T15:29:52+08:00https://flcube.com/duality-biologics-bnt324-db-1311-shows-positive-results-in-global-phase-i-iia-study-at-esmo-asia/2025-03-03T15:29:51+08:00https://flcube.com/beigene-secures-global-rights-to-duality-biologics-b7h4-targeted-adc-db1312-bg-c9074/2025-03-03T15:29:51+08:00https://flcube.com/avenzo-therapeutics-licenses-duality-biologics-egfr-her3-bispecific-adc-avzo-1418-db-1418/2025-03-03T15:29:50+08:00https://flcube.com/duality-biologics-and-avenzo-ink-exclusive-license-for-db-1418-avzo-1418/2025-03-03T15:29:49+08:00https://flcube.com/3sbio-acquires-licensing-rights-to-duality-biologics-her2-targeting-adc-db-1303/2025-03-03T15:29:48+08:00https://flcube.com/carsgens-ct041-awarded-breakthrough-therapy-designation-for-gastric-cancer/2025-03-03T15:06:16+08:00https://flcube.com/huge-dental-files-for-hong-kong-ipo-with-diverse-dental-product-portfolio/2025-03-03T14:35:15+08:00https://flcube.com/cspc-pharmaceuticals-sirolimus-receives-btd-for-malignant-pecoma-treatment/2025-03-03T14:24:40+08:00https://flcube.com/pulnovo-medical-raises-usd-100m-in-series-c-financing-for-global-expansion/2025-03-03T14:10:01+08:00https://flcube.com/grand-pharma-sells-telix-shares-for-aud-143m-to-fund-clinical-programs/2025-03-03T13:54:35+08:00https://flcube.com/shionogi-files-nda-for-s-217622-covid-19-antiviral-drug-in-china/2025-03-03T00:33:40+08:00https://flcube.com/innocare-pharmas-icp-490-receives-nmpa-approval-for-hematological-malignancies/2025-03-03T00:31:35+08:00https://flcube.com/hrain-biotech-and-novartis-receive-breakthrough-therapy-designations-for-car-t-and-zolgensma/2025-03-03T00:29:23+08:00https://flcube.com/techbank-medical-closes-rmb-100m-series-a-to-build-global-innovation-platform/2025-03-03T00:27:04+08:00https://flcube.com/packgene-and-genemagic-partner-on-aav-production-and-cdmo-services/2025-03-03T00:19:51+08:00https://flcube.com/persongen-biotherapeutics-taa06-receives-clinical-trial-approval-for-b7-h3-car-t-therapy/2025-03-03T00:15:45+08:00https://flcube.com/akeso-biopharmas-cadonilimab-achieves-national-delivery-in-china/2025-03-03T00:13:42+08:00https://flcube.com/sobis-anakinra-kineret-prioritized-for-review-in-china-for-fmf-treatment/2025-03-03T00:11:37+08:00https://flcube.com/arctic-vision-enrolls-first-patient-in-arvn003-phase-iii-trial-for-presbyopia/2025-03-03T00:08:59+08:00https://flcube.com/guangdong-releases-2022-non-immunization-vaccine-catalog-7th-batch/2025-03-03T00:07:21+08:00https://flcube.com/wuxi-biologics-mfg14-facility-approved-for-microbial-product-manufacturing/2025-03-03T00:05:47+08:00https://flcube.com/jw-therapeutics-initiates-phase-i-study-of-jwatm204-for-hepatocellular-carcinoma/2025-03-03T00:03:56+08:00https://flcube.com/beijing-tianshi-tongda-raises-rmb-140m-for-autoimmune-disease-therapies/2025-03-03T00:01:58+08:00https://flcube.com/wuhan-yzy-biopharma-raises-rmb-200m-for-bispecific-antibodies-and-covid-19-vaccine-development/2025-03-02T23:56:24+08:00https://flcube.com/shandong-xinhua-pharmaceutical-inks-tech-transfer-deal-for-lxh-2201-with-imm/2025-03-02T23:54:34+08:00https://flcube.com/ai-in-healthcare-accelerating-applications-in-diagnostics-and-multi-omics-analysis/2025-03-02T23:38:34+08:00https://flcube.com/fosun-pharmas-fs-1502-gets-nmpa-approval-for-gastric-cancer-study/2025-03-02T16:04:25+08:00https://flcube.com/genesciences-somatropin-wins-nmpa-approval-for-prader-willi-syndrome/2025-03-02T15:59:49+08:00https://flcube.com/inmagene-and-hutchmed-dose-first-patient-in-img-007-global-phase-i-study/2025-03-02T15:56:22+08:00https://flcube.com/clinchoice-raises-usd-150m-in-funding-led-by-legend-capital-for-expansion/2025-03-02T15:53:06+08:00https://flcube.com/innocare-pharmas-bcl2-inhibitor-icp-248-accepted-for-nmpa-review/2025-03-02T15:48:39+08:00https://flcube.com/shenzhen-targetrx-raises-hundreds-of-millions-in-series-b-financing-for-drug-development/2025-03-02T15:45:56+08:00https://flcube.com/ascletis-pharma-files-ind-application-for-asc10-with-us-fda/2025-03-02T15:43:46+08:00https://flcube.com/mabpharms-cmab017-receives-nmpa-approval-for-clinical-study-in-solid-tumors/2025-03-02T15:40:58+08:00https://flcube.com/zhejiang-medicines-novocodex-subsidiary-receives-rmb-402m-investment/2025-03-02T15:38:26+08:00https://flcube.com/medicilon-biomedical-plans-rmb-2-16b-private-placement-for-rd-expansion/2025-03-02T15:36:14+08:00https://flcube.com/hansoh-pharmaceuticals-generic-ibrance-approved-by-nmpa/2025-03-02T15:31:08+08:00https://flcube.com/alibaba-healths-2022-financial-report-shows-revenue-growth-net-loss/2025-03-02T15:28:32+08:00https://flcube.com/wuxi-biologics-set-to-be-removed-from-us-restricted-trade-list/2025-03-02T15:25:38+08:00https://flcube.com/cde-releases-60th-batch-of-chemical-generic-reference-preparations/2025-03-02T15:22:22+08:00https://flcube.com/biointron-biologics-files-for-public-offering-aims-for-bse-listing/2025-03-02T14:59:20+08:00https://flcube.com/biocytogen-completes-deepseek-localization-integrates-with-thousand-mice-ten-thousand-antibodies-plan/2025-03-01T21:25:25+08:00https://flcube.com/bio-thera-solutions-licenses-bat2206-to-world-medicine-for-turkey/2025-02-28T23:46:28+08:00https://flcube.com/zai-lab-and-medilink-therapeutics-partner-to-develop-lrrc15-adc-drug-zl-6201-for-solid-tumors/2025-02-28T23:29:26+08:00https://flcube.com/cstone-pharmaceuticals-partners-with-steincares-for-sugemalimab-commercialization-in-latin-america/2025-02-28T21:27:42+08:00https://flcube.com/sciwind-bio-and-verdiva-bio-partner-on-global-development-of-obesity-therapies/2025-02-28T21:14:25+08:00https://flcube.com/beigenes-q4-and-2024-financials-highlight-significant-growth-and-product-success/2025-02-28T15:46:25+08:00https://flcube.com/zai-lab-q2-and-full-year-2024-report-shows-sales-growth-and-loss-reduction/2025-02-28T15:36:27+08:00https://flcube.com/viatris-q4-and-full-year-results-show-greater-china-growth/2025-02-28T13:46:45+08:00https://flcube.com/sciclone-pharmaceuticals-licenses-eisais-tasurgratinib-for-china/2025-02-28T13:36:24+08:00https://flcube.com/sino-biopharmaceutical-and-sciwind-biosciences-partner-on-cpx102-development/2025-02-28T13:17:24+08:00https://flcube.com/bayers-bluerock-therapeutics-gets-fast-track-for-opct-001-therapy/2025-02-28T12:58:00+08:00https://flcube.com/chipscreen-biosciences-cs12088-gets-nmpa-clearance-for-hepatitis-b-study/2025-02-28T12:12:24+08:00https://flcube.com/hengrui-pharmaceuticals-gets-nmpa-green-light-for-shr-a2009-study/2025-02-28T12:06:15+08:00https://flcube.com/ge-healthcares-china-ceo-yihao-zhang-to-retire-will-song-named-successor/2025-02-28T11:57:05+08:00https://flcube.com/zhongsheng-pharmaceuticals-ray1225-gets-green-light-for-phase-iii-study/2025-02-28T11:50:28+08:00https://flcube.com/akeso-inc-completes-patient-enrollment-for-ak138d1-phase-i-study/2025-02-28T11:43:17+08:00https://flcube.com/carsgen-therapeutics-administers-kj-c2219-in-sle-patient-in-iit/2025-02-28T11:30:23+08:00https://flcube.com/adagene-starts-phase-ii-trial-of-muzastotug-for-colorectal-cancer/2025-02-28T11:21:04+08:00https://flcube.com/shanghai-moyang-biotechs-aphranel-cc-needle-wins-nmpa-approval/2025-02-28T10:56:15+08:00https://flcube.com/huadong-medicines-adc-hdm2005-granted-fda-orphan-drug-designation-for-mcl/2025-02-28T10:17:26+08:00https://flcube.com/cloudr-groups-hong-kong-ipo-nets-hkd-482-million-with-sanofi-as-investor/2025-02-27T23:16:17+08:00https://flcube.com/baifu-laser-raises-rmb-100-million-in-series-a-funding-for-optoelectronic-equipment/2025-02-27T23:13:52+08:00https://flcube.com/oriomics-launches-xiaoweian-multi-tumor-early-screening-product/2025-02-27T23:09:34+08:00https://flcube.com/zhaoke-ophthalmology-enrolls-first-patient-in-tab014-phase-iii-study-for-wamd/2025-02-27T23:04:51+08:00https://flcube.com/generulor-medical-technology-raises-funds-for-gene-editing-diagnostics/2025-02-27T23:00:56+08:00https://flcube.com/brii-biosciences-launches-anti-covid-19-antibody-cocktail-in-china/2025-02-27T22:54:31+08:00https://flcube.com/junshi-biosciences-pd-1-inhibitor-tuoyi-under-fda-review-for-npc-treatment/2025-02-27T22:52:23+08:00https://flcube.com/i-mab-and-morphosys-license-drugs-to-hibio-in-global-oncology-deal/2025-02-27T22:50:01+08:00https://flcube.com/adicon-holdings-and-guardant-health-partner-on-genomic-profiling-in-china/2025-02-27T22:47:06+08:00https://flcube.com/beigene-and-innorna-partner-on-mrna-lnp-therapeutic-development/2025-02-27T22:43:53+08:00https://flcube.com/packgene-and-sineugene-partner-on-als-gene-therapy-research/2025-02-27T22:32:28+08:00https://flcube.com/china-establishes-leadership-group-to-combat-drug-related-crimes/2025-02-27T22:27:47+08:00https://flcube.com/phil-rivers-tech-raises-rmb-100-million-for-computational-medicine-push/2025-02-27T22:25:46+08:00https://flcube.com/gan-lee-pharmaceuticals-doses-first-patient-in-gzr101-phase-i-study/2025-02-27T22:20:36+08:00https://flcube.com/epimab-and-medigene-team-up-on-tcr-tce-therapy-for-immune-related-diseases/2025-02-27T16:57:56+08:00https://flcube.com/astrazenecas-camizestrant-shows-promise-in-serena-6-breast-cancer-study/2025-02-27T16:19:26+08:00https://flcube.com/bayers-gadoquatrane-shows-positive-results-in-phase-iii-quanti-cns-study/2025-02-27T16:08:41+08:00https://flcube.com/ping-an-good-doctor-launches-ai-powered-digital-doctor-service/2025-02-27T15:53:46+08:00https://flcube.com/eli-lilly-to-establish-four-new-us-pharma-manufacturing-sites/2025-02-27T15:47:07+08:00https://flcube.com/precigens-rrp-therapy-prgn-2012-gets-fda-review/2025-02-27T15:00:16+08:00https://flcube.com/burning-rock-and-mgi-tech-partner-to-advance-oncology-precision-medicine/2025-02-27T14:50:48+08:00https://flcube.com/cell-store-and-cygenta-forge-strategic-alliance-in-cell-and-gene-therapy-field/2025-02-27T14:31:06+08:00https://flcube.com/innocare-pharmas-orelabrutinib-shows-efficacy-in-rrms-at-actrims-forum/2025-02-27T14:20:05+08:00https://flcube.com/jiangsu-hengruis-hrs-1301-receives-nmpa-approval-for-hyperlipidemia/2025-02-27T14:06:01+08:00https://flcube.com/hepalink-pharmaceuticals-enoparin-receives-argentina-approval-for-thromboembolic-diseases/2025-02-27T12:37:49+08:00https://flcube.com/shenzhen-hepalinks-subsidiary-techdow-usa-secures-distribution-rights-for-anda-approved-drug/2025-02-27T12:29:14+08:00https://flcube.com/bio-hearts-iberis-system-approved-by-nmpa-for-hypertension-treatment/2025-02-27T12:17:52+08:00https://flcube.com/fosun-pharmas-tenapanor-approved-in-china-for-ckd-dialysis-patients/2025-02-27T11:46:49+08:00https://flcube.com/wuxi-xdc-expands-mou-with-ligachem-to-advance-next-gen-adc-development/2025-02-26T22:14:49+08:00https://flcube.com/kexing-biopharm-and-bio-sincerity-pharmaceutical-form-strategic-alliance/2025-02-26T22:04:31+08:00https://flcube.com/harbour-biomed-licenses-hat001-hbm9013-to-global-partner-for-crh-targeted-therapy/2025-02-26T21:53:38+08:00https://flcube.com/basecare-and-rhea-labs-form-five-year-alliance-to-expand-ivf-markets-globally/2025-02-26T21:45:00+08:00https://flcube.com/takeda-partners-with-bridgene-to-develop-immunology-and-neurology-drug-candidates/2025-02-26T21:32:25+08:00https://flcube.com/hansoh-pharmaceuticals-hs-10561-receives-nmpa-clearance-for-chronic-spontaneous-urticaria/2025-02-26T21:23:37+08:00https://flcube.com/jj-medtech-launches-locally-produced-harmonic-7s-scalpel-in-china/2025-02-26T21:15:55+08:00https://flcube.com/thermo-fisher-to-acquire-solventums-purification-business-for-usd-4-1b/2025-02-26T20:51:27+08:00https://flcube.com/jjs-tremfya-wins-nmpa-approval-for-crohns-disease-treatment/2025-02-26T20:36:54+08:00https://flcube.com/sanofis-sarclisa-wins-new-japan-approval-for-multiple-myeloma-combination-therapy/2025-02-26T20:31:50+08:00https://flcube.com/yoltech-therapeutics-yolt-203-shows-promise-in-primary-hyperoxaluria-type-1-trial/2025-02-26T20:25:31+08:00https://flcube.com/hq-pharma-and-shanghai-pharmaceuticals-expand-collaboration-for-global-market-access/2025-02-26T20:19:00+08:00https://flcube.com/green-valley-and-vazyme-team-up-on-alzheimers-disease-initiatives/2025-02-26T20:12:31+08:00https://flcube.com/mercks-keytruda-sbla-for-la-hnscc-accepted-by-fda-for-review/2025-02-26T20:03:29+08:00https://flcube.com/carsgen-therapeutics-and-zhuhai-sb-xinchuang-invest-in-ucarsgen-for-allogeneic-car-t-therapies/2025-02-26T19:58:03+08:00https://flcube.com/eli-lilly-launches-new-zepbound-doses-with-lower-prices-for-self-pay-patients/2025-02-26T19:47:40+08:00https://flcube.com/suzhou-ribo-life-sciences-rbd2080-sirna-drug-receives-australian-clinical-trial-approval/2025-02-26T19:42:08+08:00https://flcube.com/micurx-pharmaceuticals-sues-medpace-over-breach-of-contract-in-phase-iii-study/2025-02-26T19:20:54+08:00https://flcube.com/eli-lilly-acquires-organovos-fxr-program-for-inflammatory-bowel-disease/2025-02-26T19:07:45+08:00https://flcube.com/nhsa-sets-2022-goals-for-basic-medical-insurance-funding-and-reforms/2025-02-25T22:55:31+08:00https://flcube.com/neurophths-nr082-gene-therapy-receives-btd-for-leber-hereditary-optic-neuropathy/2025-02-25T22:53:03+08:00https://flcube.com/biotheus-inc-s-pm1009-bispecific-antibody-enters-clinical-trial-review-for-solid-tumors/2025-02-25T22:50:18+08:00https://flcube.com/rainmed-medical-makes-ipo-debut-on-hong-kong-exchange-with-valuation-over-usd-764m/2025-02-25T22:48:28+08:00https://flcube.com/micurx-pharmaceuticals-approved-for-star-market-ipo-by-csrc/2025-02-25T22:45:07+08:00https://flcube.com/innovent-biologics-pemazyre-becomes-first-fgfr2-inhibitor-approved-in-china/2025-02-25T22:43:07+08:00https://flcube.com/dizal-pharmas-dzd1516-receives-nmpa-green-light-for-her2-breast-cancer-trial/2025-02-25T22:40:18+08:00https://flcube.com/wuxi-xdc-partners-with-abtis-to-advance-adc-development-and-manufacturing/2025-02-25T22:37:41+08:00https://flcube.com/genscript-biotechs-legend-biotech-terminates-lb1901-car-t-phase-i-trial/2025-02-25T22:34:54+08:00https://flcube.com/neurophth-and-abogen-partner-on-mrna-therapy-for-retinal-diseases/2025-02-25T22:30:57+08:00https://flcube.com/hong-kong-researchers-explore-tes-for-depression-and-alzheimers-treatment/2025-02-25T22:27:47+08:00https://flcube.com/casi-pharmaceuticals-invests-in-precision-immune-therapeutics-for-cid-103-development/2025-02-25T22:26:10+08:00https://flcube.com/sinopharm-in-talks-to-acquire-bbi-life-sciences-in-usd-1b-deal/2025-02-25T22:21:28+08:00https://flcube.com/acer-therapeutics-and-relief-therapeutics-awarded-china-patent-for-acer-001/2025-02-25T22:02:38+08:00https://flcube.com/bangbang-robot-raises-usd-14-9m-in-series-b-to-expand-mobility-tech/2025-02-25T21:46:53+08:00https://flcube.com/obi-pharma-halts-obi-888-trial-over-manufacturing-costs-shifts-focus-to-globo-h-adc/2025-02-25T21:43:11+08:00https://flcube.com/hengrui-medicines-shr8554-accepted-for-nmpa-review-in-postoperative-pain/2025-02-25T21:39:14+08:00https://flcube.com/insilico-medicine-identifies-novel-als-therapeutic-targets-via-ai-platform-pandaomics/2025-02-25T21:37:19+08:00https://flcube.com/cspc-pharmaceuticals-jmt103-anti-rankl-antibody-prioritized-for-cde-review/2025-02-25T21:35:36+08:00https://flcube.com/gan-lee-pharmaceuticals-gzr4-ultra-long-acting-insulin-receives-clinical-trial-approval/2025-02-25T21:33:30+08:00https://flcube.com/aden-secures-usd-29-8m-series-b-funding-to-expand-drg-dip-solutions/2025-02-25T21:31:25+08:00https://flcube.com/nmpa-issues-new-vaccine-manufacturing-and-distribution-rules/2025-02-25T21:26:28+08:00https://flcube.com/vivavision-biotechs-vvn539-enters-phase-ii-trial-for-open-angle-glaucoma-in-us/2025-02-25T21:24:51+08:00https://flcube.com/science-sun-pharma-and-mabworks-biotech-sign-strategic-cooperation-pact/2025-02-25T21:15:17+08:00https://flcube.com/hangzhou-dac-bio-partners-with-janssen-on-adc-development-deal/2025-02-25T21:12:09+08:00https://flcube.com/cde-grants-priority-review-to-ascentages-olerembatinib-and-roches-crovalimab/2025-02-25T21:09:48+08:00https://flcube.com/athenex-sells-china-subsidiaries-to-tihe-capital-for-usd-19-million/2025-02-25T21:07:21+08:00https://flcube.com/tasly-pharmaceuticals-and-mauna-kea-form-jv-to-commercialize-cellvizio-in-china/2025-02-25T21:05:28+08:00https://flcube.com/microport-medbots-honghu-robot-wins-fda-510k-certification-for-joint-replacement/2025-02-25T21:03:30+08:00https://flcube.com/venus-medtechs-transcatheter-prosthetic-pulmonary-valve-approved-by-nmpa/2025-02-25T21:01:22+08:00https://flcube.com/hengrui-medicines-shr-1701-ameile-combo-greenlit-for-egfr-mutated-nsclc-trial/2025-02-25T20:58:45+08:00https://flcube.com/eucure-biopharma-doses-first-patient-in-yh003-keytruda-trial-for-mucosal-melanoma/2025-02-25T20:56:37+08:00https://flcube.com/overland-adct-biopharma-launches-global-phase-iii-trial-for-zynlonta-in-dlbcl/2025-02-25T20:52:44+08:00https://flcube.com/bio-thera-solutions-doses-first-patient-in-bat8006-phase-i-study-for-solid-tumors/2025-02-25T20:47:30+08:00https://flcube.com/zhejiang-medicines-arx305-adc-receives-clinical-trial-approval-for-cd70-positive-cancers/2025-02-25T20:44:55+08:00https://flcube.com/genscript-probio-partners-with-act-therapeutics-on-car-t-cell-therapy-development/2025-02-25T20:25:16+08:00https://flcube.com/abbisko-therapeutics-absk021-receives-btd-for-giant-cell-tumor-treatment/2025-02-25T20:19:39+08:00https://flcube.com/nmpa-reclassifies-glucosamine-sulfate-to-otc-mandates-label-revisions/2025-02-25T20:17:33+08:00https://flcube.com/chinas-jpo-launches-vbp-round-for-orthopedic-spine-consumables/2025-02-25T20:13:43+08:00https://flcube.com/hutchmeds-orpathys-tagrisso-combo-shows-promise-in-nsclc-at-wclc/2025-02-25T20:11:30+08:00https://flcube.com/junshi-biosciences-js203-bispecific-antibody-receives-nmpa-green-light-for-nhl-study/2025-02-25T20:08:16+08:00https://flcube.com/eli-lillys-trulicity-insulin-combo-meets-goals-in-chinas-award-chn3-study/2025-02-25T20:03:43+08:00https://flcube.com/chinas-7th-vbp-round-yields-65-5-drug-price-cuts-foreign-firms-secure-bids/2025-02-25T19:58:29+08:00https://flcube.com/acotec-scientifics-acoart-orchid-dhalia-dcb-wins-china-approval-for-avf-pta/2025-02-25T18:48:11+08:00https://flcube.com/orion-holdings-to-build-jining-vaccine-plant-in-chinas-shandong-province/2025-02-25T18:31:51+08:00https://flcube.com/hangzhou-dac-biotech-doses-first-patient-in-dxc007-aml-study/2025-02-25T18:29:02+08:00https://flcube.com/shanghai-ark-bio-raises-series-d-funding-to-advance-pediatric-and-respiratory-drug-pipeline/2025-02-25T18:27:18+08:00https://flcube.com/simceres-trilaciclib-wins-nmpa-approval-for-chemotherapy-myeloprotection/2025-02-25T18:24:56+08:00https://flcube.com/chinas-2021-healthcare-report-shows-rising-life-expectancy-increased-medical-spending/2025-02-25T18:22:48+08:00https://flcube.com/sinopharm-biotec-and-ganzhou-government-partner-on-medical-testing-and-biotech-rd/2025-02-25T18:19:49+08:00https://flcube.com/basecare-medical-and-haier-biomedical-partner-on-ivf-cryopreservation-tech/2025-02-25T18:17:43+08:00https://flcube.com/huadong-medicines-biosimilar-victoza-liraglutide-accepted-for-nmpa-review/2025-02-25T18:13:28+08:00https://flcube.com/correctsequence-therapeutics-tbe-tech-wins-uspto-patent-for-gene-editing/2025-02-25T18:08:56+08:00https://flcube.com/zai-labs-efgartigimod-nda-accepted-by-nmpa-for-myasthenia-gravis/2025-02-25T18:04:15+08:00https://flcube.com/overland-adct-biopharma-doses-first-patient-in-zynlontas-phase-iii-lotis-5-study-for-dlbcl/2025-02-25T18:00:37+08:00https://flcube.com/triastek-partners-with-eli-lilly-to-explore-3d-printing-for-gi-drug-delivery/2025-02-25T17:58:10+08:00https://flcube.com/novartis-aimovig-launches-in-china-via-gba-early-access-scheme-for-migraine-treatment/2025-02-25T17:54:51+08:00https://flcube.com/cstone-pharmaceuticals-gavreto-wins-hong-kong-approval-for-ret-fusion-nsclc/2025-02-25T17:52:11+08:00https://flcube.com/nmpa-approves-rockethearts-lv-assist-system-and-our-united-groups-radiation-therapy-device/2025-02-25T17:48:29+08:00https://flcube.com/ping-an-good-doctor-partners-with-china-biotech-services-for-cancer-testing-and-bnct-treatment/2025-02-25T17:44:21+08:00https://flcube.com/kelun-pharmas-skb264-adc-receives-nmpa-green-light-for-phase-ii-solid-tumor-study/2025-02-25T17:41:49+08:00https://flcube.com/luye-pharma-initiates-phase-iii-study-of-trulicity-biosimilar-ba5101-in-china/2025-02-25T17:38:49+08:00https://flcube.com/shanghai-electric-and-siemens-partner-on-localization-of-high-end-medical-equipment/2025-02-25T17:35:51+08:00https://flcube.com/beijing-science-suns-lz901-shingles-vaccine-receives-fda-ind-approval/2025-02-25T17:33:35+08:00https://flcube.com/acotec-scientifics-vericor-catheter-wins-nmpa-approval-for-peripheral-vascular-surgery/2025-02-25T17:27:07+08:00https://flcube.com/canbridge-pharmaceuticals-doses-first-patient-in-can108-biliary-atresia-study/2025-02-25T17:25:11+08:00https://flcube.com/ningbo-hicren-biotech-completes-rmb100m-pre-series-c-financing-for-orthopedic-robots/2025-02-25T17:22:35+08:00https://flcube.com/cstone-pharmaceuticals-explores-strategic-options-including-buyout/2025-02-25T17:10:35+08:00https://flcube.com/beigenes-tislelizumab-faces-fda-delay-due-to-inspection-hurdles/2025-02-25T17:08:20+08:00https://flcube.com/frontier-biotech-and-asymchem-partner-on-covid-19-drug-fb2001-development/2025-02-25T17:05:42+08:00https://flcube.com/sandoz-launches-pyzchiva-biosimilar-of-jjs-stelara-in-us/2025-02-25T15:41:49+08:00https://flcube.com/cde-includes-chiral-techs-cerdelga-generic-in-rare-disease-care-plan/2025-02-25T15:21:09+08:00https://flcube.com/medtronics-brainsense-adaptive-dbs-wins-fda-approval-for-parkinsons-treatment/2025-02-25T15:06:42+08:00https://flcube.com/smpa-suspends-indobufen-procurement-after-patent-infringement-verdict/2025-02-25T14:57:59+08:00https://flcube.com/xellsmarts-ipsc-therapy-xs-228-receives-fda-approval-for-als-study/2025-02-25T14:21:36+08:00https://flcube.com/huadong-medicines-hdm1005-receives-nmpa-approval-for-osa-treatment/2025-02-25T14:13:36+08:00https://flcube.com/pfizers-hympavzi-marstacimab-launched-in-chinas-boao-lecheng-pilot-zone-for-hemophilia/2025-02-25T14:02:20+08:00https://flcube.com/summit-therapeutics-and-pfizer-collaborate-on-ivonescimab-adc-combo-for-solid-tumors/2025-02-25T13:56:54+08:00https://flcube.com/dizal-pharmas-2024-revenues-surge-295-to-rmb360m-loss-narrows-by-rmb251m/2025-02-25T13:24:54+08:00https://flcube.com/bristol-myers-squibbs-opdivo-yervoy-combo-nears-fda-approval-for-msi-h-colorectal-cancer/2025-02-25T13:11:57+08:00https://flcube.com/cansino-biologics-receives-nmpa-approval-for-dtcp-hib-mcv4-combined-vaccine/2025-02-25T13:02:13+08:00https://flcube.com/mgi-tech-partners-with-oncoclinicasco-to-advance-precision-medicine-in-brazil/2025-02-25T12:55:58+08:00https://flcube.com/boehringer-ingelheims-nerandomilast-receives-nmpa-review-for-ipf-treatment/2025-02-25T12:48:20+08:00https://flcube.com/qyuns-therapeutics-qx002n-meets-primary-endpoint-in-as-phase-iii-study/2025-02-25T11:40:37+08:00https://flcube.com/takedas-takhzyro-receives-ema-approval-for-new-administration-form-in-hae-patients/2025-02-25T11:30:35+08:00https://flcube.com/vbp-round-7-drug-procurement-contract-awards-top-winners-revealed/2025-02-25T00:20:07+08:00https://flcube.com/merck-kgaa-launches-uptune-program-in-asia-offers-startups-up-to-e100000/2025-02-25T00:15:05+08:00https://flcube.com/pfizer-launches-cejemly-in-china-for-stage-iii-nsclc-expands-immunotherapy-reach/2025-02-25T00:13:07+08:00https://flcube.com/sihuan-pharma-to-sell-generic-drug-businesses-shift-focus-to-aesthetics-and-biologics/2025-02-25T00:08:07+08:00https://flcube.com/luye-pharmas-lurbinectedin-receives-hainan-approval-for-sclc-treatment/2025-02-25T00:05:23+08:00https://flcube.com/fermion-secures-series-b-financing-to-advance-ai-driven-drug-development/2025-02-25T00:02:32+08:00https://flcube.com/biotree-raises-14-8m-in-series-a-financing-to-expand-multi-omics-platform/2025-02-24T23:58:01+08:00https://flcube.com/kexing-pharmaceuticals-shen26-covid-19-drug-receives-nmpa-approval-for-clinical-trials/2025-02-24T23:52:57+08:00https://flcube.com/wedoctor-partners-with-jinan-innovation-zone-to-launch-dual-healthcare-platform/2025-02-24T23:46:08+08:00https://flcube.com/immuneoncos-imm2902-receives-fda-fast-track-designation-for-cd47-her2-targeting/2025-02-24T23:44:02+08:00https://flcube.com/attec-completes-pre-series-a-financing-with-sequoia-china-backing-protein-degradation-tech/2025-02-24T23:41:25+08:00https://flcube.com/innovent-biologics-mazdutide-meets-phase-ii-goals-in-type-2-diabetes-study/2025-02-24T23:36:35+08:00https://flcube.com/digital-precision-medicine-raises-hundreds-of-millions-in-series-b-financing-for-molecular-imaging-innovation/2025-02-24T23:34:00+08:00https://flcube.com/sihuan-pharmas-fourth-gen-insulin-degludec-nda-accepted-by-nmpa-for-review/2025-02-24T23:29:14+08:00https://flcube.com/sihuan-pharmas-anaprazole-enters-phase-ii-study-for-reflux-esophagitis/2025-02-24T23:26:33+08:00https://flcube.com/takeda-opens-rd-asia-pacific-headquarters-in-shanghai-to-boost-drug-development/2025-02-24T23:24:05+08:00https://flcube.com/tongling-bionic-raises-hundreds-of-millions-in-series-b-financing-for-cardiopulmonary-equipment-development/2025-02-24T23:22:04+08:00https://flcube.com/sesen-bio-terminates-vicineum-development-after-fda-talks-citing-phase-iii-costs/2025-02-24T23:13:21+08:00https://flcube.com/huadong-medicines-gfr-monitoring-system-accepted-by-nmpa-for-review/2025-02-24T23:09:02+08:00https://flcube.com/roches-chugai-launches-edirol-in-china-for-postmenopausal-osteoporosis/2025-02-24T23:06:32+08:00https://flcube.com/brii-biosciences-partners-with-huarun-medicine-to-commercialize-covid-19-antibody-cocktail-in-china/2025-02-24T23:01:09+08:00https://flcube.com/hengrui-medicine-launches-revelutamide-for-metastatic-prostate-cancer-in-china/2025-02-24T22:58:11+08:00https://flcube.com/chongqing-lummy-pharma-cancels-yzy-biopharma-y400-partnership-secures-compensation/2025-02-24T22:56:44+08:00https://flcube.com/hutchmed-initiates-phase-i-study-of-cd47-monoclonal-antibody-hmpl-a83-in-china/2025-02-24T22:53:50+08:00https://flcube.com/grand-pharma-acquires-stake-in-xeltis-and-licenses-axess-for-hemodialysis-in-greater-china/2025-02-24T22:50:44+08:00https://flcube.com/dac-biotechs-dxc005-adc-doses-first-patient-in-beijing-cancer-hospital-trial/2025-02-24T22:14:15+08:00https://flcube.com/jj-q2-sales-rise-8-but-profits-plunge-23-amid-china-covid-lockdowns/2025-02-24T22:12:03+08:00https://flcube.com/novartis-q2-results-show-5-growth-led-by-entresto-and-cosentyx/2025-02-24T22:08:32+08:00https://flcube.com/aidea-pharmaceutical-acquires-19-96-nd-pharm-stake-to-boost-urokinase-business/2025-02-24T21:40:08+08:00https://flcube.com/nhsa-issues-new-medical-service-pricing-policy-to-enhance-public-welfare-and-innovation/2025-02-24T21:37:23+08:00https://flcube.com/microport-cardioflow-completes-first-clinical-use-of-dry-valve-transcatheter-mitral-valve-system/2025-02-24T21:34:29+08:00https://flcube.com/wuxi-biologics-to-build-1-4b-crdmo-hub-in-singapore-creating-1500-jobs/2025-02-24T21:31:48+08:00https://flcube.com/antengene-and-celularity-partner-on-bispecific-antibody-and-nk-cell-therapy-combo/2025-02-24T21:28:59+08:00https://flcube.com/kexing-pharmaceutical-launches-phase-iii-influenza-vaccine-study-in-chile/2025-02-24T21:13:54+08:00https://flcube.com/henlius-biotechs-hlx14-biosimilar-wins-tga-approval-for-global-phase-iii-osteoporosis-study/2025-02-24T21:10:56+08:00https://flcube.com/luye-pharmas-rotigotine-microspheres-meet-phase-iii-goals-in-parkinsons-study/2025-02-24T21:08:20+08:00https://flcube.com/eli-lillys-retevmo-wins-special-approval-in-chinas-lecheng-medical-pilot-zone/2025-02-24T21:06:04+08:00https://flcube.com/harbin-gloria-partners-with-genolmmune-on-pd-1-and-neoantigen-therapy-for-nsclc/2025-02-24T20:59:11+08:00https://flcube.com/maxvax-biotech-raises-rmb500m-in-series-b-to-advance-vaccine-pipelines/2025-02-24T20:52:07+08:00https://flcube.com/livzons-v-01-and-v-01d-351-vaccines-show-strong-safety-immunity-as-covid-boosters/2025-02-24T20:49:31+08:00https://flcube.com/novartis-tislelizumab-faces-fda-hurdle-in-first-line-nsclc-monotherapy/2025-02-24T20:46:58+08:00https://flcube.com/canbridge-pharmaceuticals-doses-first-patient-in-can103-gaucher-disease-trial/2025-02-24T20:44:44+08:00https://flcube.com/inxmed-receives-10m-debt-financing-from-spd-silicon-valley-bank-to-advance-fak-inhibitor-in10018/2025-02-24T20:41:51+08:00https://flcube.com/frontera-therapeutics-raises-160m-in-series-b-to-advance-gene-therapy-ft-001/2025-02-24T20:39:32+08:00https://flcube.com/national-allied-procurement-office-allows-vbp-winners-to-adjust-mah-and-manufacturing-details/2025-02-24T20:34:23+08:00https://flcube.com/ipsen-posts-8-7-revenue-growth-in-2024-driven-by-rare-diseases-and-oncology/2025-02-24T20:27:00+08:00https://flcube.com/meyer-fsmp-hong-kong-secures-nmpa-approval-for-first-fsmp-in-greater-china/2025-02-24T18:47:53+08:00https://flcube.com/pfizer-halts-global-development-of-hemophilia-b-gene-therapy-beqvez-amid-limited-demand/2025-02-24T17:13:34+08:00https://flcube.com/jointown-pharmaceutical-partners-with-shandong-dyne-to-boost-pediatric-drug-distribution/2025-02-24T17:01:23+08:00https://flcube.com/cspc-pharmaceutical-initiates-phase-iii-trial-for-ammuxetine-in-depression-treatment/2025-02-24T16:34:17+08:00https://flcube.com/subtle-medical-integrates-deepseek-with-fda-approved-supmr-ai-platform/2025-02-24T16:19:48+08:00https://flcube.com/aws-collaborates-with-msk-to-accelerate-oncology-research-via-ai-and-cloud-tech/2025-02-24T15:59:44+08:00https://flcube.com/cholesgen-raises-over-rmb100m-in-series-a-to-advance-metabolic-disease-pipelines/2025-02-24T15:43:39+08:00https://flcube.com/innornas-in013-receives-fda-rare-pediatric-designation-for-wilsons-disease-treatment/2025-02-24T15:33:27+08:00https://flcube.com/amoytop-biotech-to-acquire-skyline-therapeutics-gene-therapy-assets-for-15m-plus-milestones/2025-02-24T15:06:31+08:00https://flcube.com/novo-nordisks-emerging-business-division-vp-eve-jiang-departs-for-external-opportunities/2025-02-24T14:47:46+08:00https://flcube.com/joyo-pharmas-jyp0015-receives-cde-approval-for-ras-mutation-cancer-trials/2025-02-24T14:33:44+08:00https://flcube.com/zhejiang-huahai-pharmas-hb0056-receives-nmpa-approval-for-asthma-trials/2025-02-24T14:20:50+08:00https://flcube.com/zhejiang-dian-diagnostics-partners-with-best-covered-to-tackle-alzheimers-disease/2025-02-24T14:09:08+08:00https://flcube.com/grand-pharmaceutical-to-boost-stake-in-nanjing-kainite-medical-technology-via-exercise-of-partial-subscription-rights/2025-02-24T13:56:50+08:00https://flcube.com/coherent-biopharmas-cbp-1019-granted-fda-fast-track-status-for-endometrial-cancer/2025-02-24T13:14:52+08:00https://flcube.com/sanofi-and-tevas-duvakitug-hits-key-milestones-in-uc-and-cd-study-at-ecco-congress/2025-02-24T13:06:31+08:00https://flcube.com/triasteks-3d-printed-drug-d23-shows-promise-in-treating-iga-nephropathy/2025-02-24T12:11:29+08:00https://flcube.com/jjs-tremfya-meets-all-endpoints-in-phase-iii-uc-study-eyes-fda-approval-for-sc-induction/2025-02-24T12:00:29+08:00https://flcube.com/microport-cardioflows-anchorman-laa-occluder-system-earns-ce-mark-approval/2025-02-24T11:48:34+08:00https://flcube.com/aim-vaccine-leverages-deepseek-ai-to-optimize-mrna-shingles-vaccine-design/2025-02-24T11:38:42+08:00https://flcube.com/innovent-biologics-ipilimumab-nda-accepted-by-cde-with-priority-review-for-colon-cancer/2025-02-24T11:22:48+08:00https://flcube.com/linno-pharmaceuticals-raises-usd-14-78m-for-blood-brain-barrier-drug-delivery-tech/2025-02-24T01:11:44+08:00https://flcube.com/frontier-biotech-raises-usd-51-4m-to-advance-covid-19-drug-fb2001/2025-02-24T01:07:04+08:00https://flcube.com/curatia-medical-raises-tens-of-millions-in-funding-co-led-by-hidea-investment/2025-02-24T01:04:52+08:00https://flcube.com/novaremed-ag-licenses-nrd-e1-to-neurofront-for-greater-china-development/2025-02-24T01:00:37+08:00https://flcube.com/ascentage-pharmas-olverembatinib-receives-health-canada-approval-for-phase-ib-study/2025-02-24T00:52:18+08:00https://flcube.com/junshi-biosciences-toripalimab-receives-ec-orphan-drug-designation-for-npc/2025-02-24T00:50:19+08:00https://flcube.com/yifeng-pharmacy-chain-to-establish-new-company-with-tangshan-deshuntang/2025-02-24T00:47:52+08:00https://flcube.com/ji-xing-pharmaceuticals-enrolls-first-patient-in-oc-01-phase-iii-study-for-dry-eye/2025-02-24T00:42:06+08:00https://flcube.com/gan-lee-pharmaceuticals-doses-first-patient-in-gzr18-phase-ii-study-for-diabetes-and-obesity/2025-02-24T00:39:29+08:00https://flcube.com/sinopep-allsino-biopharms-spn0103-009-receives-nmpa-approval-for-diabetes-and-obesity-clinical-study/2025-02-24T00:36:47+08:00https://flcube.com/lepu-biopharmas-pucotenlimab-receives-conditional-nmpa-approval-for-msi-h-dmmr-tumors/2025-02-24T00:34:44+08:00https://flcube.com/fosun-pharmaceutical-to-raise-usd-662m-via-share-issue-for-drug-development-and-api-base/2025-02-24T00:31:21+08:00https://flcube.com/tris-pharma-and-pediatrixs-methylphenidate-tablet-ipsens-triptorelin-injection-awarded-priority-review-by-cde/2025-02-24T00:28:48+08:00https://flcube.com/roche-posts-5-h1-sales-growth-led-by-new-drugs-and-immunodiagnostics/2025-02-24T00:25:11+08:00https://flcube.com/innocares-tafasitamab-receives-first-prescription-in-chinas-boao-lecheng-pilot-zone/2025-02-24T00:21:59+08:00https://flcube.com/ai-in-healthcare-the-impact-of-deepseek-technology-and-industry-developments/2025-02-23T23:42:52+08:00https://flcube.com/in-depth-analysis-of-the-national-healthcare-security-policy-a-guide-to-key-reforms-and-implications/2025-02-22T20:39:01+08:00https://flcube.com/state-councils-draft-plan-boosts-innovative-drug-development-via-medical-insurance-reforms/2025-02-22T00:22:45+08:00https://flcube.com/roche-unveils-sequencing-by-expansion-sbx-technology-for-next-generation-sequencing/2025-02-22T00:14:40+08:00https://flcube.com/shanghai-issues-legal-guidebook-for-innovative-drug-marketing/2025-02-22T00:07:51+08:00https://flcube.com/china-outlines-drug-pricing-reforms-encourages-insurance-funds-for-innovation/2025-02-22T00:01:48+08:00https://flcube.com/roches-tecentriq-wins-japan-approval-for-alveolar-soft-part-sarcoma/2025-02-21T23:48:43+08:00https://flcube.com/gsks-nucala-receives-nmpa-review-for-copd-treatment/2025-02-21T23:38:54+08:00https://flcube.com/nuwacell-biotechs-ncr101-approved-for-ild-clinical-study-by-chinas-cde/2025-02-21T23:30:15+08:00https://flcube.com/nuwacell-biotechnologies-secures-rmb150-million-in-series-b-financing-for-ipsc-therapies/2025-02-21T23:27:41+08:00https://flcube.com/baxter-international-reports-q4-2024-revenues-of-usd-2-75b-up-2-yoy/2025-02-21T15:09:15+08:00https://flcube.com/horimed-raises-usd-13-8m-to-advance-optical-and-ultrasonic-imaging-tech/2025-02-21T14:31:38+08:00https://flcube.com/gene-cradle-and-byongen-therapeutics-partner-on-next-generation-dmd-gene-therapies/2025-02-21T14:14:59+08:00https://flcube.com/bristol-myers-squibbs-opdivo-shows-survival-benefit-in-checkmate-816-study/2025-02-21T13:55:49+08:00https://flcube.com/corxel-pharmaceuticals-to-test-jx10-in-acute-ischemic-stroke-patients-with-nmpa-approval/2025-02-21T13:33:59+08:00https://flcube.com/harbour-biomed-and-insilico-medicine-partner-on-ai-powered-antibody-development/2025-02-21T13:26:40+08:00https://flcube.com/gileads-livdelzi-receives-conditional-ec-approval-for-primary-biliary-cholangitis/2025-02-21T13:16:24+08:00https://flcube.com/fibrogen-to-sell-china-subsidiary-to-astrazeneca-for-160m-roxadustat-rights-included/2025-02-21T12:00:13+08:00https://flcube.com/waterdrop-integrates-deepseek-ai-to-boost-insurance-ecosystem/2025-02-21T11:22:02+08:00https://flcube.com/boehringer-ingelheim-launches-lenticlair-study-for-cf-gene-therapy-bi-3720931/2025-02-21T11:10:35+08:00https://flcube.com/huadong-medicines-biosimilar-tresiba-accepted-by-nmpa-for-review/2025-02-21T11:04:21+08:00https://flcube.com/i-mab-doses-first-patient-in-global-phase-i-study-for-tj-cd4b-in-solid-tumors/2025-02-20T22:59:56+08:00https://flcube.com/rona-therapeutics-licenses-sanofis-sirna-platform-for-global-development/2025-02-20T22:57:23+08:00https://flcube.com/apollobio-corp-initiates-pre-clinical-study-for-abc-5100-nanobody-against-covid-19/2025-02-20T22:35:40+08:00https://flcube.com/inventisbio-raises-usd-308m-in-shanghai-star-ipo-valued-at-usd-1-54b/2025-02-20T22:32:55+08:00https://flcube.com/nmpa-releases-56th-batch-of-gqce-reference-drugs-including-14-injectables/2025-02-20T22:29:54+08:00https://flcube.com/mobidrop-raises-usd-14-8m-in-series-a-to-expand-single-cell-product-pipeline/2025-02-20T22:28:00+08:00https://flcube.com/luye-pharmas-ly01005-meets-phase-iii-trial-goals-in-breast-cancer-treatment/2025-02-20T22:23:54+08:00https://flcube.com/zgc-shuimu-medtech-raises-rmb-100m-in-series-a-round-led-by-yijing-capital/2025-02-20T22:21:12+08:00https://flcube.com/innovita-biological-technologys-ipo-raises-usd-131-3m-for-poct-expansion/2025-02-20T22:15:28+08:00https://flcube.com/fidia-farmaceuticis-hyalubrix-60-shows-promise-in-treating-arthropathy-at-hainan-hospital/2025-02-20T22:11:06+08:00https://flcube.com/sichuan-kelun-pharmaceutical-and-merck-sharp-dohme-corp-ink-second-adc-licensing-deal/2025-02-20T22:06:31+08:00https://flcube.com/sinopharm-cnbgs-f61-monoclonal-antibody-receives-nmpa-clinical-trial-approval/2025-02-20T22:04:02+08:00https://flcube.com/legend-biotech-plans-usd-250m-secondary-offering-to-fund-car-t-therapy-development/2025-02-20T22:01:13+08:00https://flcube.com/abbvies-allergan-aesthetics-cooladvantage-applicator-wins-nmpa-approval/2025-02-20T21:58:43+08:00https://flcube.com/henlius-biotechs-hanquyou-approved-in-australia-for-her2-positive-cancers/2025-02-20T21:53:13+08:00https://flcube.com/hengrui-medicines-shr-1802-shr-1316-combo-receives-nmpa-approval-for-solid-tumor-study/2025-02-20T21:50:48+08:00https://flcube.com/betta-pharmaceuticals-enrolls-first-patient-in-bpi-442096-phase-i-study-for-solid-tumors/2025-02-20T21:42:09+08:00https://flcube.com/hengrui-medicines-shr-a1811-combo-receives-nmpa-approval-for-her2-nsclc-study/2025-02-20T21:39:41+08:00https://flcube.com/ascentage-pharma-launches-olverembatinib-named-patient-program-with-tanner-pharma/2025-02-20T21:36:49+08:00https://flcube.com/sirnaomics-stp705-receives-approval-for-liver-cancer-trial-in-taiwan/2025-02-20T21:32:18+08:00https://flcube.com/genfleet-therapeutics-gfh018-receives-cta-approval-for-two-clinical-trials-in-china/2025-02-20T21:28:11+08:00https://flcube.com/nmpa-approves-genuine-biotechs-azvudine-for-covid-19-fosun-pharma-inks-licensing-deal/2025-02-20T21:25:26+08:00https://flcube.com/chinese-pharmacists-association-releases-draft-vbp-drug-management-guidelines-for-public-feedback/2025-02-20T21:22:58+08:00https://flcube.com/3d-medicines-files-ipo-prospectus-for-hong-kong-listing/2025-02-20T21:20:08+08:00https://flcube.com/nuance-pharma-initiates-phase-i-study-for-ketorolac-iv-infusion-ntm-001/2025-02-20T21:17:59+08:00https://flcube.com/henlius-biotechs-hanbeitai-biosimilar-of-avastin-accepted-for-cde-review/2025-02-20T21:15:49+08:00https://flcube.com/cstone-pharmaceuticals-and-kindstar-global-partner-on-blood-tumor-precision-diagnosis-and-treatment/2025-02-20T21:12:18+08:00https://flcube.com/wanbangde-pharmaceutical-to-acquire-consun-pharma-shares-in-rmb-2-2b-deal/2025-02-20T21:09:25+08:00https://flcube.com/brii-biosciences-covid-19-antibody-cocktail-effective-against-omicron-ba-4-5-and-ba-2-12-1/2025-02-20T21:06:49+08:00https://flcube.com/cms-acquires-wuhan-yzy-biopharmas-bispecific-antibody-assets-for-fundus-disease/2025-02-20T21:04:07+08:00https://flcube.com/hitgen-and-loqus23-therapeutics-partner-on-dna-encoded-library-for-neurodegeneration/2025-02-20T21:00:34+08:00https://flcube.com/roche-diagnostics-and-topgen-biopharm-launch-innovation-center-in-chongqing/2025-02-20T20:53:01+08:00https://flcube.com/hybio-pharmaceutical-signs-tech-transfer-deal-with-chinas-cdc-for-covid-19-vaccine-peptide-sequences/2025-02-20T20:47:01+08:00https://flcube.com/yunnan-baiyao-and-huawei-partner-on-ai-driven-drug-development/2025-02-20T20:43:36+08:00https://flcube.com/yunnan-baiyaos-radiopharmaceutical-inr101-advances-to-clinical-trial-stage-with-nmpa-approval/2025-02-20T20:40:26+08:00https://flcube.com/sihuan-pharmas-xuanzhu-bio-files-for-fulvestrant-piroxetine-combo-in-advanced-breast-cancer/2025-02-20T20:37:31+08:00https://flcube.com/stabilizing-foreign-investment-chinas-comprehensive-action-plan-for-2025/2025-02-20T18:32:44+08:00https://flcube.com/nona-biosciences-licenses-h2l2-harbour-mice-platform-to-uab-for-b-cell-research/2025-02-20T18:09:40+08:00https://flcube.com/innogen-pharmaceutical-launches-efsubaglutide-alfa-for-type-2-diabetes-in-china/2025-02-20T17:55:40+08:00https://flcube.com/bayers-askbio-receives-rmat-designation-for-ab-1005-in-parkinsons-disease/2025-02-20T17:40:24+08:00https://flcube.com/phanes-therapeutics-doses-first-patient-in-peluntamig-study-for-sclc-and-nec/2025-02-20T17:30:26+08:00https://flcube.com/epitopea-and-merck-partner-to-identify-cryptigen-tumor-antigens/2025-02-20T17:23:57+08:00https://flcube.com/boehringer-ingelheims-zongertinib-nda-accepted-by-fda-for-her2-mutated-nsclc/2025-02-20T17:09:15+08:00https://flcube.com/hepalink-pharmaceuticals-h1710-heparanase-inhibitor-approved-for-phase-i-study/2025-02-20T17:03:04+08:00https://flcube.com/henlius-biotechs-avastin-biosimilar-hanbeitai-approved-in-bolivia/2025-02-20T16:12:49+08:00https://flcube.com/astellas-pharmas-xospata-wins-regular-nmpa-approval-for-flt3-mutated-aml/2025-02-20T15:46:50+08:00https://flcube.com/hanx-biopharmaceuticals-hx009-receives-nmpa-clearance-for-tnbc-study/2025-02-20T15:37:26+08:00https://flcube.com/huadong-medicines-medibeacon-tgfr-system-approved-by-nmpa-for-gfr-measurement/2025-02-20T15:28:48+08:00https://flcube.com/sunshine-guojian-and-shenyang-3sbio-license-612-and-708-programs-for-anti-tumor-development/2025-02-20T15:15:25+08:00https://flcube.com/antengene-to-boost-t-cell-engager-platform-with-ai-investment-and-deepseek-deployment/2025-02-20T15:02:31+08:00https://flcube.com/jiangxi-rimag-group-and-xunfei-healthcare-form-strategic-alliance-for-smart-healthcare/2025-02-20T14:38:39+08:00https://flcube.com/ec-healthcare-partners-with-jiangxi-rimag-group-to-expand-medical-imaging-services/2025-02-20T14:28:55+08:00https://flcube.com/jiangxi-rimag-group-sets-ipo-price-range-for-hong-kong-debut-aims-to-raise-up-to-usd-2-15-per-share/2025-02-20T14:28:54+08:00https://flcube.com/rendu-biotechnology-partners-with-green-apple-medical-system-for-rna-diagnostics-expansion/2025-02-20T14:25:32+08:00https://flcube.com/genuine-biotech-files-for-hong-kong-ipo-with-azvudine-and-zs-1003-in-pipeline/2025-02-20T13:31:40+08:00https://flcube.com/astrazeneca-faces-class-action-lawsuits-over-china-legal-issues/2025-02-20T12:21:34+08:00https://flcube.com/sun-pharmas-bicalutamide-supply-suspended-in-multiple-chinese-regions/2025-02-20T01:08:55+08:00https://flcube.com/mabpharms-cmab015-biosimilar-receives-nmpa-approval-for-clinical-study/2025-02-20T01:03:12+08:00https://flcube.com/cspc-jushi-biopharms-sysa1801-adc-secures-licensing-deal-with-elevation-oncology/2025-02-20T00:57:30+08:00https://flcube.com/cde-releases-61st-batch-of-generic-reference-preparations-34-new-specs-added/2025-02-20T00:54:20+08:00https://flcube.com/immunochina-pharmaceuticals-secures-car-t-production-license-in-beijing/2025-02-20T00:52:04+08:00https://flcube.com/kolo-medical-raises-rmb-100m-in-series-b2-to-launch-high-frequency-ultrasound-imaging-system/2025-02-20T00:49:41+08:00https://flcube.com/nestle-launches-chinas-first-cancer-focused-fsmp-product-oral-impact-su-yi-su/2025-02-20T00:45:10+08:00https://flcube.com/sanofis-hornstein-sees-chinas-online-hospitals-boosting-digital-health-strategy/2025-02-20T00:40:07+08:00https://flcube.com/sanofis-q2-earnings-show-8-1-global-sales-growth-led-by-dupixent-and-china-expansion/2025-02-20T00:37:14+08:00https://flcube.com/cspc-pharmaceuticals-albumin-bound-docetaxel-receives-orphan-drug-designation-for-gastric-cancer/2025-02-20T00:32:55+08:00https://flcube.com/hybio-pharmaceuticals-liraglutide-filing-accepted-by-nmpa-becomes-domestic-leader-in-glp-1-analog/2025-02-20T00:30:01+08:00https://flcube.com/roches-rozlytrek-wins-nmpa-approval-for-ntrk-fusion-gene-positive-tumors/2025-02-20T00:26:36+08:00https://flcube.com/kira-pharmaceuticals-kp104-receives-orphan-drug-designation-for-pnh-treatment/2025-02-20T00:23:11+08:00https://flcube.com/shenzhen-unveils-measures-to-boost-biomedical-and-medical-device-industries/2025-02-20T00:20:47+08:00https://flcube.com/mercks-q2-sales-surge-31-to-usd-14-6b-led-by-keytruda-and-china-growth/2025-02-20T00:16:41+08:00https://flcube.com/takedas-alunbrig-prescribed-in-china-for-alk-nsclc-treatment/2025-02-20T00:11:53+08:00https://flcube.com/cosmo-pharmas-winlevi-cream-secures-greater-china-licensing-deal-with-3sbio/2025-02-20T00:09:27+08:00https://flcube.com/perkinelmer-and-scut-launch-joint-translational-medicine-center/2025-02-20T00:05:36+08:00https://flcube.com/biogen-licenses-stoke-therapeutics-zorevunersen-for-dravet-syndrome-outside-americas/2025-02-19T17:41:54+08:00https://flcube.com/taho-pharmas-tah3311-oral-film-shows-bioequivalence-to-eliquis-in-study/2025-02-19T17:25:09+08:00https://flcube.com/sanofis-dupixent-receives-priority-review-from-fda-for-bullous-pemphigoid-treatment/2025-02-19T16:27:28+08:00https://flcube.com/cspc-pharma-licenses-sys-6005-to-radiance-biopharma-for-global-markets/2025-02-19T16:14:24+08:00https://flcube.com/biokin-pharmaceuticals-bl-m07d1-receives-nmpa-approval-for-phase-ii-iii-study-in-her2-breast-cancer/2025-02-19T15:57:57+08:00https://flcube.com/gilead-sciences-lenacapavir-nda-for-hiv-prevention-accepted-by-fda-for-priority-review/2025-02-19T15:49:53+08:00https://flcube.com/mercks-welireg-wins-conditional-eu-approval-for-vhl-disease-and-advanced-rcc/2025-02-19T15:42:02+08:00https://flcube.com/gsk-and-abbott-announce-leadership-changes-in-key-roles/2025-02-19T14:09:54+08:00https://flcube.com/medtronic-q3-earnings-show-4-1-organic-growth-driven-by-cardiac-ablation/2025-02-19T13:55:55+08:00https://flcube.com/quantumpharm-and-hengjian-launch-gba-ai-innovation-consortium/2025-02-19T13:48:48+08:00https://flcube.com/deepwise-information-integrates-deepseek-into-medical-data-platform/2025-02-19T01:05:45+08:00https://flcube.com/weimai-qingtong-medical-technology-completes-tens-of-millions-yuan-b-round/2025-02-19T00:31:55+08:00https://flcube.com/innocare-pharma-receives-nmpa-approval-for-mesutoclax-phase-iii-study-in-cll-sll/2025-02-18T23:34:33+08:00https://flcube.com/hengrui-pharmas-hr19034-eye-drops-for-myopia-delay-accepted-by-nmpa/2025-02-18T23:26:16+08:00https://flcube.com/gan-lee-pharmaceuticals-doses-first-patient-in-gzr4-phase-iii-study-for-diabetes/2025-02-18T23:05:37+08:00https://flcube.com/stedical-scientific-raises-rmb100m-in-series-b-financing-for-global-expansion/2025-02-18T21:23:04+08:00https://flcube.com/zelgen-biopharmaceuticals-zg005-bispecific-antibody-receives-nmpa-approval-for-biliary-tract-cancer-trials/2025-02-18T18:32:33+08:00https://flcube.com/bristol-myers-squibb-releases-five-year-data-on-sotyktus-long-term-efficacy-and-safety/2025-02-18T17:58:11+08:00https://flcube.com/wanbangde-new-building-materials-mecobalamin-earns-fda-orphan-drug-designation-for-als/2025-02-18T17:43:56+08:00https://flcube.com/biokin-pharmaceutical-registers-phase-iii-study-for-bl-b01d1-in-egfr-mutant-nsclc/2025-02-18T17:23:41+08:00https://flcube.com/accuredits-art002-becomes-first-in-vivo-gene-editing-product-to-reduce-ldl-c-in-humans/2025-02-18T17:13:06+08:00https://flcube.com/beihai-biotech-licenses-beizary-to-zydus-lifesciences-for-us-market/2025-02-18T16:50:29+08:00https://flcube.com/huadong-medicines-hdm1005-shows-positive-results-in-phase-ia-ib-study/2025-02-18T16:38:56+08:00https://flcube.com/polymed-biopharma-licenses-hpb-143-to-photys-therapeutics-for-global-development/2025-02-18T16:24:39+08:00https://flcube.com/nhc-designates-national-mental-illness-medical-centers-in-beijing-and-shanghai/2025-02-18T00:15:49+08:00https://flcube.com/innovent-and-laekna-dose-first-patient-in-afuresertib-and-tyvyt-study-for-pd-1-resistant-tumors/2025-02-18T00:13:38+08:00https://flcube.com/dongcheng-pharmaceutical-gets-nmpa-green-light-for-psma-pet-imaging-drug/2025-02-18T00:10:38+08:00https://flcube.com/cansino-biologics-launches-menhycia-meningococcal-vaccine-in-six-provinces/2025-02-18T00:08:05+08:00https://flcube.com/mabwell-bioscience-gets-fda-approval-for-nectin-4-adc-9mw2821-in-solid-tumors/2025-02-18T00:05:26+08:00https://flcube.com/lanova-medicines-gets-fda-green-light-for-lm-305-myeloma-study/2025-02-18T00:03:01+08:00https://flcube.com/origincell-therapeutics-raises-usd-120m-in-series-b-for-tumor-immunotherapy-pipeline/2025-02-18T00:00:53+08:00https://flcube.com/fosun-pharma-to-hike-aitrox-stake-to-72-63-for-usd-61m/2025-02-17T23:58:05+08:00https://flcube.com/glubio-pharma-raises-usd-22m-in-series-a-round-to-advance-tpd-pipeline/2025-02-17T23:55:18+08:00https://flcube.com/ribo-life-science-raises-usd-40m-in-series-e1-round-for-sirna-drug-development/2025-02-17T23:50:21+08:00https://flcube.com/bridgene-biosciences-completes-usd-38-5m-series-b-round-with-china-funds/2025-02-17T23:46:38+08:00https://flcube.com/basecare-medical-sells-35-stake-in-cellpro-biotech-for-usd-9-5m/2025-02-17T23:42:47+08:00https://flcube.com/sanjin-pharmas-subsidiary-gets-fda-nod-for-bc007-cancer-drug-trial/2025-02-17T23:35:38+08:00https://flcube.com/pica-partners-with-brainco-to-launch-adhd-product-in-china/2025-02-17T23:32:47+08:00https://flcube.com/astellas-pharma-posts-17-q1-sales-growth-driven-by-xtandi-and-padcev/2025-02-17T23:27:42+08:00https://flcube.com/eli-lillys-taltz-wins-second-nmpa-approval-for-ankylosing-spondylitis/2025-02-17T23:24:26+08:00https://flcube.com/china-resources-double-crane-to-acquire-stake-in-shenzhou-biotech-for-bio-fermentation-push/2025-02-17T18:58:54+08:00https://flcube.com/coherent-biopharma-raises-series-b-funds-to-advance-bi-xdc-pipeline/2025-02-17T18:55:33+08:00https://flcube.com/hengrui-medicines-pyrotinib-combo-meets-endpoints-in-her2-breast-cancer-trial/2025-02-17T18:53:31+08:00https://flcube.com/shouyao-holdings-receives-approval-for-ct-3505-alk-inhibitor-study-in-nsclc/2025-02-17T18:50:57+08:00https://flcube.com/innocare-pharma-doses-first-patient-in-icp-488-study-for-autoimmune-diseases/2025-02-17T18:48:32+08:00https://flcube.com/convalife-pharmaceuticals-licenses-karus-therapeutics-cvl237-globally/2025-02-17T18:45:58+08:00https://flcube.com/unicycive-therapeutics-licenses-renazorb-to-lees-pharma-for-asian-markets/2025-02-17T18:41:16+08:00https://flcube.com/hutchmed-initiates-china-bridging-study-for-tazverik-in-follicular-lymphoma/2025-02-17T18:37:01+08:00https://flcube.com/hainan-shuangcheng-to-transfer-triptorelin-assets-to-chongqing-lummy-for-usd-4-7m/2025-02-17T18:34:28+08:00https://flcube.com/eccogene-receives-fda-approval-for-ecc4703-phase-i-study-in-nash-and-dyslipidemia/2025-02-17T18:29:39+08:00https://flcube.com/hutchmeds-h1-2022-oncology-sales-surge-82-on-strong-product-performance/2025-02-17T18:27:37+08:00https://flcube.com/lion-tcr-enrolls-first-patient-in-liocyx-m004-study-for-hbv-related-liver-cancer/2025-02-17T18:23:37+08:00https://flcube.com/grand-pharmas-tlx591-cdx-and-tlx250-cdx-advance-in-china-with-nmpa-review/2025-02-17T18:21:43+08:00https://flcube.com/lees-pharma-completes-enrollment-for-nvk-002-myopia-trials-in-china/2025-02-17T18:18:27+08:00https://flcube.com/lynk-pharma-gets-nmpa-green-light-for-lnk01004-atopic-dermatitis-study/2025-02-17T18:15:24+08:00https://flcube.com/sciwind-biosciences-xw003-hits-phase-ii-trial-goals-in-type-2-diabetes-treatment/2025-02-17T18:13:01+08:00https://flcube.com/fosun-pharmas-proxima-ai-raises-over-rmb-100m-in-strategic-financing/2025-02-17T18:10:33+08:00https://flcube.com/taibang-biologic-raises-300m-in-post-privatization-financing-round/2025-02-17T18:04:43+08:00https://flcube.com/sironax-completes-200-million-series-b-financing-for-age-related-disease-therapies/2025-02-17T17:55:28+08:00https://flcube.com/tus-pharma-to-acquire-sinotau-pharma-for-rmb-220-million/2025-02-17T17:48:49+08:00https://flcube.com/eli-lilly-files-for-baqsimi-approval-in-china-to-treat-severe-hypoglycemia/2025-02-17T17:43:34+08:00https://flcube.com/aosaikangs-askg315-receives-ethics-approval-for-phase-i-cancer-trial-in-australia/2025-02-17T17:39:47+08:00https://flcube.com/ablaze-pharma-to-invest-100m-in-chengdu-trt-rd-and-manufacturing-hub/2025-02-17T17:24:40+08:00https://flcube.com/boehringer-ingelheim-wins-patent-infringement-ruling-against-hec-over-trajenta/2025-02-17T17:22:07+08:00https://flcube.com/zelgens-jacktinib-hits-phase-iib-endpoint-in-myelofibrosis-study/2025-02-17T17:18:47+08:00https://flcube.com/wision-a-i-s-polyp-detection-software-secures-nmpa-approval-for-colonoscopy-use/2025-02-17T17:16:09+08:00https://flcube.com/ethicons-hemostatic-granules-win-nmpa-approval-for-endoscopic-surgery-use/2025-02-17T17:11:18+08:00https://flcube.com/bloomage-biotech-terminates-medytox-pact-over-botox-supply-issues/2025-02-17T17:01:53+08:00https://flcube.com/wuxi-biologics-partners-with-astrazeneca-for-local-production-of-evusheld/2025-02-17T16:56:45+08:00https://flcube.com/structure-therapeutics-oversubscribes-usd33m-on-top-of-usd100m-series-b-round/2025-02-17T16:53:51+08:00https://flcube.com/ascletis-pharmas-asc10-receives-ind-approval-for-covid-19-treatment-in-us-and-china/2025-02-17T16:51:16+08:00https://flcube.com/profoundbio-receives-fda-approval-for-pro1184-appoints-new-cmo/2025-02-17T16:41:56+08:00https://flcube.com/astrazenecas-h1-2022-revenues-surge-48-led-by-oncology-and-vaccines/2025-02-17T16:37:52+08:00https://flcube.com/intellective-biologics-raises-over-rmb500m-in-series-c-financing-round/2025-02-17T16:32:06+08:00https://flcube.com/micurx-pharmaceuticals-completes-rmb1-06b-ipo-for-antibacterial-drug-development/2025-02-17T16:27:40+08:00https://flcube.com/invox-pharma-extends-tender-offer-for-f-star-therapeutics-to-september-19/2025-02-17T16:25:32+08:00https://flcube.com/merck-launches-prevymis-a-non-nucleoside-cmv-inhibitor-in-china/2025-02-17T16:16:02+08:00https://flcube.com/beigenes-q2-2022-revenues-surge-120-brukinsa-sales-triple/2025-02-17T16:13:18+08:00https://flcube.com/innovent-biologics-and-sanofi-announce-license-deal-for-drug-development-in-china/2025-02-17T16:09:03+08:00https://flcube.com/eli-lilly-reports-first-quarterly-revenue-dip-in-two-years-china-sales-plunge/2025-02-17T16:05:33+08:00https://flcube.com/novo-nordisks-h1-2022-results-show-strong-global-sales-growth-china-sales-dip/2025-02-17T16:02:21+08:00https://flcube.com/shanghai-pharmaceuticals-partners-with-hkstp-and-shanghai-biomedicine-fund-on-rd-collaboration/2025-02-17T15:59:56+08:00https://flcube.com/zhongsheng-pharmaceutical-completes-phase-i-study-of-ray1216-for-covid-19-treatment/2025-02-17T15:57:04+08:00https://flcube.com/cspc-pharmaceuticals-rhtnk-tpa-meets-primary-endpoint-in-stroke-study/2025-02-17T15:53:58+08:00https://flcube.com/henan-genuine-biotech-files-for-ipo-to-fund-azvudine-commercialization/2025-02-17T15:51:19+08:00https://flcube.com/innovent-biologics-q2-2022-revenues-surpass-rmb-1-billion-seven-products-approved/2025-02-17T15:48:00+08:00https://flcube.com/hybio-pharmaceuticals-hy3000-nasal-spray-for-covid-19-enters-nmpa-review/2025-02-17T15:45:28+08:00https://flcube.com/genscripts-legend-biotech-appoints-three-new-directors-to-board/2025-02-17T15:42:46+08:00https://flcube.com/samsung-bioepis-ospomyv-and-xbryk-gain-fda-approval-for-rankl-inhibitor-biosimilars/2025-02-17T15:23:05+08:00https://flcube.com/kexing-biopharms-gb05-receives-fda-approval-for-pediatric-rsv-infections/2025-02-17T15:09:28+08:00https://flcube.com/sanofis-merilog-biosimilar-wins-fda-approval-for-diabetes-treatment/2025-02-17T14:57:27+08:00https://flcube.com/yantai-dongchengs-lannacheng-bio-secures-rmb150m-to-advance-18f-spiritide-study/2025-02-17T14:11:24+08:00https://flcube.com/yantai-lannacheng-biotech-secures-rmb-300-million-in-series-b-financing-round/2025-02-17T14:02:01+08:00https://flcube.com/gsks-penmenvy-meningococcal-vaccine-approved-by-fda-for-ages-10-25/2025-02-17T13:53:24+08:00https://flcube.com/3sbio-and-sichuan-biokin-partner-to-advance-solid-tumor-treatment-in-china/2025-02-17T13:47:37+08:00https://flcube.com/lindis-biotechs-korjuny-approved-by-european-commission-for-malignant-ascites/2025-02-17T13:27:46+08:00https://flcube.com/iaso-bios-fucaso-nda-accepted-by-hong-kong-doh-for-relapsed-refractory-multiple-myeloma/2025-02-17T12:57:47+08:00https://flcube.com/innovent-biologics-ibi363-receives-fda-fast-track-designation-for-sqnsclc/2025-02-17T11:56:12+08:00https://flcube.com/tianyi-medical-acquires-bellcos-crrt-filter-business-for-eur11-99m/2025-02-17T11:44:35+08:00https://flcube.com/konruns-pharmaceuticals-kc1036-enters-phase-ii-trial-for-ewings-sarcoma-in-adolescents/2025-02-17T11:17:37+08:00https://flcube.com/hengrui-pharma-submits-ivarmacitinib-ointment-for-ad-treatment-approval/2025-02-17T11:08:26+08:00https://flcube.com/bioduro-sundia-and-x-chem-form-long-term-partnership-for-drug-discovery/2025-02-17T00:10:36+08:00https://flcube.com/dizal-pharmas-sunvozertinib-shows-promise-in-nsclc-with-egfr-exon-20-insertion/2025-02-16T23:58:24+08:00https://flcube.com/hywin-holdings-to-acquire-life-infinity-for-health-management-expansion/2025-02-16T23:48:26+08:00https://flcube.com/hutchmeds-fresco-2-study-for-elunate-in-colorectal-cancer-meets-primary-endpoint/2025-02-16T23:41:52+08:00https://flcube.com/frontier-biotech-partners-with-kindstar-to-boost-anti-infection-testing-especially-for-hiv/2025-02-16T23:35:53+08:00https://flcube.com/innovent-biologics-doses-first-subject-in-ibi324-phase-i-study-for-dme/2025-02-16T23:32:55+08:00https://flcube.com/transcenta-appoints-dr-caroline-germa-as-global-drug-development-chief/2025-02-16T23:28:34+08:00https://flcube.com/nhc-issues-notification-on-medication-safety-management-and-rational-drug-use/2025-02-16T23:25:18+08:00https://flcube.com/ningbo-health-gene-raises-hundreds-of-millions-in-series-c-financing/2025-02-16T23:22:53+08:00https://flcube.com/intuitive-surgical-fosun-jv-breaks-ground-on-shanghai-medical-robot-base/2025-02-16T23:12:24+08:00https://flcube.com/bayer-ags-q2-2022-results-show-global-sales-growth-amid-china-vbp-pressures/2025-02-16T23:09:07+08:00https://flcube.com/alphamab-oncology-doses-first-patient-in-kn046-209-study-for-nsclc/2025-02-16T16:40:16+08:00https://flcube.com/sciwinds-xw003-shows-positive-weight-loss-results-in-phase-ic-iia-study/2025-02-16T16:38:05+08:00https://flcube.com/hansoh-pharma-licenses-tiumbios-tu2670-for-endometriosis-treatment-in-greater-china/2025-02-16T16:35:51+08:00https://flcube.com/gan-lee-pharmaceuticals-gzr4-wins-fda-approval-for-diabetes-treatment/2025-02-16T16:33:28+08:00https://flcube.com/geneodx-biotechs-cervical-cancer-screening-kit-wins-nmpa-approval/2025-02-16T16:30:58+08:00https://flcube.com/microport-cardioflow-medtechs-vitaflow-liberty-and-angelguide-approved-in-colombia/2025-02-16T16:26:29+08:00https://flcube.com/henan-genuine-biotech-sets-azvudine-price-at-rmb300-per-bottle-for-covid-19-therapy/2025-02-16T16:23:55+08:00https://flcube.com/sinotherapeutics-inc-to-raise-rmb600m-via-star-board-ipo-for-generic-drug-expansion/2025-02-16T16:21:53+08:00https://flcube.com/cde-issues-qas-on-covid-19-antiviral-drug-evaluation-criteria/2025-02-16T16:17:00+08:00https://flcube.com/nmpa-approves-biofire-diagnostics-encephalitis-meningitis-detection-kit/2025-02-16T16:15:03+08:00https://flcube.com/hutchmed-and-astrazenecas-tagrisso-orpathys-combo-shows-promise-in-nsclc-study/2025-02-16T16:10:39+08:00https://flcube.com/nmpa-accepts-roches-crovalimab-filing-for-pnh-treatment-with-priority-review/2025-02-16T16:07:04+08:00https://flcube.com/kintor-pharma-completes-gt20029-phase-i-study-for-hair-loss-and-acne/2025-02-16T16:04:51+08:00https://flcube.com/nhsa-cracks-down-on-price-gouging-in-basic-medical-insurance-scheme/2025-02-16T16:01:51+08:00https://flcube.com/fibrogens-roxadustat-sales-in-china-rise-despite-price-cut/2025-02-16T15:55:56+08:00https://flcube.com/inmagene-and-hutchmed-dose-first-subject-in-img-004-phase-i-study/2025-02-16T15:53:31+08:00https://flcube.com/zai-labs-q2-2022-financials-show-revenue-growth-and-rd-cost-cut/2025-02-16T15:49:02+08:00https://flcube.com/beigenes-tislelizumab-meets-primary-endpoint-in-global-hcc-study/2025-02-16T15:46:17+08:00https://flcube.com/innovent-biologics-ibi-112-achieves-primary-endpoints-in-psoriasis-phase-ii-trial/2025-02-16T15:43:40+08:00https://flcube.com/deep-analysis-and-strategic-insights-the-impact-of-vice-president-yu-bings-departure-on-bcht-biotechnology/2025-02-16T14:48:40+08:00https://flcube.com/arbeles-arb202-enters-phase-i-trial-for-advanced-gastrointestinal-cancer/2025-02-15T23:39:04+08:00https://flcube.com/bytedance-acquires-amcare-healthcare-for-usd1-5b-via-xiaohe-health-unit/2025-02-15T23:32:26+08:00https://flcube.com/taihu-bay-healthcare-conference-launches-wuxi-ip-protection-center/2025-02-15T23:22:06+08:00https://flcube.com/united-imaging-healthcares-star-listing-raises-usd1-85-billion/2025-02-15T23:18:28+08:00https://flcube.com/boston-scientifics-rezum-system-installed-in-chinas-urinary-innovation-center/2025-02-15T23:16:01+08:00https://flcube.com/trautec-medical-raises-rmb200m-in-series-a-financing-for-recombinant-collagen-rd/2025-02-15T23:12:45+08:00https://flcube.com/suzhou-hanerxi-medical-secures-series-b-funding-to-build-asias-largest-pen-injector-facility/2025-02-15T23:09:51+08:00https://flcube.com/zhaoke-ophthalmology-enrolls-first-patient-in-zky001-phase-ii-tprk-study/2025-02-15T23:04:41+08:00https://flcube.com/insilico-medicine-closes-usd95m-series-d-financing-to-advance-ai-drug-discovery/2025-02-15T23:01:20+08:00https://flcube.com/lianbio-completes-enrollment-for-mavacamten-phase-iii-trial-in-ohcm/2025-02-15T22:59:20+08:00https://flcube.com/huadong-medicine-to-acquire-60-stake-in-wuhu-huaren-for-rmb-396-million/2025-02-15T22:48:30+08:00https://flcube.com/recbio-completes-enrollment-for-hpv-vaccine-rec603-immuno-bridging-study/2025-02-15T22:43:51+08:00https://flcube.com/everest-medicines-xerava-nda-accepted-by-taiwans-tfda/2025-02-15T22:36:50+08:00https://flcube.com/china-grand-pharmas-h1-2022-revenues-up-14-1-to-usd664m-rd-spending-rises/2025-02-15T22:31:37+08:00https://flcube.com/siemens-healthineers-q3-2022-results-show-decline-amid-covid-19-impact/2025-02-15T22:25:33+08:00https://flcube.com/chinese-researchers-map-cancer-genomic-alterations-in-10000-patients/2025-02-15T22:17:13+08:00https://flcube.com/longwood-valley-medtech-partners-with-jj-medtech-on-digital-surgery-biosystem/2025-02-15T22:13:47+08:00https://flcube.com/elite-pharma-raises-rmb100m-in-series-b-financing-for-drug-delivery-tech/2025-02-15T22:08:50+08:00https://flcube.com/wuxi-atu-licenses-tessa-technology-to-janssen-biotech-for-aav-production/2025-02-15T22:01:51+08:00https://flcube.com/medlander-medical-technologys-ipo-raises-rmb-1-billion-on-shanghais-star-board/2025-02-15T21:58:27+08:00https://flcube.com/innocare-pharmas-orelabrutinib-snda-accepted-for-marginal-zone-lymphoma/2025-02-15T21:51:40+08:00https://flcube.com/tianshiwei-raises-tens-of-millions-in-series-a-for-medical-aesthetics-expansion/2025-02-15T21:49:21+08:00https://flcube.com/beigene-partners-with-jilin-cancer-hospital-for-cancer-drug-development/2025-02-15T21:34:44+08:00https://flcube.com/china-ramps-up-monitoring-of-clinically-shortage-drugs-involving-109-varieties/2025-02-15T21:30:55+08:00https://flcube.com/roches-rozlytrek-wins-nmpa-approval-for-ros1-nsclc-treatment/2025-02-15T20:51:22+08:00https://flcube.com/eqrx-accelerates-us-development-of-two-chinese-licensed-cancer-drugs/2025-02-15T20:48:58+08:00https://flcube.com/novartis-aims-for-china-to-be-second-largest-market-by-2024/2025-02-15T20:45:19+08:00https://flcube.com/esr-group-enters-life-sciences-with-zhangjiang-neo-acquisition/2025-02-15T20:42:13+08:00https://flcube.com/cloudr-partners-with-ipsen-to-expand-dipherelines-reach-in-china/2025-02-15T20:36:38+08:00https://flcube.com/e-health-now-raises-funds-for-oncology-and-cardiovascular-digital-health-products/2025-02-15T20:33:36+08:00https://flcube.com/kingyee-and-xinsec-iot-form-strategic-partnership-for-smart-ward-solutions/2025-02-15T20:30:57+08:00https://flcube.com/chongqing-pharscins-gabexate-mesylate-passes-gqce-as-first-generic-in-china/2025-02-15T20:23:57+08:00https://flcube.com/bennu-biotherapeutics-raises-over-rmb100m-in-angel-round-for-global-pipeline-development/2025-02-15T20:19:01+08:00https://flcube.com/sunshine-guojians-ssgj-608-hits-primary-endpoint-in-psoriasis-study/2025-02-15T20:15:51+08:00https://flcube.com/zelgen-biopharmaceuticals-donafenib-receives-nmpa-approval-for-thyroid-cancer/2025-02-15T20:11:06+08:00https://flcube.com/ascletis-pharmas-gannex-initiates-ddi-study-for-asc42-in-pbc/2025-02-15T20:08:02+08:00https://flcube.com/venus-medtechs-venusp-valve-used-again-in-us-compassionate-case/2025-02-15T20:05:16+08:00https://flcube.com/luye-pharmas-goserelin-acetate-injectable-accepted-for-breast-cancer-review/2025-02-15T20:01:29+08:00https://flcube.com/healthnice-pharma-raises-rmb100m-to-expand-product-pipeline-and-rd-team-2/2025-02-15T19:59:27+08:00https://flcube.com/healthnice-pharma-raises-rmb100m-to-expand-product-pipeline-and-rd-team/2025-02-15T18:16:54+08:00https://flcube.com/gilead-transfers-trodelvy-asian-rights-to-everest-medicines-for-usd280m/2025-02-15T18:11:08+08:00https://flcube.com/cde-prioritizes-review-for-sanofis-nexviazyme-and-winhealths-ravicti/2025-02-15T18:07:42+08:00https://flcube.com/henlius-biotechs-hanbeitai-sbla-accepted-for-hcc-treatment-review/2025-02-15T18:05:15+08:00https://flcube.com/applied-protein-technology-raises-hundreds-of-millions-in-series-b-funding/2025-02-15T18:00:33+08:00https://flcube.com/applied-protein-technology-secures-series-c-financing-to-accelerate-multi-omics-innovation/2025-02-15T17:57:48+08:00https://flcube.com/sciclone-licenses-menarinis-vaborem-to-tackle-drug-resistant-infections-in-china/2025-02-15T17:54:01+08:00https://flcube.com/zelgen-biopharmaceuticals-zggs18-receives-nmpa-approval-for-solid-tumor-treatment/2025-02-15T17:50:42+08:00https://flcube.com/fortune-care-raises-hundreds-of-millions-in-series-b-for-elderly-care-expansion/2025-02-15T17:47:45+08:00https://flcube.com/bio-hearts-bioheart-ii-study-meets-primary-endpoint-for-bioresorbable-scaffolds/2025-02-15T17:43:01+08:00https://flcube.com/sihuan-pharmaceutical-restructures-with-dual-organization-model/2025-02-15T17:39:27+08:00https://flcube.com/tonghua-dongbao-pharmaceuticals-begins-clinical-trial-for-xultophy-biosimilar/2025-02-15T17:29:29+08:00https://flcube.com/sihuan-pharmaceuticals-xzp-km602-and-xzp-6877-gain-clinical-trial-approvals/2025-02-15T17:18:18+08:00https://flcube.com/sihuan-pharma-halts-xuanzhu-biopharms-ipo-on-shanghai-sci-tech-innovation-board/2025-02-15T17:18:17+08:00https://flcube.com/sihuan-pharmaceutical-plans-ipo-for-xuanzhu-biopharm-on-hong-kong-stock-exchange/2025-02-15T17:18:16+08:00https://flcube.com/sihuans-xuanzhu-biopharmaceutical-strikes-licensing-deal-with-livzon-pharmaceutical-for-fadanafil/2025-02-15T17:18:16+08:00https://flcube.com/baheal-pharmaceutical-partners-with-takeda-to-boost-drug-commercialization-in-china/2025-02-15T17:08:43+08:00https://flcube.com/belief-delivery-biomeds-bbm-h901-granted-btd-for-hemophilia-b-prevention/2025-02-15T17:06:08+08:00https://flcube.com/wyze-biotech-raises-rmb59m-to-advance-dnt-cell-therapies/2025-02-15T16:58:45+08:00https://flcube.com/sanjin-pharmas-subsidiary-gets-nmpa-nod-for-bc007-cancer-study/2025-02-15T16:56:31+08:00https://flcube.com/i-mab-and-abbvie-end-cd47-antibody-trial-but-continue-collaboration/2025-02-15T16:47:52+08:00https://flcube.com/menovo-pharmaceutical-plans-rmb892m-private-placement-to-boost-api-production/2025-02-15T16:43:55+08:00https://flcube.com/beigene-partners-with-ontada-to-accelerate-rwe-development-in-us-oncology-market/2025-02-15T16:37:54+08:00https://flcube.com/grand-pharmaceuticals-carglumic-acid-set-for-priority-review-by-cde/2025-02-15T16:34:39+08:00https://flcube.com/beijing-wanjie-medical-device-completes-near-hundred-million-yuan-b-round-financing/2025-02-15T12:58:06+08:00https://flcube.com/pharmaceutical-giants-race-to-integrate-deepseek-ai-for-efficiency-gains/2025-02-15T12:30:23+08:00https://flcube.com/shanghai-runda-medical-science-and-technology-partners-with-huawei-cloud-on-ai-in-healthcare/2025-02-15T12:15:58+08:00https://flcube.com/meinian-onehealth-collaborates-with-huawei-cloud-and-runda-medical-on-ai-health-robot/2025-02-15T12:15:57+08:00https://flcube.com/bristol-myers-squibbs-opdualag-fails-to-meet-primary-endpoint-in-melanoma-study/2025-02-14T23:56:34+08:00https://flcube.com/linkzill-completes-multi-million-dollar-a-round-financing-led-by-proximaventures/2025-02-14T23:55:00+08:00https://flcube.com/new-guidelines-for-advanced-gastric-cancer-drug-development-released-in-china/2025-02-14T23:23:40+08:00https://flcube.com/hengruis-vunakizumab-receives-nmpa-approval-for-nr-axspa-treatment/2025-02-14T18:37:45+08:00https://flcube.com/ge-healthcare-posts-1-annual-revenue-growth-in-2024-financials/2025-02-14T18:27:33+08:00https://flcube.com/jemincare-licenses-oral-androgen-receptor-degrader-to-roches-genentech/2025-02-14T18:17:41+08:00https://flcube.com/betta-pharma-files-for-ema-approval-of-alk-inhibitor-ensartinib/2025-02-14T18:16:12+08:00https://flcube.com/lee-kai-and-yangshun-partner-on-polyvinyl-alcohol-embolization-microspheres/2025-02-14T18:08:32+08:00https://flcube.com/nanos-medical-raises-over-rmb300m-to-boost-otolaryngology-device-lead/2025-02-14T17:52:08+08:00https://flcube.com/sciclones-vibativ-approved-by-nmpa-for-habp-vabp-treatment/2025-02-14T17:07:46+08:00https://flcube.com/trinomabs-antitetanus-mab-injection-tnm002-approved-by-nmpa/2025-02-14T16:49:08+08:00https://flcube.com/nmpa-releases-90th-batch-of-reference-drugs-for-gqce/2025-02-14T16:19:14+08:00https://flcube.com/accropeutics-doses-first-patient-in-ac-101-phase-ib-uc-study/2025-02-14T16:11:43+08:00https://flcube.com/accropeutics-receives-hrec-approval-for-ac-201-phase-i-trial/2025-02-14T16:04:07+08:00https://flcube.com/accropeutics-gets-fda-green-light-for-phase-ii-uc-study-of-ripk2-inhibitor-ac-101/2025-02-14T16:04:06+08:00https://flcube.com/china-launches-major-public-health-initiatives-to-enhance-healthcare-accessibility/2025-02-14T15:44:18+08:00https://flcube.com/sanofi-and-jjs-e-coli-vaccine-fails-phase-iii-study/2025-02-14T15:25:19+08:00https://flcube.com/antengenes-xpovio-included-in-taiwans-nhi-drug-list-for-myeloma-treatment/2025-02-14T13:52:57+08:00https://flcube.com/boehringer-ingelheim-partners-with-expressionedits-on-gene-therapy-tech/2025-02-14T13:41:26+08:00https://flcube.com/mercks-zerbaxa-approved-by-chinas-nmpa-for-complex-infections/2025-02-14T12:56:35+08:00https://flcube.com/spinrazas-nrdl-inclusion-boosts-sma-patient-treatment-in-china/2025-02-14T09:41:21+08:00https://flcube.com/cde-releases-draft-guidelines-for-rwe-backed-drug-registration-applications/2025-02-14T09:37:28+08:00https://flcube.com/icts-gcc19cart-enters-us-phase-i-study-for-colorectal-cancer/2025-02-14T09:34:11+08:00https://flcube.com/brl-medicines-brl-101-receives-clinical-trial-approval-for-beta-thalassemia/2025-02-14T09:28:45+08:00https://flcube.com/genscript-biotech-sues-former-cso-fan-xiaohu-for-trade-secret-infringement/2025-02-14T09:25:37+08:00https://flcube.com/innovent-biologics-initiates-phase-i-study-of-ibi311-for-thyroid-associated-ophthalmopathy/2025-02-14T09:00:16+08:00https://flcube.com/baidu-healths-precision-matching-engine-powers-public-hospitals/2025-02-14T08:56:35+08:00https://flcube.com/wuxi-biologics-revenues-surge-63-5-in-h1-2022-on-strong-crdmo-growth/2025-02-14T08:53:37+08:00https://flcube.com/mingmed-biotechs-hong-kong-ipo-signals-push-for-first-in-class-drugs/2025-02-14T08:50:36+08:00https://flcube.com/junshi-biosciences-junmaikang-biosimilar-gets-nmpa-approval-filing/2025-02-14T08:44:56+08:00https://flcube.com/hainan-unveils-biomedical-new-technology-policy-to-boost-medical-innovation/2025-02-14T00:14:01+08:00https://flcube.com/roches-evrysdi-tablet-approved-by-fda-for-spinal-muscular-atrophy/2025-02-13T23:50:03+08:00https://flcube.com/shanghais-ambitious-plan-to-revolutionize-brain-computer-interfaces/2025-02-13T23:39:02+08:00https://flcube.com/pfizers-adcetris-gets-new-fda-approval-for-lymphoma-treatment/2025-02-13T23:22:34+08:00https://flcube.com/stairmed-raises-record-rmb350m-for-implantable-bci-development/2025-02-13T23:15:21+08:00https://flcube.com/lundbecks-amlenetug-receives-fda-fast-track-for-multiple-system-atrophy/2025-02-13T23:00:33+08:00https://flcube.com/oncusp-therapeutics-cusp06-receives-fda-fast-track-for-ovarian-cancer/2025-02-13T22:37:53+08:00https://flcube.com/jj-considers-selling-stroke-care-business-cerenovus-for-usd1-1-5-billion/2025-02-13T22:24:08+08:00https://flcube.com/anhui-anke-to-invest-in-visen-pharmas-hong-kong-ipo-as-cornerstone-investor/2025-02-13T22:17:52+08:00https://flcube.com/boao-airport-customs-releases-first-batch-of-modulen-ibd-for-crohns-disease-management/2025-02-13T22:06:34+08:00https://flcube.com/abbvie-collaborates-with-xilio-therapeutics-on-tumor-activated-immunotherapies/2025-02-13T21:58:49+08:00https://flcube.com/astellas-pharmas-izervay-gets-fda-approval-for-ga-treatment-without-dosing-limit/2025-02-13T21:47:49+08:00https://flcube.com/andon-health-to-fully-control-ihealth-by-acquiring-best-ventures-stake/2025-02-13T21:32:43+08:00https://flcube.com/hengrui-pharmas-bd-head-dr-chen-dong-departs-for-abbvies-external-innovation-role/2025-02-13T14:49:32+08:00https://flcube.com/huadong-medicines-biosimilar-saiyuexin-seeks-nmpa-approval-for-crohns-disease/2025-02-13T14:33:11+08:00https://flcube.com/jj-innovative-medicine-china-appoints-new-general-manager-and-oncology-vp/2025-02-13T14:21:30+08:00https://flcube.com/liaoning-chengda-biotech-to-see-actual-controller-change-of-controlling-shareholder/2025-02-13T14:03:13+08:00https://flcube.com/liaoning-chengdas-acyw135-meningococcal-vaccine-receives-nmpa-clearance/2025-02-13T13:52:55+08:00https://flcube.com/bayers-acoramidis-beyonttra-gets-ema-marketing-approval-for-attr-cm-treatment-in-eu/2025-02-13T13:38:40+08:00https://flcube.com/livzon-pharmaceuticals-jp-1366-approved-for-peptic-ulcer-study-by-nmpa/2025-02-13T13:25:48+08:00https://flcube.com/pfizer-partners-with-alloy-therapeutics-to-develop-new-antibody-platform/2025-02-13T12:54:08+08:00https://flcube.com/lifetech-scientifics-aortic-stent-graft-system-wins-nmpa-approval/2025-02-13T12:42:54+08:00https://flcube.com/mprobe-raises-funds-in-series-b1-round-led-by-astrazeneca-and-cicc/2025-02-13T00:30:43+08:00https://flcube.com/huahai-pharma-to-manufacture-pfizers-paxlovid-for-china-market/2025-02-13T00:22:13+08:00https://flcube.com/recbio-completes-phase-ii-trial-enrollment-for-recov-covid-19-vaccine/2025-02-13T00:19:42+08:00https://flcube.com/healsun-biopharm-raises-usd-36-7-million-in-series-b-financing-for-antibody-cdmo-expansion/2025-02-13T00:17:02+08:00https://flcube.com/sirnaomics-initiates-phase-i-ii-trial-for-stp705-in-facial-squamous-cell-carcinoma/2025-02-13T00:12:44+08:00https://flcube.com/nhc-ndrc-issue-guidelines-to-boost-chinas-birth-rates-with-reproductive-support-measures/2025-02-13T00:10:05+08:00https://flcube.com/biocytogen-pharmaceuticals-makes-hkse-debut-with-usd-70-million-ipo/2025-02-13T00:07:50+08:00https://flcube.com/cspc-pharmaceuticals-mitoxantrone-liposome-approved-for-nmosd-clinical-study/2025-02-13T00:04:46+08:00https://flcube.com/daiichi-sankyos-enhertu-accepted-for-review-in-china-for-her2-low-breast-cancer/2025-02-13T00:00:09+08:00https://flcube.com/nhsa-proposes-regulations-to-standardize-oral-implant-charges-and-reduce-costs/2025-02-12T23:57:12+08:00https://flcube.com/ping-an-good-doctor-reports-2022-interim-results-with-revenue-decline-and-user-growth/2025-02-12T23:54:30+08:00https://flcube.com/wuxi-sta-breaks-ground-on-new-us-manufacturing-site-in-delaware/2025-02-12T23:51:41+08:00